WO2008089093A2 - Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone - Google Patents
Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone Download PDFInfo
- Publication number
- WO2008089093A2 WO2008089093A2 PCT/US2008/050906 US2008050906W WO2008089093A2 WO 2008089093 A2 WO2008089093 A2 WO 2008089093A2 US 2008050906 W US2008050906 W US 2008050906W WO 2008089093 A2 WO2008089093 A2 WO 2008089093A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- compound
- formula
- converting
- vitamin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 116
- 150000003710 vitamin D derivatives Chemical class 0.000 title claims abstract description 74
- 150000003431 steroids Chemical class 0.000 title claims abstract description 49
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 title claims description 58
- 229960000249 pregnenolone Drugs 0.000 title claims description 26
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 title claims description 25
- 230000008569 process Effects 0.000 title description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 118
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- -1 -O-alkanoyl Chemical group 0.000 claims description 78
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 73
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 59
- 239000011710 vitamin D Substances 0.000 claims description 59
- 229940046008 vitamin d Drugs 0.000 claims description 59
- 229930003316 Vitamin D Natural products 0.000 claims description 57
- 235000019166 vitamin D Nutrition 0.000 claims description 57
- 239000002904 solvent Substances 0.000 claims description 51
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 claims description 33
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 31
- 239000000543 intermediate Substances 0.000 claims description 30
- 125000006239 protecting group Chemical group 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 26
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 23
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 11
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 7
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000005345 deuteroalkyl group Chemical group 0.000 claims description 2
- 150000001723 carbon free-radicals Chemical class 0.000 claims 2
- HZSAJDVWZRBGIF-UHFFFAOYSA-O thiamine monophosphate Chemical compound CC1=C(CCOP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N HZSAJDVWZRBGIF-UHFFFAOYSA-O 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 81
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 80
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 80
- 239000000203 mixture Substances 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 72
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 66
- 150000001299 aldehydes Chemical class 0.000 description 53
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 52
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 49
- 150000002576 ketones Chemical class 0.000 description 47
- 239000000047 product Substances 0.000 description 44
- 239000007787 solid Substances 0.000 description 42
- 229910052757 nitrogen Inorganic materials 0.000 description 41
- 230000002829 reductive effect Effects 0.000 description 41
- 230000015572 biosynthetic process Effects 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- 235000019441 ethanol Nutrition 0.000 description 38
- 235000019439 ethyl acetate Nutrition 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 230000003637 steroidlike Effects 0.000 description 29
- 238000006303 photolysis reaction Methods 0.000 description 28
- 230000015843 photosynthesis, light reaction Effects 0.000 description 28
- 150000002924 oxiranes Chemical class 0.000 description 27
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 26
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 24
- 238000001953 recrystallisation Methods 0.000 description 21
- QSLUXQQUPXBIHH-YHSKWIAJSA-N (1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2s)-butan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](C)CC)=C\C=C1C[C@@H](O)C(=C)[C@H](O)C1 QSLUXQQUPXBIHH-YHSKWIAJSA-N 0.000 description 20
- 150000001993 dienes Chemical class 0.000 description 20
- 0 C*C(C)[C@@](CC1)[C@@](C)(CC2)[C@]1[C@@]1[C@]2[C@@](C)(CCC(C2)O*)C2=CC1 Chemical compound C*C(C)[C@@](CC1)[C@@](C)(CC2)[C@]1[C@@]1[C@]2[C@@](C)(CCC(C2)O*)C2=CC1 0.000 description 19
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 17
- 238000007792 addition Methods 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000002002 slurry Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 15
- 229950004199 becocalcidiol Drugs 0.000 description 15
- 150000005671 trienes Chemical class 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 14
- 238000003379 elimination reaction Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 150000003462 sulfoxides Chemical class 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 239000002243 precursor Substances 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 12
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 11
- 229910001623 magnesium bromide Inorganic materials 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000003647 oxidation Effects 0.000 description 11
- 238000007254 oxidation reaction Methods 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 230000031709 bromination Effects 0.000 description 10
- 238000005893 bromination reaction Methods 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000010511 deprotection reaction Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000003638 chemical reducing agent Substances 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000006241 alcohol protecting group Chemical group 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000012279 sodium borohydride Substances 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- 239000002841 Lewis acid Substances 0.000 description 7
- CRRKVZVYZQXICQ-RJJCNJEVSA-N Pregnenolone acetate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](C(C)=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 CRRKVZVYZQXICQ-RJJCNJEVSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- GZRYBYIBLHMWCD-UHFFFAOYSA-N dimethyl(methylidene)-$l^{4}-sulfane Chemical compound CS(C)=C GZRYBYIBLHMWCD-UHFFFAOYSA-N 0.000 description 7
- 238000006073 displacement reaction Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 150000004795 grignard reagents Chemical class 0.000 description 7
- 150000007517 lewis acids Chemical class 0.000 description 7
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 7
- VKCYHJWLYTUGCC-UHFFFAOYSA-N nonan-2-one Chemical compound CCCCCCCC(C)=O VKCYHJWLYTUGCC-UHFFFAOYSA-N 0.000 description 7
- 238000005949 ozonolysis reaction Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical class CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 150000001649 bromium compounds Chemical class 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 150000002009 diols Chemical class 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 150000003131 pregnenolone derivatives Chemical class 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 5
- FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical compound [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 238000007269 dehydrobromination reaction Methods 0.000 description 5
- 238000005828 desilylation reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000012039 electrophile Substances 0.000 description 5
- 238000006735 epoxidation reaction Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000006317 isomerization reaction Methods 0.000 description 5
- 239000012038 nucleophile Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000001301 oxygen Chemical group 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 5
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- XQFJZHAVTPYDIQ-LETJEVNCSA-N (1s)-3-[(e)-2-[(1r,3ar,7ar)-1-[(e,2r,5r)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-1,2,3,3a,6,7-hexahydroinden-4-yl]ethenyl]-4-methylcyclohex-3-en-1-ol Chemical class C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)/C=C/[C@H](C)C(C)C)\C=C\C1=C(C)CC[C@H](O)C1 XQFJZHAVTPYDIQ-LETJEVNCSA-N 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 4
- FCYQTGCEDUOHLT-LEKSSAKUSA-N 1-[(8s,9s,10r,13s,14s,17s)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 FCYQTGCEDUOHLT-LEKSSAKUSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 239000007818 Grignard reagent Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000000746 allylic group Chemical group 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010216 calcium carbonate Nutrition 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052744 lithium Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 150000003457 sulfones Chemical class 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229960002882 calcipotriol Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000006356 dehydrogenation reaction Methods 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229950007545 falecalcitriol Drugs 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 150000003944 halohydrins Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- WJGVYRMMIIWBAU-UHFFFAOYSA-M magnesium;2-methylbutane;bromide Chemical compound [Mg+2].[Br-].CC(C)C[CH2-] WJGVYRMMIIWBAU-UHFFFAOYSA-M 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- VLYLVPWRADZEDL-UHFFFAOYSA-N methylsulfanylmethane;hydroiodide Chemical compound [I-].C[SH+]C VLYLVPWRADZEDL-UHFFFAOYSA-N 0.000 description 3
- LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 238000007699 photoisomerization reaction Methods 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 238000007070 tosylation reaction Methods 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 238000003828 vacuum filtration Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- QTVNPWWLYMFLEI-JOHQXWBISA-N 1-[(9s,10r,13s,14r,17s)-3-hydroxy-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H](C(=O)C)CC[C@H]33)C)C3=CC=C21 QTVNPWWLYMFLEI-JOHQXWBISA-N 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NZEDMAWEJPYWCD-UHFFFAOYSA-N 3-prop-2-enylsulfonylprop-1-ene Chemical compound C=CCS(=O)(=O)CC=C NZEDMAWEJPYWCD-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 229910015844 BCl3 Inorganic materials 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229910005267 GaCl3 Inorganic materials 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229910010084 LiAlH4 Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 238000010547 Norrish type II reaction Methods 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229910018162 SeO2 Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000005575 aldol reaction Methods 0.000 description 2
- 150000001336 alkenes Chemical group 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000010504 bond cleavage reaction Methods 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- JJNHBFYGCSOONU-UHFFFAOYSA-M carbanide;cyclopenta-1,3-diene;dimethylaluminum;titanium(4+);chloride Chemical compound [CH3-].[Ti+3]Cl.C[Al]C.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 JJNHBFYGCSOONU-UHFFFAOYSA-M 0.000 description 2
- YNBJMIXWGPOBGE-UHFFFAOYSA-N carbanide;cyclopenta-1,3-diene;titanium(4+) Chemical compound [CH3-].[CH3-].[Ti+4].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YNBJMIXWGPOBGE-UHFFFAOYSA-N 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- HCJWWBBBSCXJMS-UHFFFAOYSA-J copper;dilithium;tetrachloride Chemical compound [Li+].[Li+].[Cl-].[Cl-].[Cl-].[Cl-].[Cu+2] HCJWWBBBSCXJMS-UHFFFAOYSA-J 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- MKNXBRLZBFVUPV-UHFFFAOYSA-L cyclopenta-1,3-diene;dichlorotitanium Chemical compound Cl[Ti]Cl.C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 MKNXBRLZBFVUPV-UHFFFAOYSA-L 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960002061 ergocalciferol Drugs 0.000 description 2
- BLHLJVCOVBYQQS-UHFFFAOYSA-N ethyllithium Chemical compound [Li]CC BLHLJVCOVBYQQS-UHFFFAOYSA-N 0.000 description 2
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229920000591 gum Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BXBLTKZWYAHPKM-UHFFFAOYSA-M magnesium;methanidyl(trimethyl)silane;chloride Chemical compound [Mg+2].[Cl-].C[Si](C)(C)[CH2-] BXBLTKZWYAHPKM-UHFFFAOYSA-M 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- JNMIXMFEVJHFNY-UHFFFAOYSA-M methyl(triphenyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 JNMIXMFEVJHFNY-UHFFFAOYSA-M 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- XYDYWTJEGDZLTH-UHFFFAOYSA-N methylenetriphenylphosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=C)C1=CC=CC=C1 XYDYWTJEGDZLTH-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- URMYFQFQMJBCNT-UHFFFAOYSA-N nonan-2-ol Chemical compound CCCCCCCC(C)O.CCCCCCCC(C)O URMYFQFQMJBCNT-UHFFFAOYSA-N 0.000 description 2
- NGDNVOAEIVQRFH-UHFFFAOYSA-N nonan-2-ol Natural products CCCCCCCC(C)O NGDNVOAEIVQRFH-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Chemical group 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000005547 pivalate group Chemical group 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 229950009921 seocalcitol Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical class [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 2
- 150000003509 tertiary alcohols Chemical group 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 238000001149 thermolysis Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 125000005490 tosylate group Chemical group 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- 239000005314 uranium glass Substances 0.000 description 2
- 238000009849 vacuum degassing Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- BHSFAGUCNBKOPP-YFTKGUKSSA-N (1r,7ar)-1-butan-2-yl-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-one Chemical compound O=C1CCC[C@]2(C)[C@@H](C(C)CC)CCC21 BHSFAGUCNBKOPP-YFTKGUKSSA-N 0.000 description 1
- FKHQVTZBKCBVOA-JGVFFNPUSA-N (3ar,7as)-1,2,3,3a,5,6,7,7a-octahydroinden-4-one Chemical compound O=C1CCC[C@@H]2CCC[C@@H]12 FKHQVTZBKCBVOA-JGVFFNPUSA-N 0.000 description 1
- HVYWMOMLDIMFJA-VEIPTCAHSA-N (3r,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical class C1C=C2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-VEIPTCAHSA-N 0.000 description 1
- JKZHMFCLVQVUDE-DXUGQKIESA-N (9s,10r,13r,14r,17s)-17-ethyl-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthrene Chemical class C1CCC[C@]2(C)[C@@H](CC[C@@]3([C@@H](CC)CC[C@H]33)C)C3=CC=C21 JKZHMFCLVQVUDE-DXUGQKIESA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- GQVPYCDCRPAHKB-UHFFFAOYSA-N 1,3-benzothiazol-2-yl thiohypochlorite Chemical compound C1=CC=C2SC(SCl)=NC2=C1 GQVPYCDCRPAHKB-UHFFFAOYSA-N 0.000 description 1
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 1
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 1
- YJRWWZQIAAWTJE-OZIWPBGVSA-N 1-[(8S,9S,10R,13S,14S,17S)-10,13-dimethyl-3-silyloxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical class [SiH3]OC1CC2=CC[C@H]3[C@@H]4CC[C@H](C(C)=O)[C@]4(CC[C@@H]3[C@]2(CC1)C)C YJRWWZQIAAWTJE-OZIWPBGVSA-N 0.000 description 1
- ULHDGLCVXWEXSM-JOHQXWBISA-N 1-[(9S,10R,13S,14R,17S)-10,13-dimethyl-3-silyloxy-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical class [SiH3]OC1CC2=CC=C3[C@@H]4CC[C@H](C(C)=O)[C@]4(CC[C@@H]3[C@]2(CC1)C)C ULHDGLCVXWEXSM-JOHQXWBISA-N 0.000 description 1
- NXXNVJDXUHMAHU-UHFFFAOYSA-N 1-anthracen-9-ylethanone Chemical compound C1=CC=C2C(C(=O)C)=C(C=CC=C3)C3=CC2=C1 NXXNVJDXUHMAHU-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- ZIXXRXGPBFMPFD-UHFFFAOYSA-N 1-chloro-4-[(4-chlorophenyl)disulfanyl]benzene Chemical compound C1=CC(Cl)=CC=C1SSC1=CC=C(Cl)C=C1 ZIXXRXGPBFMPFD-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- XYGIHYNABFJESU-UHFFFAOYSA-N 3-prop-2-enylsulfinylprop-1-ene Chemical compound C=CCS(=O)CC=C XYGIHYNABFJESU-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 1
- YIROYDNZEPTFOL-UHFFFAOYSA-N 5,5-Dimethylhydantoin Chemical compound CC1(C)NC(=O)NC1=O YIROYDNZEPTFOL-UHFFFAOYSA-N 0.000 description 1
- HTMGQIXFZMZZKD-UHFFFAOYSA-N 5,6,7,8-tetrahydroisoquinoline Chemical compound N1=CC=C2CCCCC2=C1 HTMGQIXFZMZZKD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000004358 Butane-1, 3-diol Substances 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- QYSXJUFSXHHAJI-NAMRDOMMSA-N CC(C)CCC[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](CC1)O)\C1=C Chemical compound CC(C)CCC[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](CC1)O)\C1=C QYSXJUFSXHHAJI-NAMRDOMMSA-N 0.000 description 1
- OFHCOWSQAMBJIW-MUUMFMJRSA-N CC(C)CCC[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C Chemical compound CC(C)CCC[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C OFHCOWSQAMBJIW-MUUMFMJRSA-N 0.000 description 1
- LVLLALCJVJNGQQ-PCYSJUIESA-N CCC(CC)(/C=C/C=C/[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C)O Chemical compound CCC(CC)(/C=C/C=C/[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C)O LVLLALCJVJNGQQ-PCYSJUIESA-N 0.000 description 1
- PRSMNTCFGOCDOZ-USLQEWEHSA-N CCC(CC)(CCC[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)O Chemical compound CCC(CC)(CCC[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)O PRSMNTCFGOCDOZ-USLQEWEHSA-N 0.000 description 1
- XPYGGHVSFMUHLH-UQRNCMAVSA-N C[C@@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C Chemical compound C[C@@H](CCCC(C(F)(F)F)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C XPYGGHVSFMUHLH-UQRNCMAVSA-N 0.000 description 1
- JWUBBDSIWDLEOM-MTYAKMCYSA-N C[C@@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](CC1)O)\C1=C Chemical compound C[C@@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](CC1)O)\C1=C JWUBBDSIWDLEOM-MTYAKMCYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-WJBPREEXSA-N C[C@@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C Chemical compound C[C@@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C GMRQFYUYWCNGIN-WJBPREEXSA-N 0.000 description 1
- UHMPCVGLSKFXHR-NAQZCRMNSA-N C[C@@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O Chemical compound C[C@@H](CCCC(C)(C)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O UHMPCVGLSKFXHR-NAQZCRMNSA-N 0.000 description 1
- GWZWZNSHCINSJV-ADXPTBHWSA-N C[C@@H](CCCC1(CCCC1)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O Chemical compound C[C@@H](CCCC1(CCCC1)O)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O GWZWZNSHCINSJV-ADXPTBHWSA-N 0.000 description 1
- CTZNNVRIDJCSDL-BECVIIKMSA-N C[C@H]([C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C)/C=C/C1(CCC1)O Chemical compound C[C@H]([C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(/C[C@H](C[C@@H]1O)O)\C1=C)/C=C/C1(CCC1)O CTZNNVRIDJCSDL-BECVIIKMSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 238000006957 Michael reaction Methods 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 238000003799 Mukaiyama Aldol addition reaction Methods 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 238000006921 Stevens reaction Methods 0.000 description 1
- 241001385887 Tachys Species 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- SNIYGPDAYLBEMK-UHFFFAOYSA-M [I-].[Mg+]C1=CC=CC=C1 Chemical compound [I-].[Mg+]C1=CC=CC=C1 SNIYGPDAYLBEMK-UHFFFAOYSA-M 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000000125 calcaemic effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- GGNALUCSASGNCK-UHFFFAOYSA-N carbon dioxide;propan-2-ol Chemical compound O=C=O.CC(C)O GGNALUCSASGNCK-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- XGRJZXREYAXTGV-UHFFFAOYSA-N chlorodiphenylphosphine Chemical compound C=1C=CC=CC=1P(Cl)C1=CC=CC=C1 XGRJZXREYAXTGV-UHFFFAOYSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007337 electrophilic addition reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- NNQYFBSGBOKZKP-UHFFFAOYSA-N ethylidene(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC)C1=CC=CC=C1 NNQYFBSGBOKZKP-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000011552 falling film Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004434 industrial solvent Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- SNHOZPMHMQQMNI-UHFFFAOYSA-N lithium;2h-thiophen-2-ide Chemical compound [Li+].C=1C=[C-]SC=1 SNHOZPMHMQQMNI-UHFFFAOYSA-N 0.000 description 1
- KVWLUDFGXDFFON-UHFFFAOYSA-N lithium;methanidyl(trimethyl)silane Chemical compound [Li+].C[Si](C)(C)[CH2-] KVWLUDFGXDFFON-UHFFFAOYSA-N 0.000 description 1
- VCPPTNDHEILJHD-UHFFFAOYSA-N lithium;prop-1-ene Chemical compound [Li+].[CH2-]C=C VCPPTNDHEILJHD-UHFFFAOYSA-N 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- BLQJIBCZHWBKSL-UHFFFAOYSA-L magnesium iodide Chemical compound [Mg+2].[I-].[I-] BLQJIBCZHWBKSL-UHFFFAOYSA-L 0.000 description 1
- 229910001641 magnesium iodide Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- OKCUWCABNKFTCU-UHFFFAOYSA-M magnesium;2-methylbut-2-ene;bromide Chemical compound [Mg+2].[Br-].CC(C)=C[CH2-] OKCUWCABNKFTCU-UHFFFAOYSA-M 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000005822 methylenation reaction Methods 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000002875 norsteroids Chemical class 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 238000006385 ozonation reaction Methods 0.000 description 1
- FZUGPQWGEGAKET-UHFFFAOYSA-N parbenate Chemical compound CCOC(=O)C1=CC=C(N(C)C)C=C1 FZUGPQWGEGAKET-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- YUGCAAVRZWBXEQ-WHTXLNIXSA-N previtamin D3 Chemical class C=1([C@@H]2CC[C@@H]([C@]2(CCC=1)C)[C@H](C)CCCC(C)C)\C=C/C1=C(C)CC[C@H](O)C1 YUGCAAVRZWBXEQ-WHTXLNIXSA-N 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- ZSBJCQGJFPHZRC-UHFFFAOYSA-N prop-2-enyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCC=C)C=C1 ZSBJCQGJFPHZRC-UHFFFAOYSA-N 0.000 description 1
- QHJWOSHIGFDANE-UHFFFAOYSA-N prop-2-enylphosphane Chemical compound PCC=C QHJWOSHIGFDANE-UHFFFAOYSA-N 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- LVLLALCJVJNGQQ-ZCPUWASBSA-N seocalcitol Chemical compound C1(/[C@H]2CC[C@@H]([C@@]2(CCC1)C)[C@H](C)/C=C/C=C/C(O)(CC)CC)=C/C=C1/C[C@H](O)C[C@@H](O)C1=C LVLLALCJVJNGQQ-ZCPUWASBSA-N 0.000 description 1
- 125000005374 siloxide group Chemical group 0.000 description 1
- 238000006884 silylation reaction Methods 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- MBDNRNMVTZADMQ-UHFFFAOYSA-N sulfolene Chemical compound O=S1(=O)CC=CC1 MBDNRNMVTZADMQ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VPIXCEWVXNLQCR-QRRGNZNSSA-N tert-butyl-[(1s,3r)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)-2-methylidenecyclohexyl]oxy-dimethylsilane Chemical compound C1[C@H](O[Si](C)(C)C(C)(C)C)C(=C)[C@H](O[Si](C)(C)C(C)(C)C)CC1=CCP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 VPIXCEWVXNLQCR-QRRGNZNSSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229940041677 topical spray Drugs 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/21—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/48—Halogenated derivatives
- C07C35/52—Alcohols with a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
Definitions
- This method allows for the elaboration of the steroidal side chain in good overall yield and stereochemical purity, and utilizes a cheap steroid starting material, pregn-5-en-3 ⁇ -ol-20-one, which is 1) available in ton quantities, 2) one of the cheapest steroids commercially available, and as a result 3) is an excellent starting material for industrial processes.
- the method further uses intermediates that are solids, most of which can be purified to a high degree by recrystallization from commonly used industrial solvents, or by simple column chromatography.
- Described herein are methods useful in converting pregn-5-en-3 ⁇ -ol-20-one, and certain of its simple derivatives to a steroidal 5,7-diene with a partially or completely C20-homologated side chain with the unnatural ⁇ -conf ⁇ guration (usually S, 21-epi) of the C21 substituent (usually C21 methyl).
- This diene is then converted to the corresponding 21 ⁇ -Vitamin D derivative, using a well established photochemical, and thermal process, which is used industrially on a very large scale to convert 7-dehydrocholesterol to Vitamin D3 and ergosterol to ergocalciferol.
- Vitamin D derivatives this will complete the synthesis, but for many, especially those with non-natural A-ring moieties, the unwanted A-ring can now be removed oxidatively in a well established process to produce a Windhaus-Grundmann ketone, with the overall photolysis-rearrangement-ozonolysis sequence leading to a scission of the A and B rings and the C 8 position of the steroid being converted to a ketone.
- the desired A ring and seco-B ring can be added back using chemistry well established in the art, to make the desired, unnatural A-ring containing Vitamin D with the ⁇ -configuration at C21.
- an unmodified A ring Vitamin D precursor can be made and turned into the 3 ⁇ -hydroxy Vitamin D analogue by simple photolysis and deprotection of the key C20 homologated pregna- 5,7-diene derivatives described herein.
- pregn-5-en-3 ⁇ -ol-20-one, or other suitable 20-ketosteriod precursor into an appropriately diprotected l ⁇ ,3 ⁇ - pregn-5-endiol-20-one derivative, which can then be 7,8-dehydrogenated using methods described herein, and then C20 homologated to the appropriate 20 ⁇ -methyl (20-epi) steroidal 5,7-diene, which can be photo lysed and deprotected to give the desired l ⁇ ,3 ⁇ -20-epi Vitamin D analogue.
- the 3 ⁇ ,20 ⁇ - Vitamin D derivative can be l ⁇ -hydroxylated using an isomerization-allylic hydroxylation- reisomerization sequence.
- Another example of the utility of this method is to photo lyse the steroidal 5,7-diene produced by this process to the Vitamin D triene, and ozonize it, and then do a Lythgoe or Julia coupling on the resultant CD-ring ring Windaus-Grundmann ketone, to produce a 20-epi Vitamin D analogue with a non- natural A-ring substitution pattern.
- This latter exemplification of the method also provides the desired bicycle (below) in improved chemical yield and acceptable stereochemical purity over the currently published methods.
- R is alkyl, alkenyl, alkynyl, -O-alkanoyl, alkoxy, alkoxyalkoxy, -O-silyl (where the silyl group includes such groups as TMS, TBDMS, TPS, TIPS, and TBDPS), OH, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein each is optionally substituted with one or more groups that are independently alkyl, halogen, alkoxy, amino, monoalkylamino, dialkylamino, cyano, -O-trityl, -O- pivaloyl, or other alcohol protecting groups known in the art.
- pregnenolone (1) to produce O- protected 20R,22-homopregnen-22-al (2) and O-protected 20R,22-homopregnen-22- ol (3) derivatives in good overall yield, and high diastereomeric purity at C20, where the protecting groups are preferably silyl ethers.
- pregn-5-en-3 ⁇ -ol-20-one (1) to produce 3, O-protected 20R,22-homopregna-5,7-dien-22-al (4) and 3,0 -protected 20R,22-homopregna-5,7-dien-22-ol (5) derivatives in good overall yield, and high diastereomeric purity at C20.
- pregn-5-en-3 ⁇ -ol-20-one (1) to produce pregna-5,7-dien-3 ⁇ -ol-20-one (6) in a high yielding, short and convenient, synthetic process.
- Vitamin D derivatives are useful in the production of unnatural C20 configuration, (usually S stereochemistry), steroid derivatives, especially Vitamin D derivatives.
- Vitamin D derivatives can also be elaborated from the key intermediates, (2), (3), (4) and (5) described herein, all of which contain the desired chirality at C20, using a wide variety of methods, for example as described in "Synthesis of Vitamin D (Calciferol)" Zhu, G.-D., Okamura, W. H. Chem. Rev., 95 1877-1952, (1995).
- the convenient and efficient synthesis of (2-5) from pregn-5-en-3 ⁇ -ol-20-one is also described herein.
- the aldehyde (2) may be homologated into a very wide variety of steroidal side chains, for example by being reacted with a Grignard reagent, or an olefmating reagent, or a primary or secondary amine and a reducing agent, or an enolate, etc., or reduced to alcohol (3) with an appropriate reducing agent.
- the alcohol moiety in (3) may be reacted to form an ether, or an ester, or it may be converted into a leaving group, such as a sulfonate ester or a halide and then reacted with a nucleophile, which may be used to install a C22-C23 carbon, nitrogen, oxygen, phosphorus or sulfur bond.
- C22 halides can be transformed into C22 metal species, which further adds to the synthetic utility of this invention, using many electrophilic agents, obvious to one skilled in the art. Consequently, the above method affords a practical and cost effective entry into a vast array of possible C20-epi steroidal and Vitamin D side chains, each having its own unique biological activity.
- compositions comprising the steroids and/or Vitamin D analogues made using the methods of the invention or compounds disclosed herein are also contemplated.
- pregnenolone also called pregn-5-en-3 ⁇ -ol-20- one
- the method comprising a) reacting the 3 -hydroxy group of pregnenolone with a protecting group to form a compound of the formula: b) converting the product from step a) into a compound of the formula: c) converting the product from step b) into a compound of the formula: d) converting the product from step c) into a compound of the formula: e) converting the product from step d) into a compound of the formula: f) converting the product from step e) into a compound of the formula: g) converting the product from step f) into the desired product.
- R is methyl
- PG is a Ci -C 4 alkyl, benzyl or silyl group.
- PG is a silyl group that is TBS, TES, or TIPS.
- R is Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 - C 6 alkynyl, -O- C 2 -C 6 alkanoyl, C 1 -C 6 alkoxy, C 1 -C 4 alkoxy C 1 -C 4 alkoxy, -O-TBS, - O-TIPS, -O-TES, OH, C 3 -C 6 cycloalkyl, phenyl, pyridyl, thiazolyl, pyrimidyl, piperidinyl, pyrrolidinyl, morpholinyl, wherein each (except for H) is optionally substituted with one or more groups that are independently alkyl, halogen, alkoxy, OH, amino, monoalkylamino, dialkylamino or cyano.
- the 3-hydroxyl protecting group is a silyl group (such as TIPS, TES, TBS or TMS), benzyl, or Ci-C 4 alkoxy.
- R is methyl
- R is suitably hydroxyl protected 3- hydroxy-3 -methylbutyl, 3 -hydroxy-3 -ethylpentyl, 2-( 1 -hydroxy cyclopenyl)ethyl, 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butyl.
- PG is a silyl group.
- PG is t-butyldimethylsilyl (abbreviated as TBS or TBDMS), triethylsilyl (abbreviated as TES) or triisopropylsilyl (abbreviated as TIPS) group and R is methyl.
- TBS t-butyldimethylsilyl
- TES triethylsilyl
- TIPS triisopropylsilyl
- the epoxidation of the product from step a) is carried out by treating the methyl ketone with methyl sulfonium ylide in a solvent.
- Suitable solvents include THF.
- the ylide can be generated from dimethylsulfonium iodide or bromide and a strong base, such as KHMDS.
- the epoxidation of the product from step a) is carried out by treating the methyl ketone with methyl sulfonium ylide in a solvent at low temperatures in the range of about -4O 0 C to about -8O 0 C.
- Suitable solvents include THF -toluene mixtures.
- the conversion of the epoxide from step b) to the aldehyde is performed using a Lewis acid, such as BF 3 etherate, BCl 3 , MgCl 2 , MgBr 2 , Al(OPO 3 , Ti(OP ⁇ t ) 4 , titanocene dichloride, ZnCl 2 etherate, GaCl 3 , and In(OTf) 3 or Lewis acidic reagents (which cause the epoxide to rearrange to the aldehyde, and then react with the aldehyde in situ) such as MeMgBr, TMSCH 2 MgCl, TMSCH 2 MgBr, BH 3 /BF 3 , BH 3 /BC1 3 , Tebbe reagent, Petasis reagent, and DIBAL-H.
- a Lewis acid such as BF 3 etherate, BCl 3 , MgCl 2 , MgBr 2 , Al(OPO 3
- a preferred Lewis acid is MgBr 2 .
- Non-polar solvents such as toluene are also preferred. Reaction temps between about -2O 0 C and O 0 C are also preferred. MgBr 2 , in toluene at about -1O 0 C is also preferred.
- the aldehyde is optionally reacted with an olefmatmg reagent (such as methylenetriphenylphosphorane, ethylidenetriphenylphosphine, trimethylsilylmethyllithium, carbon tetrabromide/triphenylphosphine, 1 -lithiotrimethylphosphonoacetate, organometallic reagents such as the Grignard reagents, methylmagnesium bromide, methylmagnesium chloride, isopentyl magnesium bromide, phenylmagnesium iodide or bromide, vinylmagnesium bromide, and organolithium compounds such as methyl lithium, 2-thienyllithium, allyl lithium and phenyl lithium, a reducing agents, such as NaBH 4 , Ca(BH 4 ) 2 , NaCNBH 3 or LAH (in one embodiment, the epoxide rearrangement to form the aldeh
- Vitamin D derivatives with the C19 methylene group, and possible l ⁇ -hydroxyls, can be made directly from the steroidal monoene and diene and the Vitamin D triene intermediates claimed in the scheme above.
- Much chemistry has been described in the Vitamin D area to modify the A-ring of steroidal Vitamin D precursors exactly analogous to those claimed above, and all of this chemistry may be used with the current invention to produce 20-epi isomers of these known compounds.
- examples of R include, but are not limited to, methyl, ethyl, 3-methylbutyl, 3-hydroxy-3-methylbutyl, 3-hydroxy-3-ethylpentyl, 2- (1 -hydroxy cyclopenyl)ethyl, 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butyl, E,E,3-hydroxy-3-ethylpent-2-enyliden-l-yl, E-2R-2-cyclopropyl-2-hydroxyethyliden- 1-yl, with hydroxyls suitably protected using chemistry known in the art.
- the 7-position is brominated with a brominating reagent, such as l,3-dibromo-5,5-dimethylhydantoin ("Bromantin", "DMDBH”), or NBS.
- a brominating reagent such as l,3-dibromo-5,5-dimethylhydantoin ("Bromantin", "DMDBH"), or NBS.
- DMDBH is a preferred brominating agent.
- the 7-bromo compound may then be subjected to base-induced dehydrobromination conditions, thereby generating the diene.
- the 7-bromo compound is reacted with an aryl sulfide (such as, for example 4-chlorophenylthiol) thereby forming a 7-thioether with is oxidized to the sulfoxide using an oxidizing agents, such as MCPBA or oxone.
- an oxidizing agents such as MCPBA or oxone.
- the sulfoxide is then heated in the presence of a base, such as TEA, Hunig's base, or pyridine, thereby generating the 5,7-diene.
- the diene produced above is photolyzed first at a short wavelength, then at a longer wavelength, and then the resulting triene is thermally equilibrated, as is known in the art.
- the Vitamin D triene so produced may be the desired product or a protected form thereof, or it may be ozonolyzed to form the desired Windhau-Grundmann ketone product.
- pregnenolone (1) can be used to produce a compound of the formula (Scheme 2):
- R is as defined above, via a method comprising a) reacting the 3 -hydroxy group of pregnenolone with a protecting group to form a compound of the formula:
- step b) converting the product from step a) into a compound of the formula:
- step b) converting the product from step b) into a compound of the formula:
- step c) optionally (if necessary for removal or exchange of the protecting group, the need for which is understood by one of skill in the art) converting the product from step c) into a compound of the formula:
- step f) converting the product from step e) into a compound of the formula, where PG and PG* may be the same or different: g) converting the product from step f) into a compound of the formula:
- step g) converting the product from step g) into a compound of the formula:
- step g) converting the product from step g) into a compound of the formula:
- step j) converting the product from step h) into the desired product.
- first and second aspects also entail reducing the ketone of the formula:
- the reducing agent may be LAH, NaBH 4 , Ca(B H 4 ) 2 , or a transition metal catalyst and hydrogen.
- PG is a silyl group, Ci-C 4 alkyl (such as methyl), benzyl optionally substituted with one or two OCH 3 groups, or an alkanoyl protecting group and PG* is a silyl protecting group.
- PG is acetate and PG* is the t-butyldimethylsilyl group.
- PG is acetate and PG* is the t-butyldimethylsilyl group and R is methyl.
- Suitable solvents include THF.
- the ylide can be generated from dimethylsulfonium iodide or bromide and a strong base, such as KHMDS.
- the reaction is also performed at low temperature, such as about -8O 0 C to about -2O 0 C, optionally in the presence of a cosolvent, such as toluene.
- the solvent is THF and PG* is a TBDMS or TIPS group.
- PG is acetate and PG* is TIPS.
- PG and PG* are both TBS or TIPS.
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- the methods of the first and second aspects may be used to make the following compounds:
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- R H, TMS, MEM, TPS, TBDMS, or
- TBS groups may be replaced with a TIPS group and that the TMS group may be replaced with TBS, TES, MEM, or Ci-C 6 alkoxy.
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- R H, TMS, MEM, TBDPS, or TPS.
- the methods of the first and second aspects may be used to make the compounds of the formula:
- R H, pivaloate, TMS, MEM, TBDPS, or TPS.
- the methods of the first and second aspects may be used to make the compounds of the formula:
- R H, pivaloate, TMS, MEM, TBDPS, or TPS.
- the methods of the first and second aspects may be used to make the compounds of the formulas:
- R TMS, Trityl, TBDMS, pivaloyl, TPS, TIPS, TBDPS, or other alcohol protecting groups known in the art and where R 2 may also be H.
- the methods of the first and second aspects may be used to make the compounds of the formula:
- R 2 TMS, Trityl, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups known in the art and where R 2 may also be H.
- the methods of the first and second aspects may be used to make the compounds of the formula:
- R 2 and R 3 are different, and drawn from the group; H, TMS, Trityl, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups, in such a combination that R 2 can be removed in the presence of R 3 , which are known in the art.
- the methods of the first and second aspects may be used to make the compounds of the formula:
- R TMS, acetate, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups known in the art and where R3 may also be H.
- the methods of the first and second aspects may be used to make the compounds of the formula:
- R TMS, acetate, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups known in the art and where R 3 may also be H.
- compositions comprising steroids and Vitamin D derivates made using the method of the first or second aspects and at least one pharmaceutically acceptable carrier, excipient, adjuvant or glidant.
- compositions comprising the following compounds:
- the methods of the first and second aspects may be used to make the compounds of the formula X:
- the C23-C24 bond may be a single, double or triple bond
- R 1 , R 2 , R3 and R 4 are each independently C 1 -C 4 alkyl, C 1 -C 4 deuteroalkyl, hydroxyalkyl or haloalkyl;
- R 5 , R 6 and R 7 are each independently OH, OC(O)Ci-C 4 alkyl, OC(O)hydroxyalkyl or
- Xi is CH 2 ;
- the methods of the first and second aspects may also be used to prepare compounds of formula X, wherein R 7 is OH, and R 1 , R 2 , R3 and R 4 are each independently C 1 -C 4 alkyl, hydroxy C 1 -C 4 alkyl or Ci-C 2 haloalkyl.
- the methods of the first and second aspects may also be used to prepare stereospecifically at C20 compounds of formulas:
- aryl refers to an aromatic hydrocarbon ring system containing at least one aromatic ring.
- the aromatic ring may optionally be fused or otherwise attached to other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings.
- the aryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups.
- Preferred examples of aryl groups include phenyl, naphthyl, and anthracenyl. More preferred aryl groups are phenyl and naphthyl. Most preferred is phenyl.
- cycloalkyl refers to a C 3 -Cg cyclic hydrocarbon.
- examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- heterocycloalkyl refers to a ring or ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein said heteroatom is in a non-aromatic ring.
- the heterocycloalkyl ring is optionally fused to or otherwise attached to other heterocycloalkyl rings and/or non-aromatic hydrocarbon rings and/or phenyl rings.
- Preferred heterocycloalkyl groups have from 3 to 7 members.
- heterocycloalkyl groups include, for example, 1,2,3,4- tetrahydroisoquinolinyl, piperazinyl, morpholinyl, piperidinyl, tetrahydrofuranyl, pyrrolidinyl, pyridinonyl, and pyrazolidinyl.
- Preferred heterocycloalkyl groups include piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, and dihydropyrrolidinyl.
- heteroaryl refers to an aromatic ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur.
- the heteroaryl ring may be fused or otherwise attached to one or more heteroaryl rings, aromatic or non-aromatic hydrocarbon rings or heterocycloalkyl rings.
- heteroaryl groups include, for example, pyridine, furan, thienyl, 5,6,7,8-tetrahydroisoquinoline and pyrimidine.
- heteroaryl groups include thienyl, benzothienyl, pyridyl, quinolyl, pyrazolyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, dibenzofuranyl, thiazolyl, benzothiazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, benzisothiazolyl, triazolyl, pyrrolyl, indolyl, pyrazolyl, and benzopyrazolyl. More preferred heteroaryl rings include pyridyl, pyrrolyl, thienyl, and pyrimidyl.
- the invention provides the use of pregnenolone (1) to produce O-protected 20R,22-homopregn(adi)en-22-als (2 & 4) and O-protected 20R,22-homopregn(adi)en-22-ols (3 & 5) derivatives in good overall yield, and high diastereomeric purity at C20.
- the alcohol protecting groups described in Protecting Groups in Organic Synthesis by Greene may be used in this process if compatible with the next two steps, but in a preferred aspect, the protecting group, PG, is a silyl protecting group.
- Both the t-butyldimethylsilyl (TBDMS or TBS) ether (7) and the triisopropylsilyl (TIPS) ether (8) are especially preferred and are relatively inexpensive.
- many other protecting groups especially other silyl ethers such as t-butyldiphenylsilyl (TBDPS) and phenyldimethylsilyl (PDMS), are also useful.
- ester protecting groups tend to be cleaved by the preferred nucleophilic epoxidizing agent used in the key step to set up C20 stereochemistry, and further limit the chemistries which may be used to elaborate key intermediates (4) and (5).
- the TBDMS ether (7) was obtained in excellent purity and 98% yield by direct crystallization from the reaction mixture.
- TIPS ether (8) was not quite as easy to obtain, and yet was obtained in 84% yield after recrystallization, or about 90% yield after column chromatography, and these protecting groups proved very satisfactory when the C 17 side chain was introduced first, as shown in Scheme 1.
- the preferred base proved to be fluoride ion (see below), and for both cost and convenience, pregnenolone acetate (9) was used as the starting material, and a switch was made to the TBDMS ether at a later stage in the synthesis.
- Pregnenolone acetate can be made from pregnenolone in above 99% yield, or bought commercially.
- Other protecting groups which may be used at the 3 -hydroxy include methyl (produced by solvolysis from the corresponding sulfonates), benzyl and allyl (which may be derived from the corresponding O-substituted trichloroacetimidates).
- the O-protected pregnenolone derivatives, (7-9) described above can all be allylically brominated by a variety of brominating agents at the 7-position to give bromides (10), as described in the literature. Numerous bases are described to dehydrobrominate (10) to the corresponding protected dienone (11). As this transformation is usually described for the conversion of O-protected cholesterol derivatives into 7-dehydrocholesterol derivatives, it should be especially suitable to the conversion of protected 22,23-bishomopregn-5-en-3 ⁇ -ol derivatives (12) to the corresponding bromides (13), which can then be eliminated to the desired diene (14).
- This reaction sequence has three major drawbacks.
- the first is that the 7 ⁇ - bromide is the only one set up to eliminate properly, that is transdiaxially to H8 ⁇ , and bromination of different steroids can give very variable 7 ⁇ / ⁇ mixtures, sometimes with the unwanted equatorial ⁇ -isomer predominating.
- a soluble bromide source such as tetra-n-butylammonium bromide (TBAB)
- TBAB tetra-n-butylammonium bromide
- the second problem is that a lot of the literature describing these reactions is very old, and the analytical techniques used did not always distinguish the desired 5,7-diene product, a product of an expected trans-diaxial 1 ,2-elimination, from the unexpected trans-diaxial 1 ,4-elimination, which leads to the unwanted 4,6-diene.
- Molecular modeling shows that the 8 ⁇ -proton, which is the proton extracted in the desired 1 ,2-elimination, is considerably more hindered by the ⁇ -methyls Cl 8 and C19 than is the 4 ⁇ -proton, abstraction of which leads via 1 ,4-elimination to the 4,6-diene.
- literature reaction conditions which can produce almost exclusively the 4,6-diene when applied to some steroidal precursors. Other side products were often not detected in the older literature, and often they cannot be reliably removed by crystallization, or chromatography.
- the third problem is that the allylic bromides (10, 13) are rather unstable, and the range of reagents and solvents usable with the 7-bromides is very limited.
- the bromides cannot be purified by normal phase silica gel chromatography, and the base/solvent combinations to do the 7,8-elimination are rather limited. This is especially true for pregnenolone derivatives, which have a tendency to epimerize at C 17, and/or enolize at C21, when treated with very strong bases.
- NMR spectra of the crude reaction products suggest that this product is formed in 85-90% yield, with very little of the unwanted 7 ⁇ -bromide.
- NMR analysis of the thiol displacement product(s) also indicates a 7 ⁇ :7 ⁇ ratio of at least 10:1. Again the instability of the bromide product (25) to silica gel, makes analysis of the reaction by tic difficult, but it does allow one to monitor for the disappearance of starting material reliably.
- the reaction mixture is filtered hot to remove unreacted dibromantin and the 5,5-dimethyl hydantoin side product.
- TBAF tetra-n-butylammonium fluoride
- pregna-5,7-dien-3 ⁇ -ol-20-one acetate (27) is obtained in 70- 98% purity, and 90-96% crude yield.
- the acetate group does not appear to be as desirable as using silyl ether protecting groups. Therefore the acetate group needs to be cleaved, which can be done in very high yield with methanol and catalytic solid potassium carbonate to give pregna-5,7-dien-3 ⁇ -ol-20-one (21).
- This route is shown in Scheme 5, and results in overall yields of (21) from pregn-5-en-3 ⁇ -ol-20-one (1) of 50-65%.
- acetate (26) is not useable in the chemistry described below, and alcohol (21) can only be used in said chemistry after being suitably protected, these two compounds are useful intermediates in a wide variety of other steroid/Vitamin D syntheses, as they combine a B-ring diene and a readily modified C 17 side chain, and are obtained in very few steps, and good overall yields from pregn-5-en-3 ⁇ -ol-20-one (1).
- Pregna-5,7-dien-3 ⁇ -ol-20-one (21) can be protected on the alcohol oxygen using many different protecting groups, as described in Protective Groups in Organic Synthesis 3 rd Edn. by Greene and Wuts.
- the B-ring 5,7-diene system can be modified in many different ways, especially oxidatively to produce a wide variety of biologically active steroids with highly functionalized, or even cleaved B-rings.
- Silylation of pregna-5,7-dien-3 ⁇ -ol-20-one (21) can be carried out conveniently with t-butyldimethylsilyl chloride and pyridine with DMAP catalysis in DMF in the temperature range 25-55 0 C.
- DMAP catalysis in DMF in the temperature range 25-55 0 C.
- the desired product 3O-(t-butyldimethylsilyl)pregna-5,7-dien-3 ⁇ -ol-20- one (20) precipitates in good yields, 80-93%, and with a considerable increase in purity over the starting alcohol. If the starting alcohol is >90% pure this allows for the product to be obtained directly from the reaction mixture in >98% purity, which is adequate for the succeeding chemistry without need of further purification.
- Both the steroid and the ylide are sparingly soluble in DMF, and the reaction is very slow, taking up to a week to go to completion. This requires a very concentrated reaction mixture, and one ends up with a thick paste, which is difficult to stir even on a small scale.
- the protected alcohol-ketones (7), (8) and (20) were also converted into the epoxides (27)-(29) using the ylide derived from triimethylsulfonium iodide.
- ylide derived from triimethylsulfonium iodide.
- a wide variety of strong bases, obvious to one skilled in the art will produce this ylide from trimethylsulfonium iodide or bromide, exemplified by, but not limited to, potassium hexamethyldisilazane.
- These reactions were complete in 10 minutes at room temperature in THF and the reactions were homogenous solutions, with some salt precipitation, without any of the stirring problems seen with the sulfonium ylide.
- the surprisingly good diastereoselectivity seen with the THP derivative was also seen in these cases, and these reactions, for which no workable conditions were found at all with dimethylsulfonium methylide, were simple to do and very high
- the reaction between the ylide derived from dimethylsulfonium iodide and the TBS or TIPS protected pregn(adi)enolone affords a product that is increasingly clean, diastereoselective, and high yielding.
- epoxides (27)-(29) are produced with diastereoselectivities in the 40-55:1 range, and yields above 90% with overall reaction times of a few hours.
- the C21 -methyl side chain may be elaborated by generating a kinetic enolate via C21 proton abstraction, using a base, such as LDA, NaHMDS, KHMDS or others as known in the art in a solvent, such as THF, usually at low temperature, and then reacting the enolate with an electrophile as shown in Scheme 6.
- a base such as LDA, NaHMDS, KHMDS or others as known in the art in a solvent, such as THF, usually at low temperature
- the R group may be the same or different and is selected from methyl, ethyl, isopropyl, tert-butyl and phenyl.
- Preferred R 3 Si groups include TBDMS, and TIPS.
- the conversion of the epoxides (27)-(29) to aldehydes (30)-(32) is performed using a Lewis acid.
- This reaction is neither stereospecif ⁇ c nor chemospecif ⁇ c, and at least three products other than the 20-R aldehyde are produced in this reaction, regardless of which epoxide is used.
- the undesired S-aldehyde (33) is present as 2- 45% of the mixture, and simple halide induced S N 2 opening of the epoxide to form a halohydrin (34) consumes 0.5-15% of the epoxide, and an apparently base-induced epoxide opening to 1-10% of an allyl alcohol (35) also occurs.
- Lewis acids have been examined for this transformation in the monoene series; BF3 etherate, BCl 3 , MgCl 2 , MgBr 2 , MgI 2 , Al(OP ⁇ ) 3 , Ti(OPr' ⁇ , titanocene dichloride, ZnCl 2 etherate, GaCl 3 , and In(OTf) 3 .
- the optimal Lewis acid for this transformation was found to be magnesium bromide, used as the solid bis-diethyl etherate. This was then optimized for solvent, stoichiometry, and temperature.
- the optimal conditions for all three epoxides (27), (28) and (29) were found to be with toluene as solvent, 0.2-0.5 equivalents of the Lewis acid, and temperatures in the -10 to 0 0 C range, which 1) consistently afforded a C20 R: S ratio of 25:1 or better, and 2) reduces the production of the byproducts to about 5%.
- C20 R:S diastereomeric ratios of 15-20:1 can be obtained using unpurified epoxides (27)-(29) in the reaction mixture, and that the diastereomeric purity of the product can be raised up to about 65:1 20R:S for TBDMS aldehyde (30), and 35:1 for TIPS aldehyde (31) after a single recrystallization from acetone or isopropanol respectively in approximately 70% yield.
- a second recrystallization gave (30) in a >200: 1 , and (31) in a 65:1 C20 R:S ratio, both in at least 55% yield.
- Aldehydes (30), (31) and (32) are very valuable intermediates for synthesis of pharmaceuticals with the unnatural, 20 ⁇ configuration.
- a great deal of chemistry has been developed to elaborate the C22 S-aldehyde position, which is usually obtained by oxidative cleavage of ergosterol, and most of that chemistry could be used on R- aldehydes (30)-(32) (Kutner, A., Perlman, K. L., Sicinski, R. R., Phelps, M. E., Schnoes, H. K., DeLuca, H. F. Tetrahedron Letters, (1987), 28, 6129-6132).
- reaction of aldehydes (30) and (32) with methylenetriphenylphosphorane leads to 20S,3 ⁇ -(£-butyldimethylsiloxy)22,23- bishomopregna-5,21-diene (36), and 20S,3 ⁇ -(£-butyldimethylsiloxy)22,23- bishomopregna-5,7,21-triene (37), which can be selectively catalytically reduced to the key intermediates 20S,3 ⁇ -(t-butyldimethylsiloxy)22,23-bishomopregna-5,7-diene (38) and 20S,3 ⁇ -(t-butyldimethylsiloxy)22,23-bishomopregna-5,7-diene (39) respectively.
- aldehydes (30)-(32) they may be reacted with reagents such as PPri 3 /CBr 4 , followed by butyl lithium or diethyl 1- lithio-1-diazophosphonate, thereby producing alkyne derivatives (40)-(42).
- reagents such as PPri 3 /CBr 4
- butyl lithium or diethyl 1- lithio-1-diazophosphonate thereby producing alkyne derivatives (40)-(42).
- These compounds can be elaborated to a wide variety of 20-epi-steroids, using reactions familiar to one skilled in the art, such as alkylations, electrocyclic, and electrophilic additions on the alkyne to elaborate out many different kinds of side chain.
- Aldehydes (30)-(32) can be reduced to the corresponding primary [R]- alcohols (43)-(45) by a very wide array of reducing agents (as described in Larock's Modern Synthetic Reactions) with no loss of C20 stereochemical purity.
- Particularly favored reagents include metal hydride reducing agents such as, but not limited to, DIBAL, NaBH 4 and LiAlH 4 .
- All three [20R] -alcohols are readily distinguished from their [20S]-epimers by thin layer chromatography, and can be obtained essentially diastereomerically pure (2OR: S >200:l) by column chromatography, in 40-60% isolated yield from pregnenolone, or by recrystallization protocols. This means that sufficiently diastereomerically enriched material for drug substances can be obtained in 4-steps and over 40% yield from pregnenolone.
- These alcohols are also valuable intermediates for the synthesis of pharmaceuticals with a 2OS configuration.
- the epoxide rearrangement and the aldehyde reduction can be combined into a single step, precluding isolation of the aldehyde.
- this can be carried out on crude epoxide, it means that the only purification step introduced during the entire side chain synthetic sequence to this point is the chromatography at this step, although the chromatography can be replaced by recrystallization, albeit at some loss of yield.
- carrying out such a two step transformation on epoxide (27) can be obtained in 79.5% yield, which is 74% overall on pregnenolone.
- 20R,3 ⁇ -(t-Butyldimethylsiloxy)-22-homopregna-5,7-dien-22-ol (45) can be obtained in very high isomeric purity, by using recrystallized aldehyde, or by recrystallization, or column chromatography of less isomerically pure aldehyde.
- Ethyl acetate has been found to be a good solvent for this recrystallization, and two recrystallizations can improve the DE of alcohol (45) to >98%.
- alcohols (43)-(45) Another useful transformation of alcohols (43)-(45) is conversion of the alcohol into a halide, preferably bromide or iodide, for example by use of appropriate phosphorus halide derivatives, or Ph 3 PZCX 4 , or other techniques disclosed in "Comprehensive Organic Transformations 2 nd Edition" by R. C. Larock followed by displacement of the halide by an appropriate nucleophile.
- a halide preferably bromide or iodide
- ketone (49) therefore has utility as a synthetic intermediate, and methods of making (49) which would allow it to be produced more readily and/or at lower cost than at current methodologies, which are not particularly efficient, would be advantageous.
- the current invention can be used to produce ketone (49) much more cheaply, and in considerably better yield than the described route from ergosterol. (DeLuca, H. F.; et al. US Patent, 6,835,723).
- Compound (49) presents several synthetic problems. It is chiral, and a trans bicyclo[4.3.0]nonan-2-one. It has a quaternary center and a c ⁇ -6,7-dialkyl substitution pattern, and the steroidal side chain has the unnatural [S]-configuration at C20.
- a naturally occurring steroid one can readily solve the problems of chirality, the quaternary center and the trans-bicyclononanone structure.
- one must be able to ensure that the steroidal A and B rings are efficiently removed, whilst leaving only the C2 (C8 steroidal) position functionalized, and one must also ensure the correct stereochemistry at C17 and C20, and that the C 14 stereochemistry is retained.
- the dienes (15) and (39) are chemically very close analogues of 7- dehydrocholesterol, and of ergosterol, and can be photochemically ring opened to the Vitamin D triene analogues under similar conditions to those used in commercial Vitamin D syntheses. (See M. Okabe. Organic Syntheses, 76, 275, (1999). Steroidal 5,7-diene (39) has been photolysed as described by Okabe with a Hanovia mercury lamp, to give a mixture of the pre -Vitamin D analogue (54) and the tachysterol analogue (55).
- Triene (53) can be ozonized to form the key ketone intermediate (49), a Windhaus-Grundmann ketone, which is a well known reaction in Vitamin D chemistry. Because of the possible lability of the trans ring junction in ketone (49), it was not directly isolated, but was reduced to the known tr ⁇ ns-octahydroindanol (56) in situ.
- Alcohol (56) was obtained pure, in overall 36% yield from diene (39) in this four step process in up to a gram scale. It is anticipated that this yield can be improved by using better photolysis apparatus, such as recirculating photolysis apparatus, and falling film apparatus. Alcohol (56) can be oxidized to ketone (49) in 99% yield with pyridinium dichromate, as described in the literature. (DeLuca, H. F.; et al. US Patent, 6,835,723 (2004)).
- this chemistry represents a 16 reaction synthesis of ketone (49) from pregnenolone (1).
- Two of the steps can be functionally simplified by being carried out in situ, and both photolyses, the thermal isomerization and the ozonolysis/reduction are carried out without a purification, and only an evaporation down and reconstitution of the reaction solution, leading to an 11 "pot" conversion.
- Each of the isolated intermediates is a crystalline solid, and can be recrystallized if required.
- Ketone (49) was treated with the lithium anion of phosphine oxide (50), as described in the literature, and underwent Lythgoe coupling to give the Vitamin D analogue (51) in 79.7% yield.
- TBAF deprotection, and crystallization gave Becocalcidiol (52) in 85.1% yield, as described in the literature.
- Becocalcidiol (52) in overall 7.6% yield from pregnenolone (1).
- CD-ring ketones (66)-(68) Carrying these compounds through the photolysis-ozonolysis sequence will give the CD-ring ketones (66)-(68), which can then be Lythgoe coupled (or Julia sulfone coupled) with phosphine oxide (50) to produce Vitamin D analogues (57)-(59) after desilylation.
- Another method by which these side chains may be attached to the [20R],C22-homologated pregnenols is to convert alcohols such as (45), sulfonates, exemplified by (47) and halides exemplified by (48) to the corresponding sulfides, exemplified by aryl sulfide (69).
- alcohols such as (45), sulfonates, exemplified by (47) and halides exemplified by (48)
- aryl sulfide (69) This can be done via a Mitsunobu reaction on (45), or simple nucleophilic displacement of the leaving groups of (47) and (48) with a thiolate anion.
- Oxidation of the sulfide to the sulfone (70) may be difficult in the presence of the diene, but (45), (47) and (48) can be converted directly to the sulfone by use of an appropriate sulfmate nucleophile (Schrotter, E., Schonecker, B., Hauschild, U. Droescher, P, Schick, H. Synthesis, 193-5 (1990).).
- Generation of an anion at the C22 position can be carried out with alkyl lithium or lithium amide bases, and these in turn can be alkylated as described in the literature (Schrotter, E., Schonecker, B., Hauschild, U. Droescher, P, Schick, H. Synthesis, 193-5 (1990)), to produce compounds such as (71), which can be desulfonated to produce the corresponding epi-cholesterol derivatives, in this case (63).
- 20-epi Vitamin D (72) can be readily prepared is by coupling tosylate (47) with isopentyl magnesium bromide to give 20-epicholesta-5,7-diene (73), followed by photolysis and deprotection.
- the aldehyde (32) can be converted to (72) by several other methods, obvious to one skilled in the art.
- coupling of (47) with the corresponding 3-silyl ethers, such as (74) to form the protected cholestadiendiol (75), followed by photolysis and deprotection will lead to 20-epi-25 -hydroxy Vitamin D (76).
- the TPS (TBDPS) group may be removed before the photolysis.
- the 1,3-dihydroxy groups may need to be appropriately protected before the photolysis, and deprotected after the photolysis, along with the TPS (TBDPS) group.
- Other protecting group strategies could be used in the side chain, as loss of the tertiary alcohol protecting group prior to the DDQ oxidation should not be problematic, and a wide variety of protecting groups could be reintroduced to the tertiary alcohol immediately after DDQ oxidation.
- the chemistry described above can be used to efficiently produce the C20 epimers of several important Vitamin D derivatives.
- the above three compounds are l ⁇ -hydroxy Vitamin D derivatives, and can be readily obtained in protected form from either compound (32) or (47/88), or their TIPS-protected analogues.
- the sequence in Scheme 8 can be used.
- Compound (104), or its appropriately 1,3-diprotected analogue can then photo lysed/isomerized and appropriately deprotected to give (91), or can be photo lysed/isomerized directly to triene (105), which in turn can be 5Z to 5E- isomerized via sulfur dioxide cycloaddition-elimination to give (106), which can be allylically hydroxylated to (107), and then 5E to 5Z isomerized by long wavelength photolysis and deprotected, to give (91).
- a preparation of (92) can be carried out by analogy with the preparation of (90) from aldehyde (19) as described above.
- Reaction of (32) with the conjugated stable ylide (108) will give the E,E-dienone (109), which can be reacted with two equivalents of ethyl lithium, and pivaloyl chloride/DMAP to produce key intermediate (110).
- Desilylation of this, followed by the same DDQ-deconjugation- oxidation-reduction sequence as described previously will give the desired dienediol (111).
- Aldehyde (124) is a very useful common intermediate for l ⁇ -hydroxy-20-epi-22-alkenyl Vitamin D analogues.
- electrophiles reacted with enolates (128) and (135) in the above illustrations are described as alkyl halides, which would obviously include allylic and benzylic halides, there are many other electrophiles, obvious to one skilled in the art, such as aldehydes, ketones, esters, amides and acyl halides, and Michael acceptors which could be used in this process. Additionally, intermediates (136) and (139) can be desaturated to form the corresponding 5,7-dienes, and then converted to Vitamin D derivatives.
- Scheme 12 starts with alkylation of ketone (20) with LDA and methyl iodide, to give ketone (146), which is epoxidized, rearranged with magnesium bromide and reduced to alcohol (147) with NaBH 4 .
- Tosylation and copper-catalysed coupling of ethylmagnesium bromide gives the photolysis precursor (148). Going through the photolysis-isomerization and ozonolysis sequence gives the corresponding Windhaus- Grundmann ketone, which is reduced in situ to alcohol (149). Oxidation of the alcohol, back to the Windhaus-Grundmann ketone, followed by Lythgoe coupling and deprotection, as demonstrated for Becocalcidiol will give its bis-homo analogue (140).
- Scheme 12 Synthesis of 20S-21.22-bisnor-Becocalcidiol (140) from TBDMS Pregna-5.7-dien-3-ol-20-one (20).
- Scheme 13 is very similar to Scheme 12, starting with alkylation of ketone (20) with LDA and ethyl iodide, to give ketone (150).
- the sequence is continued exactly as in Scheme 12, except that the tosylate derived from alcohol (151) is coupled with methylmagnesium bromide and LiCuCl 4 , to form the steroid (152), which is converted as before to bicycloalcohol (153) and Becocalcidiol analogue (141).
- silyl ether (16) can be methylated on C21 to give the 21-homopregnenolone (160), which can be epoxidized with dimethylsulfonium methylide to form (161), which can be rearranged to the aldehyde (162).
- aldehyde (162) with an isopentyl Wittig reagent gives the homocholesterol derivative (163), whereupon selective side chain hydrogenation and desilylation gives 20S-21 -homocholesterol (144).
- This can either be displaced with lithium diphenyl phosphide or sodium 2-thiobenzothiazole, followed by oxidation to give allyl phosphine oxide (176) or allyl sulfone (177). Either of these can be treated with butyl lithium or LDA, followed by ketone (178) (DeLuca and Sicinski, US Patent 5,843,928) to give protected Becocalcidiol analogue (51), which is deprotected to Becocalcidiol (52).
- a B amford- Stevens reaction will give the vinyl compound (184), which can be oxidized to the allyl alcohol (185) by SeO 2 , either stoichiometrically or catalytically, with another oxidant such as t-butyl hydroperoxide.
- the hydrogen at C8 is axial, and other good enophile oxidizing agents such as EtO 2 CNSO, should also allow for this conversion.
- Reaction with a strong base and chlorodiphenylphosphine should produce the allylic phosphenite ester (186) which upon 3,2-rearrangement should give purely the E- isomer (176) shown.
- allyl alcohol (185) Treatment of allyl alcohol (185) with benzothiazole-2-sulfenyl chloride will give the allyl sulfenate ester (187) which will rearrange thermally to an allyl sulfoxide, which can be oxidized in situ with mCPBA or other mild oxidants to the allyl sulfone (177).
- the intermediates (176) and (177) can then be taken onto Becocalcidiol as described in Scheme 18.
- photolysis can be used to describe several different photochemical processes. If the process is simply described as a photolysis, or photo lysis/isomerization, to turn a steroidal B-ring 5,7-diene into a Vitamin D derivative, with no further elaboration, it can refer to one of two processes.
- a second irradiation at longer wavelength preferably around 350 nM, for example using a uranium glass filter, to isomerize most of the Tachysterol analogue back to the desired "pre Vitamin D” analogue, and is then followed by a thermal 1,7-hydride shift to give the desired 5Z,7E- ⁇ io-i9,5-6,7-8 trienic "Vitamin D” analogue.
- the second process involves a descending film photolysis technique carried out at room temperature or above, in a specialized photolysis apparatus, which allows for the ring opening and 1 ,7-hydride shift to be done, producing a preponderance of the desired 5Z,7E- ⁇ 10-1 9 j5- 6, 7- 8 trienic "Vitamin D" analogue in a single pass.
- photolysis to produce the 6E- ⁇ s_io,6-7,8-9 trienic "pre Vitamin D” analogue is specifically described, depending on the context, it will refer either to a single shorter wavelength photolysis, which is understood to produce a 6E- ⁇ s_io,6-7,8-9 trienic "pre Vitamin D”/ 6Z- ⁇ s_io,6-7,8-9 trienic "tachysterol” analogue mixture, or the short wavelength photolysis, followed by the longer wavelength 6Z to 6E deequilibration photolysis, and in each case done at low enough temperatures to suppress the 1,7-hydride shift to the 5Z,7E- ⁇ 10-1 9 j5- 6, 7- 8 trienic "Vitamin D" analogue.
- the reaction was allowed to stir at -7O 0 C for another hour, and was then allowed to warm slowly to -6O 0 C over 1 hour and to -5 0 C over another hour.
- the reaction was quenched by the rapid addition of acetic acid (2.0 rnL) forming a much thicker slurry.
- Water (100 mL) and NaHSO 3 (0.10 g) were added with rapid stirring, and the phases were separated.
- the aqueous phase was extracted with MTBE (2 x 50 mL), and the combined organic extracts were washed with water (2 x 50 mL), saturated aqueous sodium bicarbonate solution (50 mL) and saturated brine (50 mL), and dried (MgSO 4 ).
- Example 5 20R,3 ⁇ -(t-Butyldimethylsiloxy)-22-homopregn-5-en-22-al.
- the cold solution was quenched with dilute hydrochloric acid (0.1 M, 10 mL), and the phases were separated.
- the aqueous phase was extracted with MTBE (10 mL), and the combined organic phases were washed with water (10 mL), saturated brine (10 mL) and dried (MgSO 4 ).
- the solvent was removed rigorously under reduced pressure to give 842 mgs of white slightly waxy solid, which nmr analysis showed to contain a 20:1 ratio of 2OR: S aldehyde.
- Example 7 20S,3 ⁇ - ⁇ Butyldimethylsiloxy)-22,23-bishomopregna-5,22-diene.
- n-Butyl lithium 2.5 M in hexanes, 0.65 mL, 1.625 mmol
- methyltriphenylphosphonium iodide 608 mg, 1.5 mmol
- THF 5 mL
- 20R,3 ⁇ -(t-butyldimethylsiloxy)-22-homopregn-5-en-22-al 222.4 mg, 0.50 mmol
- Example 10 20S,3 ⁇ -(Triisopropylsiloxy)-22,23-bishomopregn-5-ene.
- Example 11 20R.3 ⁇ -(t-Butyldimethylsiloxy)-22-homopregn-5-en-22-ol.
- Example 12 One flask, 2 step, preparation of 20R,3 ⁇ -(f-butyldimethylsiloxy)-22- homopregn-5 -en-22-ol from 3 ⁇ -(t-butyldimethylsiloxy)-22-homopregn-5-en-20R,22- epoxide.
- Example 13 20R,3 ⁇ -(Triisopropylsiloxy)-22-homopregn-5-en-22-ol.
- Example 14 20R,3 ⁇ -(Triisopropylsiloxy)-22-homopregn-5-en-22-yl methanesulfonate .
- Example 15 20R,3 ⁇ -(Triisopropylsiloxy)-22-homopregn-5-en-22-yl p- toluenesulfonate.
- Example 16 20S,3 ⁇ -(Triisopropylsiloxy)-22,23-bishomopregn-5-ene.
- Example 17 20S,7 ⁇ / ⁇ -Bromo-3 ⁇ -(triisopropylsiloxy)-22,23-bishomopregn-5-ene.
- Example 18 20S.7 ⁇ -(4-Chlorophenylthio)-3 ⁇ (triisopropylsiloxy)-22.23- bishomopregn-5-ene.
- Tetra-n-butylammonium bromide (2.91 g, 9.04 mmol) was added in one portion to a solution of crude 20S,7- ⁇ / ⁇ -bromo-3 ⁇ -(triisopropylsiloxy)-22,23- bishomopregn-5-ene (4.52 mmol, obtained from the previous reaction) in toluene/acetone (4: 1 , 40 mL), stirred on an ice bath under nitrogen. After 2 hours, triethylamine (0.94 mL, 6.78 mmol) and 4-chlorothiophenol (0.65 g, 4.52 mmol) were added sequentially, and the ice bath was removed, and the reaction mixture was stirred at 25 0 C for 2 hours.
- Example 19 20S.7 ⁇ -(4-ChlorophenylsulfinylV3 ⁇ -(triisopropylsiloxyV22.23- bishomopregn-5-ene.
- m-Chloroperoxybenzoic acid (77%, 1.11 g, 4.95 mmol) was added in one portion to a solution of crude 20S,7 ⁇ -(4-chlorophenylthio)-3 ⁇ (triisopropylsiloxy)- 22,23-bishomopregn-5-ene (3.17 g, 4.52 mmol) in EtOAc (50 mL) stirred under nitrogen at O 0 C.
- Example 20 20S,3 ⁇ -(Triisopropylsiloxy)-22,23-bishomopregna-5,7-diene.
- the solvent was removed under reduced pressure at 45 0 C, and the residual partially solidified light yellow oil was sonicated, and kept at 4 0 C for 68 h.
- the solids were collected by vacuum filtration and rinsed with cyclohexane (1.0 mL) to give 7 ⁇ -bromo-3,0-(t- butyldimethylsilyl)pregn-5-en-3 ⁇ -ol-20-one (303.2 mg, 59.5%) as a pale yellow solid. A further amount (17.7 mg, 2.9%) was recovered from the mother liquors.
- Example 23 3,Q-(t-butyldimethylsilyl)-7 ⁇ -(4-chlorophenylsulf ⁇ nyl)pregn-5-en-3 ⁇ - ol-20-one m-Chloroperoxybenzoic acid (77%, 219.2 mg, 0.978 mmol) was added to a light yellow solution of give 3,0-(t-butyldimethylsilyl)-7 ⁇ -(4- chlorophenylthio)pregn-5-en-3 ⁇ -ol-20-one (567.3 mg, 0.989 mmol) in dichloromethane (5.0 mL) stirred under nitrogen at 0 oC.
- Example 29 3 ⁇ -(f-Butyldimethylsiloxy)pregna-5,7-dien-20-one.
- t-Butyldimethylsilyl chloride (76.4 mg, 0.507 mmol)
- 4-(NJV- dimethylamino)pyridine 4.5 mg, 0.037 mmol
- pyridine 0.1 mL
- 3 ⁇ -pregna-5,7-dienol-20-one 127 mg, 0.404 mmol
- DMF 0.5 mL
- reaction mixture was cooled on an ice bath for 15 minutes, and the solids were collected by Buchner filtration, rinsed with cold DMF, (1.0, 0.5 mL) and dried in a vacuum oven at 50 oC, to give 3 ⁇ -(t-butyldimethylsiloxy)pregna-5,7-dien-20-one (154.4 mg, 89.1%) as a white solid.
- Example 30 3 ⁇ -( ⁇ Butyldimethylsiloxy)-22-homopregna-5,7-diene-20R,22-epoxide.
- Potassium hexamethyldisilazane (2.49 g, 12.48 mmol) in THF (15 mL) was added to a slurry of trimethylsulfonium iodide (2.55 g, 12.48 mmol) in THF (15 mL) stirred under nitrogen at 25 0 C. The slurry was stirred 10 minutes, then toluene (10 mL) was added and the mixture was cooled to -7O 0 C in a dry ice / isopropanol bath for 15 min.
- Example 31 20R.3 ⁇ -( " t-ButyldimethylsiloxyV22-homopregna-5.7-dien-22-al.
- Example 32 20S,3 ⁇ - ⁇ Butyldimethylsiloxy)-22,23-bishomopregna-5,7,22-triene Methyltriphenylphosphonium iodide (405.6 mg, 1.0 mmol) and potassium hexamethyldisilazane (190.1 mg. 0.95 mmol) were stirred together in THF (2.0 mL) under nitrogen at 25 0 C, and then the bright yellow slurry was cooled to 0 0 C, and 20R,3 ⁇ -(t-butyldimethylsiloxy)-22-homopregn-5-en-22-al (133.0 mg, 0.30 mmol) in THF (3.0 mL) was added dropwise over 2 minutes.
- reaction mixture was diluted with hexanes (50 mL), and stirred with celite (1.0 g) at 0 0 C for 20 minutes.
- celite 1.0 g
- the reaction mixture was eluted through a small silica gel plug, and the solvent was removed under reduced pressure to give 20S,3 ⁇ -(t- butyldimethylsiloxy)-22,23-bishomopregna-5,7,22-triene (103.5 mg, 78%) as a pale yellow waxy solid.
- Example 33 One flask, 2 step, preparation of 20R,3 ⁇ -(f-butyldimethylsiloxy)-22- homopregna-5 ,7-dien-22-ol from 3 ⁇ -(t-butyldimethylsiloxy)-22-homopregna-5 ,7- diene-20R,22-epoxide.
- Triphenylphosphine (65.1, 65.4, 64.9 mg) was added in three batches at intervals of 10 minutes to a colourless solution of 20R,3 ⁇ -(£-butyldimethylsiloxy)- 22-homopregna-5,7-dien-22-ol (222.3 mg, 0.50 mmol), carbon tetrabromide (247.1 mg, 0.745 mmol) and collidine (103.2 mg, 0.852 mmol) in dichloromethane (5 mL), stirred under nitrogen at 25 0 C. The reaction mixture became a pale yellow solution, and 45 minutes after the first phosphine addition, celite (2 g) was added followed by hexanes (20 mL).
- nmr analysis shows about a 6:47:47 mixture of starting material (Compound 39), pre-Vitamin D isomer (compound 54), and Tachy-isomer (compound 55).
- 9-acetylanthracene (0.026 g, 0.118 mmol) was added to the solution and a uranium glass filter was placed in the lamp well, to cut off shorter wavelengths than 350 nm, and irradiation was continued at -1O 0 C for another 20 minutes, when nmr analysis showed almost complete disappearance of tachy isomer (55).
- the solution was then stripped to dryness to give crude 20S,6Z,3 ⁇ -(t-butyldimethylsiloxy)-22,23-bishomo-9,10- secopregna-5(10),6,8(9)-triene as a light yellow oil.
- Example 38 Thermal rearrangement of 20S,6Z,3 ⁇ -(t-butyldimethylsiloxy)-22,23- bishomo-9 J0-secopregna-5(10).6.8(9Vtriene to 20S.7Z.7E.3B-(f- butyldimethylsiloxy)-22,23-bishomo-9J0-secopregna-5,7,10(19)-triene.
- Example 41 (20S)- 1 ⁇ -(f-Butyldimethylsiloxy)-30-(t-butyldimethylsilvO-2- methylene- 19-nor-22,23-bishomopregnacalciferol n-Butyl lithium (1.6 M in hexanes, 3.3 mL, 5.28 mmol) was added dropwise over 5 min to a solution of P-(2- ⁇ [3S,5R]-3,5-bis(t-butyldimethylsiloxy)-4- methylidenecyclohexylidene ⁇ ethyl)diphenylphosphine oxide (3.45 g, 5.92 mmol) in THF (30 mL).
- Tetra-n-butylammonium fluoride hydrate (7.80 g, 30 mmol) was added to a solution of (20S)- 1 ⁇ -(£-butyldimethylsiloxy)-30-(£-butyldimethylsilyl)-2-methylene- 19-nor-22,23-bishomopregnacalciferol (1.72 g, 3.00 mmol) in THF (25 mL), stirred under nitrogen at 2O 0 C. A modest endotherm was noted, and the pale gray solution was stirred at 2O 0 C for a further 20 hours. The solution was concentrated under reduced pressure with slight heating, and the residual solution was added to water (50 mL) and was extracted with MTBE (50 mL).
- the steroids and Vitamin D derivatives disclosed herein may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like.
- a pharmaceutical formulation comprising a compound which may be made via this process and a pharmaceutically acceptable carrier.
- One or more compounds which may be made via this process may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients.
- compositions containing compounds which may be made via this process may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preservative agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques. In some cases such coatings may be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules, wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Formulations for oral use may also be presented as lozenges.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl- methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monoo
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- preservatives for example ethyl, or n-propyl p-hydroxybenzoate
- coloring agents for example ethyl, or n-propyl p-hydroxybenzoate
- flavoring agents for example ethyl, or n-propyl p-hydroxybenzoate
- sweetening agents such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- Pharmaceutical compositions of the invention may also be in the form of oil- in- water emulsions.
- the oily phase may be a vegetable oil or a mineral oil or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono-or diglycerides.
- fatty acids such as oleic acid find use in the preparation of injectables.
- compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter and polyethylene glycols.
- compositions which may be made via this process disclosed herein may be administered parenterally in a sterile medium.
- the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
- the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.0001 to 0.25%w/w, preferably, 0.0005-0.1% w/w and most preferably 0.0025- 0.05% w/w.
- the active ingredients may be employed with either paraffinic or a water-miscible ointment base.
- the active ingredients may be formulated in a cream with an oil- in- water cream base.
- the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane- 1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof.
- the topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs.
- the compounds of this invention can also be administered by a transdermal device.
- topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety.
- the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient.
- the encapsulating agent may also function as the membrane.
- the transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch.
- the oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner.
- the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
- a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat.
- the emulsifier(s) with or without stabilizer(s) make-up the so- called emulsifying wax, and the wax together with the oil and fat make up the so- called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
- Emulsif ⁇ ers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others.
- the choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low.
- the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
- Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
- Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients.
- suitable carrier especially an aqueous solvent for the active ingredients.
- the antiinflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w.
- the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration.
- the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
- Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
- Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
- the compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
- Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
- Dosage levels of the order of from about 0.000001 mg to about 0.01 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 ⁇ g to about 0.5 mg per patient per day).
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 ⁇ g to about 5 mg of an active ingredient.
- the daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.
- the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
- the composition may also be added to the animal feed or drinking water. It may be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It may also be convenient to present the composition as a premix for addition to the feed or drinking water.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Disclosed herein are methods for preparing steroids and Vitamin D derivatives having the unnatural beta (usually S) configuration at C20, the methods comprising the use of compounds of the formula: wherein R is as defined herein. Also disclosed are steroids and Vitamin D derivatives made using the methods disclosed herein and pharmaceutical compositions comprising said steroids and Vitamin D derivatives.
Description
Efficient Processes for Preparing Steroids and Vitamin D Derivatives with the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
FIELD OF THE INVENTION
Methods for preparing Steroids and Vitamin D derivatives with the unnatural beta (usually S) configuration at C20 from Pregnenolone are disclosed. The methods are used to synthesize (20S)-lα-hydroxy-2-methylene-19- norbishomopregnacalciferol and other related compounds. Several intermediates and pharmaceutical compositions comprising the steroids and Vitamin D derivates made using the methods disclosed herein are also described.
BACKGROUND OF THE INVENTION
In recent years certain steroid derivatives, but especially Vitamin D derivatives, have been shown to have very interesting biological properties if the 21- methyl group in the C17-steroidal side chain is inverted from the natural α, usually 2OR, configuration to the unnatural β, usually 2OS, configuration. There are many published ways of introducing the unnatural 2OS stereochemistry into steroids, but they all suffer from one (or more) of four problems. First, the starting material is expensive, or requires extensive chemical manipulation. Second, the synthetic procedure will be long, and require multiple chromatographies, thereby making the cost of goods produced through said synthetic scheme exorbitant. Third, the synthesis may contain steps or reagents that are not readily used on an industrial scale. And fourth, the synthesis may not provide the desired product in acceptable yields or stereochemical purity for use as a drug substance.
The Applicants disclose herein a chemical process for introducing the unnatural, usually S 20 methyl configuration (21-epi) into the C 17 steroidal side chain of steroidal 5,7-dienes, which are the precursors of Vitamin D and its many analogues. This method allows for the elaboration of the steroidal side chain in good overall yield and stereochemical purity, and utilizes a cheap steroid starting material, pregn-5-en-3β-ol-20-one, which is 1) available in ton quantities, 2) one of the cheapest steroids commercially available, and as a result 3) is an excellent starting material for industrial processes. The method further uses intermediates that are
solids, most of which can be purified to a high degree by recrystallization from commonly used industrial solvents, or by simple column chromatography.
Described herein are methods useful in converting pregn-5-en-3β-ol-20-one, and certain of its simple derivatives to a steroidal 5,7-diene with a partially or completely C20-homologated side chain with the unnatural β-confϊguration (usually S, 21-epi) of the C21 substituent (usually C21 methyl). This diene is then converted to the corresponding 21β-Vitamin D derivative, using a well established photochemical, and thermal process, which is used industrially on a very large scale to convert 7-dehydrocholesterol to Vitamin D3 and ergosterol to ergocalciferol. For some Vitamin D derivatives, this will complete the synthesis, but for many, especially those with non-natural A-ring moieties, the unwanted A-ring can now be removed oxidatively in a well established process to produce a Windhaus-Grundmann ketone, with the overall photolysis-rearrangement-ozonolysis sequence leading to a scission of the A and B rings and the C 8 position of the steroid being converted to a ketone. The desired A ring and seco-B ring can be added back using chemistry well established in the art, to make the desired, unnatural A-ring containing Vitamin D with the β-configuration at C21. Two sequences to make the desired steroidal diene are described, which differ in the order in which the double bond is introduced, and when the side chain construction is performed, are described herein. The processes are enabled by disclosing a full synthesis of (20S)-I α-hydroxy-2 -methylene- 19- norbishomopregnacalciferol, (Becocalcidiol). The use of this technology to make other known, and many novel Vitamin D and steroid derivatives is also revealed herein. Also described are some alternative ways of degrading C21-β steroids to Vitamin D precursors with retention of the C6 and C7 carbons.
SUMMARY OF THE INVENTION
For the production of (20S)-I α-hydroxy-2 -methylene- 19- norbishomopregnacalciferol, the sequence, which introduces the 7,8-double bond before elaborating the C17 side chain, is more efficient, and more convenient than the sequence, whereby the 7,8-double bond is introduced after the C17 side chain has been elaborated. Either variant of this method can be used to prepare a large number
of 20β-methyl (20-epi) Vitamin D derivatives, by simple extensions of the key processes described herein. For example, as described herein, an unmodified A ring Vitamin D precursor can be made and turned into the 3β-hydroxy Vitamin D analogue by simple photolysis and deprotection of the key C20 homologated pregna- 5,7-diene derivatives described herein. Or in another manifestation, by using chemistry obvious to one skilled in the art, one can convert pregn-5-en-3β-ol-20-one, or other suitable 20-ketosteriod precursor into an appropriately diprotected lα,3β- pregn-5-endiol-20-one derivative, which can then be 7,8-dehydrogenated using methods described herein, and then C20 homologated to the appropriate 20β-methyl (20-epi) steroidal 5,7-diene, which can be photo lysed and deprotected to give the desired lα,3β-20-epi Vitamin D analogue. Alternatively, the 3 β,20β- Vitamin D derivative can be lα-hydroxylated using an isomerization-allylic hydroxylation- reisomerization sequence. Another example of the utility of this method is to photo lyse the steroidal 5,7-diene produced by this process to the Vitamin D triene, and ozonize it, and then do a Lythgoe or Julia coupling on the resultant CD-ring ring Windaus-Grundmann ketone, to produce a 20-epi Vitamin D analogue with a non- natural A-ring substitution pattern. This latter exemplification of the method also provides the desired bicycle (below) in improved chemical yield and acceptable stereochemical purity over the currently published methods. A minor variation on this sequence allows for the C17 21-epi side chain to be built onto the steroidal nucleus, and the AB-ring scission is then carried out by ozono lysis of the steroidal monoene, followed by a Norrish type II photochemical cleavage to give a norsteroid which still contains C6 and C7 of the B-ring. This can then be converted to a 21-epi Vitamin D derivative by methods described in the literature.
In a broad aspect methods of converting pregnenolone (1) into (lR,7aR)-l- sec-butyl-7a-methylhexahydro-lH-inden-4(2H)-one (where R is H) and which has the following structure
or into derivatives thereof, where
R is alkyl, alkenyl, alkynyl, -O-alkanoyl, alkoxy, alkoxyalkoxy, -O-silyl (where the silyl group includes such groups as TMS, TBDMS, TPS, TIPS, and TBDPS), OH, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein each is optionally substituted with one or more groups that are independently alkyl, halogen, alkoxy, amino, monoalkylamino, dialkylamino, cyano, -O-trityl, -O- pivaloyl, or other alcohol protecting groups known in the art.
In another aspect, disclosed is the use of pregnenolone (1) to produce O- protected 20R,22-homopregnen-22-al (2) and O-protected 20R,22-homopregnen-22- ol (3) derivatives in good overall yield, and high diastereomeric purity at C20, where the protecting groups are preferably silyl ethers.
In another aspect, disclosed is the use of pregn-5-en-3β-ol-20-one (1) to produce 3, O-protected 20R,22-homopregna-5,7-dien-22-al (4) and 3,0 -protected 20R,22-homopregna-5,7-dien-22-ol (5) derivatives in good overall yield, and high diastereomeric purity at C20.
In another aspect, disclosed is the use of pregn-5-en-3β-ol-20-one (1) to produce pregna-5,7-dien-3β-ol-20-one (6) in a high yielding, short and convenient, synthetic process.
These compounds are useful in the production of unnatural C20 configuration, (usually S stereochemistry), steroid derivatives, especially Vitamin D derivatives.
These Vitamin D derivatives can also be elaborated from the key intermediates, (2), (3), (4) and (5) described herein, all of which contain the desired chirality at C20, using a wide variety of methods, for example as described in "Synthesis of Vitamin D (Calciferol)" Zhu, G.-D., Okamura, W. H. Chem. Rev., 95 1877-1952, (1995). In turn, the convenient and efficient synthesis of (2-5) from pregn-5-en-3β-ol-20-one is also described herein. For example, the aldehyde (2) may be homologated into a very wide variety of steroidal side chains, for example by being reacted with a Grignard reagent, or an olefmating reagent, or a primary or secondary amine and a reducing agent, or an enolate, etc., or reduced to alcohol (3) with an appropriate reducing agent. In turn, the alcohol moiety in (3) may be reacted to form an ether, or an ester, or it may be converted into a leaving group, such as a sulfonate ester or a halide and then reacted with a nucleophile, which may be used to install a C22-C23 carbon, nitrogen, oxygen, phosphorus or sulfur bond. Furthermore C22 halides (see below) can be transformed into C22 metal species, which further adds to the synthetic utility of this invention, using many electrophilic agents, obvious to one skilled in the art. Consequently, the above method affords a practical and cost effective entry into a vast array of possible C20-epi steroidal and Vitamin D side chains, each having its own unique biological activity. This concept is illustrated by a synthesis of the C20- epi-C22,C23- bishomopregnacalciferol precursor (lR,3αR,7αR)-7-methyl-l-([lS]- methylprop-l-yl)octahydroinden-4-one, and its subsequent conversion by known chemistry to (20S)-lα-hydroxy-2-methylene-19-norbishomopregnacalciferol but is not limited in any way to this particular manifestation.
Pharmaceutical compositions comprising the steroids and/or Vitamin D analogues made using the methods of the invention or compounds disclosed herein are also contemplated.
DETAILED DESCRIPTION
The conversion of the most suitable, commonly available and cheap steroids
(typical examples of which are illustrated above) into precursors for Vitamin D requires two separate sets of chemical transformation of the steroid. These steroids do not have a large C17 side chain, as natural steroid-cleaving Cyp enzymes degrade most steroids to either a C17 ketone (eg androgens, estrogen, DHEA) or to a C17 acetyl group, (eg pregnenolone, progesterone, possibly hydroxylated as in the corticosteroids). Therefore, the desired C 17 side chain has to be built up from the C17 keto or acetyl function. Herein we describe how to do that efficiently from the 17-acetyl group for compounds which have the unnatural β-(epi) methyl group at C20, although the methodology can be extended to include stereospecifϊc syntheses of the natural C20 configuration, as discussed herein. The other functionality crucial for Vitamin D synthesis by the usual commercial processes is a B-ring 5,7-diene, and this functionality is missing from all commonly available steroids, except for certain plant steroids, which do not contain a 17-keto or acetyl group. Therefore, this functionality also has to be introduced. There are techniques described in the literature to introduce this diene system either from the 5-ene steroids, or from the 3- oxo-4-ene steroids. Herein we describe how to introduce a C 17 side chain for 20- epi-steroids, and then subsequently, for specific Vitamin D analogue synthesis, introduce the 7,8-double bond, using the readily available and cheap 17-acetyl-5-ene steroid pregn-5-en-3β-ol-20-one, as illustrated in Scheme 1 below.
In a first aspect (Scheme 1), pregnenolone (also called pregn-5-en-3β-ol-20- one) (1)
(1) is used to prepare a compound of the formula:
where R is as defined above, the method comprising
a) reacting the 3 -hydroxy group of pregnenolone with a protecting group to form a compound of the formula:
b) converting the product from step a) into a compound of the formula:
c) converting the product from step b) into a compound of the formula:
d) converting the product from step c) into a compound of the formula:
e) converting the product from step d) into a compound of the formula:
f) converting the product from step e) into a compound of the formula:
g) converting the product from step f) into the desired product.
In an embodiment of the first aspect, R is methyl.
In another embodiment of the first aspect, PG is a Ci -C4 alkyl, benzyl or silyl group.
In still another embodiment of the first aspect, PG is a silyl group that is TBS, TES, or TIPS.
In an embodiment of the first aspect, when R is methyl, the product of step c) is converted to the product of step d) by treatment with CH2=S(CHs)2, in a solvent, at low temperature.
In another embodiment of the first aspect, R is Ci-C6 alkyl, C2-C6alkenyl, C2- C6 alkynyl, -O- C2-C6 alkanoyl, C1-C6 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, -O-TBS, - O-TIPS, -O-TES, OH, C3-C6cycloalkyl, phenyl, pyridyl, thiazolyl, pyrimidyl, piperidinyl, pyrrolidinyl, morpholinyl, wherein each (except for H) is optionally substituted with one or more groups that are independently alkyl, halogen, alkoxy, OH, amino, monoalkylamino, dialkylamino or cyano.
In yet another embodiment of the first aspect, the 3-hydroxyl protecting group is a silyl group (such as TIPS, TES, TBS or TMS), benzyl, or Ci-C4 alkoxy.
In another embodiment of the first aspect, R is methyl.
In another embodiment of the first aspect, R is suitably hydroxyl protected 3- hydroxy-3 -methylbutyl, 3 -hydroxy-3 -ethylpentyl, 2-( 1 -hydroxy cyclopenyl)ethyl, 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butyl.
In yet another embodiment of the first aspect, PG is a silyl group.
In yet still another embodiment of the first aspect, PG is t-butyldimethylsilyl (abbreviated as TBS or TBDMS), triethylsilyl (abbreviated as TES) or triisopropylsilyl (abbreviated as TIPS) group and R is methyl.
In another embodiment of the first aspect, the epoxidation of the product from step a) is carried out by treating the methyl ketone with methyl sulfonium ylide in a solvent. Suitable solvents include THF. The ylide can be generated from
dimethylsulfonium iodide or bromide and a strong base, such as KHMDS.
In another embodiment of the first aspect, the epoxidation of the product from step a) is carried out by treating the methyl ketone with methyl sulfonium ylide in a solvent at low temperatures in the range of about -4O0C to about -8O0C. Suitable solvents include THF -toluene mixtures.
In yet another embodiment of the first aspect, the conversion of the epoxide from step b) to the aldehyde is performed using a Lewis acid, such as BF3 etherate, BCl3, MgCl2, MgBr2, Al(OPO3, Ti(OPτt)4, titanocene dichloride, ZnCl2 etherate, GaCl3, and In(OTf)3 or Lewis acidic reagents (which cause the epoxide to rearrange to the aldehyde, and then react with the aldehyde in situ) such as MeMgBr, TMSCH2MgCl, TMSCH2MgBr, BH3/BF3, BH3/BC13, Tebbe reagent, Petasis reagent, and DIBAL-H. A preferred Lewis acid is MgBr2. Non-polar solvents, such as toluene are also preferred. Reaction temps between about -2O0C and O0C are also preferred. MgBr2, in toluene at about -1O0C is also preferred.
In still another embodiment of the first aspect, the aldehyde is optionally reacted with an olefmatmg reagent (such as methylenetriphenylphosphorane, ethylidenetriphenylphosphine, trimethylsilylmethyllithium, carbon tetrabromide/triphenylphosphine, 1 -lithiotrimethylphosphonoacetate, organometallic reagents such as the Grignard reagents, methylmagnesium bromide, methylmagnesium chloride, isopentyl magnesium bromide, phenylmagnesium iodide or bromide, vinylmagnesium bromide, and organolithium compounds such as methyl lithium, 2-thienyllithium, allyl lithium and phenyl lithium, a reducing agents, such as NaBH4, Ca(BH4)2, NaCNBH3 or LAH (in one embodiment, the epoxide rearrangement to form the aldehyde and the reduction of the aldehyde to an alcohol are performed in a one pot reaction, without isolation of the aldehyde); directed aldol reaction conditions, such as the use of preformed lithium, silyl or boron enolates, all well known to one skilled in the art. Additional specific examples of compounds, where PG or PG* is TBS, TIPS or acetate may be found below.
Furthermore, many Vitamin D derivatives, with the C19 methylene group, and possible lα-hydroxyls, can be made directly from the steroidal monoene and diene and the Vitamin D triene intermediates claimed in the scheme above. Much chemistry has been described in the Vitamin D area to modify the A-ring of steroidal Vitamin D precursors exactly analogous to those claimed above, and all of this
chemistry may be used with the current invention to produce 20-epi isomers of these known compounds. In such cases, examples of R include, but are not limited to, methyl, ethyl, 3-methylbutyl, 3-hydroxy-3-methylbutyl, 3-hydroxy-3-ethylpentyl, 2- (1 -hydroxy cyclopenyl)ethyl, 4,4,4-trifluoro-3-hydroxy-3-(trifluoromethyl)butyl, E,E,3-hydroxy-3-ethylpent-2-enyliden-l-yl, E-2R-2-cyclopropyl-2-hydroxyethyliden- 1-yl, with hydroxyls suitably protected using chemistry known in the art.
In still another embodiment of the first aspect, the 7-position is brominated with a brominating reagent, such as l,3-dibromo-5,5-dimethylhydantoin ("Bromantin", "DMDBH"), or NBS. DMDBH is a preferred brominating agent. The 7-bromo compound may then be subjected to base-induced dehydrobromination conditions, thereby generating the diene. Alternatively, the 7-bromo compound is reacted with an aryl sulfide (such as, for example 4-chlorophenylthiol) thereby forming a 7-thioether with is oxidized to the sulfoxide using an oxidizing agents, such as MCPBA or oxone. The sulfoxide is then heated in the presence of a base, such as TEA, Hunig's base, or pyridine, thereby generating the 5,7-diene.
In yet still another embodiment of the first aspect, the diene produced above is photolyzed first at a short wavelength, then at a longer wavelength, and then the resulting triene is thermally equilibrated, as is known in the art. The Vitamin D triene so produced may be the desired product or a protected form thereof, or it may be ozonolyzed to form the desired Windhau-Grundmann ketone product.
All references disclosed herein are incorporated by reference.
We also describe a variation of this method using pregn-5-en-3β-ol-20-one in the synthesis of 20-epi-Vitamin D derivatives, which introduces the double bond before the C17 side chain is elaborated (see Scheme 2, below).
Alternatively, in a second aspect, pregnenolone (1) can be used to produce a compound of the formula (Scheme 2):
where R is as defined above, via a method comprising
a) reacting the 3 -hydroxy group of pregnenolone with a protecting group to form a compound of the formula:
d) optionally (if necessary for removal or exchange of the protecting group, the need for which is understood by one of skill in the art) converting the product from step c) into a compound of the formula:
e) optionally (if necessary for exchange of the protecting group converting the product from step d) into a compound of the formula:
f) converting the product from step e) into a compound of the formula, where PG and PG* may be the same or different:
g) converting the product from step f) into a compound of the formula:
In a further embodiment, the first and second aspects also entail reducing the ketone of the formula:
O to an alcohol of the formula: OH by treatment with a reducing agent. The reducing agent may be LAH, NaBH4, Ca(B H4)2, or a transition metal catalyst and hydrogen.
In yet another embodiment of the second aspect, PG is a silyl group, Ci-C4
alkyl (such as methyl), benzyl optionally substituted with one or two OCH3 groups, or an alkanoyl protecting group and PG* is a silyl protecting group.
In still another embodiment of the second aspect, PG is acetate and PG* is the t-butyldimethylsilyl group.
In yet still another embodiment of the second aspect, PG is acetate and PG* is the t-butyldimethylsilyl group and R is methyl.
In another embodiment of the second aspect, when R is methyl, the epoxidation of the product from step e) is carried out by treating the methyl ketone with methyl sulfonium ylide (CH2=S(CHs)2) in a solvent. Suitable solvents include THF. The ylide can be generated from dimethylsulfonium iodide or bromide and a strong base, such as KHMDS. The reaction is also performed at low temperature, such as about -8O0C to about -2O0C, optionally in the presence of a cosolvent, such as toluene.
In still another embodiment of the second aspect, the solvent is THF and PG* is a TBDMS or TIPS group.
In yet another embodiment of the second aspect, PG is acetate and PG* is TIPS.
In still another embodiment of the second aspect, PG and PG* are both TBS or TIPS.
The synthetic sequences from the first and second aspects can be used to make the following compounds:
Both the sequences shown in Scheme 1 and Scheme 2 have been used to prepare 20S,3β-(trialkylsiloxy)-22,23-bishomopregna-5,7-dienes (15) and (39), the key steroidal diene intermediates for the synthesis of (20S)-lα-hydroxy-2-methylene- 19-norbishomopregnacalciferol (52) (Becocalcidiol). In this synthesis it is advantageous to introduce the 7,8-double bond directly into pregnenolone rather than into the fully C17-elaborated steroid, as this order is more efficient overall, as well as operationally simpler to carry out, making Scheme 2 preferable to Scheme 1.
In another aspect, disclosed herein is a method of preparing 20S-lα-hydroxy- 2-methylene-22,23-bishomopregnacalciferol comprising reacting
One of skill in the art will appreciate that silyl groups, such as TIPS could be used instead of TBDMS.
The methods of the first and second aspects may be used to make the compounds of the formulas:
These compounds may be used to make the compounds of disclosed in this paper.
The methods of the first and second aspects may be used to make the compounds of the formulas:
The methods of the first and second aspects may be used to make the compounds of the formulas:
The methods of the first and second aspects may be used to make the following compounds:
The methods of the first and second aspects may be used to make the compounds of the formulas:
One of skill in the art will appreciate that the TBS groups (above) may be replaced with a TIPS group and that the TMS group may be replaced with TBS, TES, MEM, or Ci-C6 alkoxy.
The methods of the first and second aspects may be used to make the compounds of the formulas:
The methods of the first and second aspects may be used to make the compounds of the formula:
The methods of the first and second aspects may be used to make the compounds of the formula:
The methods of the first and second aspects may be used to make the compounds of the formulas:
where R = TMS, Trityl, TBDMS, pivaloyl, TPS, TIPS, TBDPS, or other alcohol protecting groups known in the art and where R2 may also be H.
The methods of the first and second aspects may be used to make the compounds of the formula:
where R2 = TMS, Trityl, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups known in the art and where R2 may also be H.
The methods of the first and second aspects may be used to make the compounds of the formula:
where R2 and R3 are different, and drawn from the group; H, TMS, Trityl, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups, in such a combination that
R2 can be removed in the presence of R3, which are known in the art.
The methods of the first and second aspects may be used to make the compounds of the formula:
where R = TMS, acetate, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups known in the art and where R3 may also be H.
The methods of the first and second aspects may be used to make the compounds of the formula:
where R = TMS, acetate, TBDMS, pivaloyl, TPS, TBDPS, or other alcohol protecting groups known in the art and where R3 may also be H.
Further disclosed are pharmaceutical compositions comprising steroids and Vitamin D derivates made using the method of the first or second aspects and at least one pharmaceutically acceptable carrier, excipient, adjuvant or glidant.
Further disclosed are pharmaceutical compositions comprising the following compounds:
The methods of the first and second aspects may be used to make the compounds of the formula X:
R1, R2, R3 and R4 are each independently C1-C4 alkyl, C1-C4 deuteroalkyl, hydroxyalkyl or haloalkyl;
R5, R6 and R7 are each independently OH, OC(O)Ci-C4 alkyl, OC(O)hydroxyalkyl or
OC(O)haloalkyl;
Xi is CH2;
Z is H, OH, =0, SH or NH2.
The methods of the first and second aspects may also be used to prepare compounds
of formula X, wherein R7 is OH, and R1, R2, R3 and R4 are each independently C1-C4 alkyl, hydroxy C1-C4 alkyl or Ci-C2 haloalkyl.
The methods of the first and second aspects may also be used to prepare stereospecifically at C20 compounds of formulas:
DEFINITIONS
The term "aryl" refers to an aromatic hydrocarbon ring system containing at least one aromatic ring. The aromatic ring may optionally be fused or otherwise attached to other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings. The aryl groups herein are unsubstituted or, as specified, substituted in one or more substitutable positions with various groups. Preferred examples of aryl groups include phenyl, naphthyl, and anthracenyl. More preferred aryl groups are phenyl and naphthyl. Most preferred is phenyl.
The term "cycloalkyl" refers to a C3-Cg cyclic hydrocarbon. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
The term "heterocycloalkyl" refers to a ring or ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur, wherein said heteroatom is in a non-aromatic ring. The heterocycloalkyl ring is optionally fused to or otherwise attached to other heterocycloalkyl rings and/or non-aromatic hydrocarbon rings and/or phenyl rings. Preferred heterocycloalkyl groups have from 3 to 7 members. Examples of heterocycloalkyl groups include, for example, 1,2,3,4- tetrahydroisoquinolinyl, piperazinyl, morpholinyl, piperidinyl, tetrahydrofuranyl, pyrrolidinyl, pyridinonyl, and pyrazolidinyl. Preferred heterocycloalkyl groups include piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, and dihydropyrrolidinyl.
The term "heteroaryl" refers to an aromatic ring system containing at least one heteroatom selected from nitrogen, oxygen, and sulfur. The heteroaryl ring may be
fused or otherwise attached to one or more heteroaryl rings, aromatic or non-aromatic hydrocarbon rings or heterocycloalkyl rings. Examples of heteroaryl groups include, for example, pyridine, furan, thienyl, 5,6,7,8-tetrahydroisoquinoline and pyrimidine. Preferred examples of heteroaryl groups include thienyl, benzothienyl, pyridyl, quinolyl, pyrazolyl, pyrimidyl, imidazolyl, benzimidazolyl, furanyl, benzofuranyl, dibenzofuranyl, thiazolyl, benzothiazolyl, isoxazolyl, oxadiazolyl, isothiazolyl, benzisothiazolyl, triazolyl, pyrrolyl, indolyl, pyrazolyl, and benzopyrazolyl. More preferred heteroaryl rings include pyridyl, pyrrolyl, thienyl, and pyrimidyl.
A. Hydroxyl Protection of Pregn-5-en-3β-ol-20-one As described above, in one aspect the invention provides the use of pregnenolone (1) to produce O-protected 20R,22-homopregn(adi)en-22-als (2 & 4) and O-protected 20R,22-homopregn(adi)en-22-ols (3 & 5) derivatives in good overall yield, and high diastereomeric purity at C20. Generally, the alcohol protecting groups described in Protecting Groups in Organic Synthesis by Greene, may be used in this process if compatible with the next two steps, but in a preferred aspect, the protecting group, PG, is a silyl protecting group. Both the t-butyldimethylsilyl (TBDMS or TBS) ether (7) and the triisopropylsilyl (TIPS) ether (8) are especially preferred and are relatively inexpensive. Moreover, many other protecting groups, especially other silyl ethers such as t-butyldiphenylsilyl (TBDPS) and phenyldimethylsilyl (PDMS), are also useful. While still useable, ester protecting groups tend to be cleaved by the preferred nucleophilic epoxidizing agent used in the key step to set up C20 stereochemistry, and further limit the chemistries which may be used to elaborate key intermediates (4) and (5). The TBDMS ether (7) was obtained in excellent purity and 98% yield by direct crystallization from the reaction mixture. TIPS ether (8) was not quite as easy to obtain, and yet was obtained in 84% yield after recrystallization, or about 90% yield after column chromatography, and these protecting groups proved very satisfactory when the C 17 side chain was introduced first, as shown in Scheme 1. However, when the 7,8-unsaturation was introduced first, the preferred base proved to be fluoride ion (see below), and for both cost and convenience, pregnenolone acetate (9) was used as the starting material, and a switch was made to the TBDMS ether at a later stage in the synthesis. Pregnenolone acetate can be made from pregnenolone in above 99% yield, or bought
commercially. Other protecting groups which may be used at the 3 -hydroxy include methyl (produced by solvolysis from the corresponding sulfonates), benzyl and allyl (which may be derived from the corresponding O-substituted trichloroacetimidates).
(7) (8) (9)
B. Introduction of the 7,8-Double Bond to Pregn-5-en-3β-ol-20-one and
22,23-Bishomopregn-5-en-3 β-ol Derivatives
The O-protected pregnenolone derivatives, (7-9) described above can all be allylically brominated by a variety of brominating agents at the 7-position to give bromides (10), as described in the literature. Numerous bases are described to dehydrobrominate (10) to the corresponding protected dienone (11). As this transformation is usually described for the conversion of O-protected cholesterol derivatives into 7-dehydrocholesterol derivatives, it should be especially suitable to the conversion of protected 22,23-bishomopregn-5-en-3β-ol derivatives (12) to the corresponding bromides (13), which can then be eliminated to the desired diene (14).
(12) (13) (14)
This reaction sequence has three major drawbacks. The first is that the 7α- bromide is the only one set up to eliminate properly, that is transdiaxially to H8β, and bromination of different steroids can give very variable 7α/β mixtures, sometimes
with the unwanted equatorial β-isomer predominating. The use of a soluble bromide source (such as tetra-n-butylammonium bromide (TBAB)) in a suitable solvent equilibrates the two bromides, and such equilibria generally favour the desired α- (axial) isomer by 2.5-4: 1 ratios, ameliorating this problem considerably. This problem is exacerbated by the fact that these α/β mixtures of bromides are often very difficult to reliably quantitate, even by highfield proton nmr.
The second problem is that a lot of the literature describing these reactions is very old, and the analytical techniques used did not always distinguish the desired 5,7-diene product, a product of an expected trans-diaxial 1 ,2-elimination, from the unexpected trans-diaxial 1 ,4-elimination, which leads to the unwanted 4,6-diene. Molecular modeling shows that the 8β-proton, which is the proton extracted in the desired 1 ,2-elimination, is considerably more hindered by the β-methyls Cl 8 and C19 than is the 4β-proton, abstraction of which leads via 1 ,4-elimination to the 4,6-diene. We have found literature reaction conditions which can produce almost exclusively the 4,6-diene when applied to some steroidal precursors. Other side products were often not detected in the older literature, and often they cannot be reliably removed by crystallization, or chromatography.
The third problem is that the allylic bromides (10, 13) are rather unstable, and the range of reagents and solvents usable with the 7-bromides is very limited. For example, the bromides cannot be purified by normal phase silica gel chromatography, and the base/solvent combinations to do the 7,8-elimination are rather limited. This is especially true for pregnenolone derivatives, which have a tendency to epimerize at C 17, and/or enolize at C21, when treated with very strong bases. We examined a variety of bases on 7-bromopregnenolone derivatives, and found that many bases induced no elimination under conditions close to causing carbonyl-related problems, or when they did eliminate, there were unacceptably high, sometimes even major, amounts of the 4,6-dienes produced. In fact this latter point led to the development by Confalone et al. (Confalone, P. N., Kulesha, I. D., Uskovic, M. R. J. Org. Chem. (1981), 46, 1030-2.) of a three step conversion of the 7α-bromide into the corresponding 5,7-diene, which involves displacement of the bromide by an aryl thiol, to form a thioether, oxidation of said thioether to the corresponding sulfoxide, and a pyro lytic sulfoxide elimination to form the diene specifically in the 5,7-
position. This four step reaction sequence can work in around 50% yield, and produce very clean 5,7-dienes. This is towards the upper end of reported yields for sequences involving a direct bromination-dehydrobromination, which generally work in 35-50% overall yields. We have found that this sequence works reasonably well in a Scheme 1 based preparation of 2OS, 3β-(triisopropylsiloxy)-22,23-bishomopregna- 5,7-diene, (15, (14, PG = TIPS)), converting the corresponding monoene (16, (12, PG = TIPS)) into (15) in up to overall 50% yield, as illustrated in Scheme 3. However, the initial bromination to make (17) is difficult to monitor, and highly reproducible conditions for pushing the reaction to completion were not found. The 7α:7β bromination ratio appeared to be rather unfavorable, although the crude nmrs generally look as though they contain predominantly a single isomer. However, direct reaction of the crude bromide with 4-chlorothiophenol gave a complex mixture, where the major component is not the same as that seen if a TBAB equilibration step is included, and where the desired β-thioether (18) is clearly not the major species present. Thiol displacement, after TBAB equilibration, as demonstrated by an axial H7-proton at 3.3 lδ, with an 8.5 Hz coupling constant, gives the β-thioether (18) in good yield with only 10-15% of the unwanted α-isomer being present. Oxidation to the sulfoxide (19) could be carried out satisfactorily with mCPBA, although both diastereoisomeric sulfoxides were produced, as described by Confalone. The thermolysis to (15) went smoothly, although again as described by Confalone, the minor diastereoisomeric sulfoxide decomposes a lot more slowly than the major one. However, removal of the disulfide byproducts, and unreacted (16) proved very difficult. Because this double bond introduction involves the lowest yielding reactions in the entire sequence, it was decided to examine carrying it out earlier, where comparable material losses should be less costly.
Scheme 3. 7,8-Dehydrogenation of C22,C23-bishomopregnenol TIPS ether via the Confalone Sulfoxide route.
In order to make the overall process more cost effective, we examined the allylic C7 bromination of pregnenolone derivatives, with the intention of following a Scheme 2 sequence, whereby the 7,8-double bond was introduced prior to C17 side chain elaboration. One can envision using this sequence on a silyl-protected pregnenolone derivative such as TBDMS-pregnenolone (7), to produce the most desired O-silylpregnadienone derivative (20, (11, PG = TBDMS)) (see below). Literature on the bromination of pregnenolone derivatives is very sparse, but a bromination-dehydrobromination sequence on pregnenolone acetate (9), which works in around 50% yield has been described (Siddiqui, A. U., Wilson, W. K., Swaminathan, S., Schroepfer, G. J. Chemistry and Physics of Lipids, (1992), 63, 115- 129).
We have examined the sequences, shown in Schemes 4 and 5, in order to introduce the 7,8-double bond early in the sequence. Although the desired final product from this sequence for the 20-epi derivatives is the silyldienone (20), the shortest route involving the bromination of silylether (7), followed by base-induced dehydrobromination was not deemed practical, as the only base we found which produced a high enough 5,7- over 4,6-diene selectivity was fluoride ion, which also removes the TBDMS group. Thus the product will be the free dienol (21), which would have to be resilylated to make (20). This not only introduces an extra step, but it also means doing two protections with a rather expensive protecting group, TBDMS chloride, and it uses up an extra equivalent of the rather expensive base TBAF. Therefore, we examined the Confalone procedure with silyl ether (7), and chose to examine the acetate (9) with the base-induced double bond introduction, as
the acetate is very cheap, easy to put on, and will not require extra fluoride in the elimination. However, the need to change protecting groups does add two extra steps, even if the yields are very good.
Scheme 4. 7,8-Dehydrogenation of Pregn-5-en-3β-ol-20-one TBDMS ether via Conf alone Sulfoxide route.
Bromination of silylpregnenolone (7) with l,3-dibromo-5,5- dimethylhydantoin ("Bromantin", "DMDBH") went smoothly, afforded a relatively clean 7-bromide product assigned as (22). Although the product is not stable to thin layer chromatography (tic), and shows multiple spots, all major ones are slower than (7), allowing reaction completion to be monitored. NMR analysis of the crude reaction mixture is suggestive that one isomeric bromide greatly predominates, and that the second isomer, if present at all, is one of several minor (<10%) impurities. As discussed above, this apparent selectivity was also seen with the bromination of (16), but did not appear to reflect the true ratio, which was worse than 1 :1. However, in this case, the "Confalone" analysis, done once the bromide had been displaced by a thiol, but without any form of bromide equilibration, suggests that the 7α:7β bromide ratio is usually >10:l, which is at least as good as one would get after equilibration. Although this crude mixture appears to be quite clean by nmr, carrying it on without purification at this step led to lower overall yields than expected. Both attempts to purify the sulfide, or to carry the crude mixture through the remaining reaction sequence to diene (20), led overall to lower yields than expected, and best yields of (20) from (7) were around 35%. Therefore, crystallization of bromide (22) was examined. The crude product tends to partially solidify, but simple recrystallization tends to give less than 50% yield of (22). However, careful examination of
crystallization conditions allowed for bromide (22) to be isolated in 65% yield in over 90% purity. Reaction of this bromide with 4-chlorothiophenol led to the sulfide (23) in 92.7% yield. This could be oxidized to a diastereoisomeric mixture of sulfoxides (24) in 82% yield, and this in turn yielded the diene (20) in 80.6% yield after a gentle pyro lysis at 70 0C, in the presence of triethylamine, for an overall yield of 40% from
O)-
Scheme 5. 7,8-Dehydrogenation of Pregn-5-en-3β-ol-20-one to Pregna-5,7- dien-3β-ol-20-one (21) via Base-induced dehalohalogenation.
A study of the bromination of pregnenolone acetate (9) demonstrated that it is also readily brominated at the 7-position by 0.65 molar equivalents of Bromantin in degassed cyclohexane with moderate heating (55-75 0C) to form mainly 7α- bromopregnenolone acetate (25) as reported by Siddiqui et al. (Siddiqui, A. U., Wilson, W. K., Swaminathan, S., Schroepfer, G. J. Chemistry and Physics of Lipids, (1992), 63, 115-129). NMR spectra of the crude reaction products suggest that this product is formed in 85-90% yield, with very little of the unwanted 7β-bromide. NMR analysis of the thiol displacement product(s) also indicates a 7α:7β ratio of at least 10:1. Again the instability of the bromide product (25) to silica gel, makes analysis of the reaction by tic difficult, but it does allow one to monitor for the disappearance of starting material reliably. Once the reaction is essentially complete by tic, the reaction mixture is filtered hot to remove unreacted dibromantin and the 5,5-dimethyl hydantoin side product. This solution can be stripped to dryness to give the bromide (25) as a solid white to light yellow foam in crude quantitative yield, which appears to be 85-90% pure by nmr spectroscopy. As with the TBDMS ether,
use of this material crude led to much lower yields than expected in later steps, and it was also found advantageous to crystallize bromide (25). As the reaction mixture is concentrated to the 0.5-1.0 M range under reduced pressure, 7α-bromopregnenolone acetate (16) of 95-99% purity starts crystallizing out. However, this process does not produce much above 50% of (25), and further crystallizations of the mother liquors are required to get the yields of (25) up to 68-75%.
The tetra-n-butylammonium fluoride (TBAF) induced dehydrobromination reaction on 7α-bromopregnenolone acetate (25) as described by Siddiqui et al. (Siddiqui, A. U., Wilson, W. K., Swaminathan, S., Schroepfer, G. J. Chemistry and Physics of Lipids, (1992), 63, 115-129) was examined. Treatment of recrystallized 7α-bromopregnenolone acetate (25) with three equivalents of TBAF solution in THF at temperatures between 0 0C and reflux, for times between five minutes and three hours leads to complete loss of the starting material. Depending on the quality of the starting bromide and the TBAF solution, which appears to be mainly a question of how dry the solution is, pregna-5,7-dien-3β-ol-20-one acetate (27) is obtained in 70- 98% purity, and 90-96% crude yield. For use in making 20-epi-Vitamin D derivatives, the acetate group does not appear to be as desirable as using silyl ether protecting groups. Therefore the acetate group needs to be cleaved, which can be done in very high yield with methanol and catalytic solid potassium carbonate to give pregna-5,7-dien-3β-ol-20-one (21). This route is shown in Scheme 5, and results in overall yields of (21) from pregn-5-en-3β-ol-20-one (1) of 50-65%.
A very useful extension of this methodology is revealed herein, whereby the elimination and deesterification steps are combined together. Thus, upon completion of the TBAF elimination reaction, the reaction mixture is treated with at least an equal volume of methanol, and a molar excess of potassium carbonate over the originally added TBAF. After a few hours stirring this mixture at 25 0C, the reaction can be quenched with excess ice-water, and the crude pregna-5,7-dien-3β-ol-20-one can be collected in 90-95% overall yield by a simple Buchner filtration. The material obtained is of about 90% or better purity, and can be used without purification.
Although acetate (26) is not useable in the chemistry described below, and alcohol (21) can only be used in said chemistry after being suitably protected, these two compounds are useful intermediates in a wide variety of other steroid/Vitamin D
syntheses, as they combine a B-ring diene and a readily modified C 17 side chain, and are obtained in very few steps, and good overall yields from pregn-5-en-3β-ol-20-one (1). Pregna-5,7-dien-3β-ol-20-one (21) can be protected on the alcohol oxygen using many different protecting groups, as described in Protective Groups in Organic Synthesis 3rd Edn. by Greene and Wuts. The B-ring 5,7-diene system can be modified in many different ways, especially oxidatively to produce a wide variety of biologically active steroids with highly functionalized, or even cleaved B-rings.
Silylation of pregna-5,7-dien-3β-ol-20-one (21) can be carried out conveniently with t-butyldimethylsilyl chloride and pyridine with DMAP catalysis in DMF in the temperature range 25-55 0C. By running this reaction rather concentrated, the desired product, 3O-(t-butyldimethylsilyl)pregna-5,7-dien-3β-ol-20- one (20) precipitates in good yields, 80-93%, and with a considerable increase in purity over the starting alcohol. If the starting alcohol is >90% pure this allows for the product to be obtained directly from the reaction mixture in >98% purity, which is adequate for the succeeding chemistry without need of further purification.
C. Introduction of the C17-rS1.2-Butyl Side Chain to Pregn-5-en-3β-ol- 20-one and Pregna-5,7-dien-3β-ol-20-one Derivatives
(27) (28) (29)
The 3-THP ether of pregnenolone is reported to react with dimethylsulfonium methylide in DMF at room temperature to produce the corresponding 20[S]-epoxide (Koreeda, M.; Koizumi, N. Tetrahedron Letters, 19, 1641-4, (1978)). We examined this reaction by nmr, and found that it appears to have a diastereoselectivity of around 19:1 for 20[S]:20[R]. However, it is difficult to be confident of that ratio, as the THP
itself introduces an uncontrolled chiral center. This reaction has two further disadvantages. Both the steroid and the ylide are sparingly soluble in DMF, and the reaction is very slow, taking up to a week to go to completion. This requires a very concentrated reaction mixture, and one ends up with a thick paste, which is difficult to stir even on a small scale.
To overcome this problem, we examined several different protected pregnenolone derivatives, different solvents, and increasing the reaction temperature. Apart from a slight improvement by using N-methylpyrrolidone, all other solvents examined failed to improve the reaction, dilution slowed the reaction drastically, and heating led to predominant production of unwanted side products. The only 3- derivative which gave comparable results to the THP-ether was the methoxyethoxymethyl (MEM) ether, and this confirmed the diastereoselectivity ratio at C20 to be around 15:1. Most other 3 -derivatives were either cleaved (most esters) by the ylide, or reduced the solubility of the steroid in DMF and NMP so much that virtually no reaction occurred.
Most nucleophiles do not attack the carbonyl of pregnenolone with a very high diastereo facial selectivity, so the good diastereoselectivity of the sulfonium ylide attack is on the face of it rather surprising. However, dimethylsulfonium methylide is a rather stable anion, and its addition to ketone carbonyls is generally reversible. This means that the reaction can come under thermodynamic, rather than kinetic control, but one would not expect the final diastereoisomeric epoxides to differ appreciably in stability. However, when one examines the rather rigid transition state, required to convert the intermediate betaine into the corresponding epoxide, it becomes evident that the transperiplanar geometry required for the alkoxide, and dimethylsulfonium leading groups can only be accommodated in a single conformation. In this conformation, the transition state for the minor [S]-epoxide has a severe steric clash between the Cl 8 and C21 methyl groups, whereas the [R]-epoxide transition state avoids this interaction completely. This suggests that the diastereoselectivity arises because only the [R]-epoxide forming transition state is readily attainable, and carbanion addition from the si-face attack is likely to reverse more readily than it is to go to the epoxide thermodynamic sink.
As dimethylsulfonium methylide is rather less stable, and hence a more reactive anion, than its sulfonium analogue, one would expect the initial carbonyl
addition to be less readily reversed, and consequently, one would expect the diastereoselectivity to be more affected by the initial nucleophilic attack, and hence rather poorer. Surprisingly, when we examined the reaction of 3- tetrahydropyranylpregnenolone with dimethylsulfonium methylide at room temperature in THF, the diastereoselectivity of epoxide formation was almost as good as was seen with the sulfonium ylide.
The protected alcohol-ketones (7), (8) and (20) were also converted into the epoxides (27)-(29) using the ylide derived from triimethylsulfonium iodide. A wide variety of strong bases, obvious to one skilled in the art will produce this ylide from trimethylsulfonium iodide or bromide, exemplified by, but not limited to, potassium hexamethyldisilazane. These reactions were complete in 10 minutes at room temperature in THF and the reactions were homogenous solutions, with some salt precipitation, without any of the stirring problems seen with the sulfonium ylide. The surprisingly good diastereoselectivity seen with the THP derivative was also seen in these cases, and these reactions, for which no workable conditions were found at all with dimethylsulfonium methylide, were simple to do and very high yielding.
Upon using the TBS or TIPS protecting group and lowering the reaction temperature, the reaction between the ylide derived from dimethylsulfonium iodide and the TBS or TIPS protected pregn(adi)enolone affords a product that is increasingly clean, diastereoselective, and high yielding. For example, in a dry ice- isopropanol bath, epoxides (27)-(29) are produced with diastereoselectivities in the 40-55:1 range, and yields above 90% with overall reaction times of a few hours. The rather poor low temperature solubility of these substrates in ethereal solvents makes the use of a cosolvent, preferably toluene, essential for this reaction to run well. Furthermore, if desired, the epoxides can be recrystallized to much higher diastereomeric purities, using solvents obvious to one skilled in the art. For example a C20 R: S ratio in of the range of 200:1 was obtained after a single recrystallization from acetone at 0 0C, in an overall 75% yield for epoxide (27). However, despite the excellent diastereoselectivities available after recrystallization, it appears to be most advantageous to accept the high crude yields in this step, and to purify compounds later in the sequence. Due to major differences in the chemical shifts of the C22 (epoxide) protons, and the C18-methyl protons between the two diastereoisomers, their ratios are readily determined by nmr to better than 0.5% accuracy.
Before converting protected alcohol-ketones (7), (8) and 20) into epoxides (27), (28) and (29), the C21 -methyl side chain may be elaborated by generating a kinetic enolate via C21 proton abstraction, using a base, such as LDA, NaHMDS, KHMDS or others as known in the art in a solvent, such as THF, usually at low temperature, and then reacting the enolate with an electrophile as shown in Scheme 6. (Konopelski, J. P., Djerassi, C. J. Med. Chem., 23, 722-6, (1980).) Examples of such reactions include, enolate alkylation, directed Claisen reactions, the directed aldol reaction, the Mukaiyama aldol reaction, the Michael reaction and others. The resulting compound may then be converted diastereoselectively into the C20-C22 epoxide as described above, and further elaborated at C22, as described below.
Scheme 6. Preparation of C21 -extended Precursors for later incorporation into C21 -extended Steroids and Vitamin D derivatives.
In scheme 6, the R group may be the same or different and is selected from methyl, ethyl, isopropyl, tert-butyl and phenyl. Preferred R3Si groups include TBDMS, and TIPS.
The conversion of the epoxides (27)-(29) to aldehydes (30)-(32) is performed using a Lewis acid. This reaction is neither stereospecifϊc nor chemospecifϊc, and at least three products other than the 20-R aldehyde are produced in this reaction,
regardless of which epoxide is used. The undesired S-aldehyde (33) is present as 2- 45% of the mixture, and simple halide induced SN2 opening of the epoxide to form a halohydrin (34) consumes 0.5-15% of the epoxide, and an apparently base-induced epoxide opening to 1-10% of an allyl alcohol (35) also occurs. A wide variety of Lewis acids have been examined for this transformation in the monoene series; BF3 etherate, BCl3, MgCl2, MgBr2, MgI2, Al(OP^)3, Ti(OPr'^, titanocene dichloride, ZnCl2 etherate, GaCl3, and In(OTf)3. Additionally, various Lewis acidic reagents, which should cause the epoxide to rearrange to the aldehyde, and then react with the aldehyde in situ were also examined in the monoene series; MeMgBr, TMSCH2MgCl, TMSCH2MgBr, BH3/BF3, BH3/BC13, Tebbe reagent, Petasis reagent, and DIBAL-H. Almost all of these reagents gave the desired products, and often in good overall yields, but none were judged stereoselective enough to be used preparatively, with DE's of -33-85% being obtained. The optimal Lewis acid for this transformation was found to be magnesium bromide, used as the solid bis-diethyl etherate. This was then optimized for solvent, stoichiometry, and temperature. The optimal conditions for all three epoxides (27), (28) and (29) were found to be with toluene as solvent, 0.2-0.5 equivalents of the Lewis acid, and temperatures in the -10 to 0 0C range, which 1) consistently afforded a C20 R: S ratio of 25:1 or better, and 2) reduces the production of the byproducts to about 5%. We have found that C20 R:S diastereomeric ratios of 15-20:1 can be obtained using unpurified epoxides (27)-(29) in the reaction mixture, and that the diastereomeric purity of the product can be raised up to about 65:1 20R:S for TBDMS aldehyde (30), and 35:1 for TIPS aldehyde (31) after a single recrystallization from acetone or isopropanol respectively in approximately 70% yield. A second recrystallization gave (30) in a >200: 1 , and (31) in a 65:1 C20 R:S ratio, both in at least 55% yield. Repeated recrystallization of the mother liquors of (30) added another 10.8% of diastereoisomerically enriched (C20 R: S ratio 100:1) material. With aldehyde (32) we did not pursue recrystallization in the same degree of detail, although it also recrystallizes well from acetone, because a better purification was found at the next step. As a result of the above optimizations, diastereomerically enriched material (20R:S >200:l) can be obtained in 3-steps and 65% yield (compound (30)) and over 40% yield (compound (31)) respectively.
Aldehydes (30), (31) and (32) are very valuable intermediates for synthesis of pharmaceuticals with the unnatural, 20β configuration. A great deal of chemistry has
been developed to elaborate the C22 S-aldehyde position, which is usually obtained by oxidative cleavage of ergosterol, and most of that chemistry could be used on R- aldehydes (30)-(32) (Kutner, A., Perlman, K. L., Sicinski, R. R., Phelps, M. E., Schnoes, H. K., DeLuca, H. F. Tetrahedron Letters, (1987), 28, 6129-6132). From this literature, it is known that many different nucleophiles can be added to the C22 aldehyde, without any epimerization of C20, and these intermediates can be elaborated to steroidal-5,7-diene precursors of Vitamin D analogues via full elaboration of the C 17 side chain by methods known to those skilled in the art.
For example, use of a Wittig reaction or other olefmation reagents on 20R,3β- (t-butyldimethylsiloxy)22-homopregna-5,7-dien-22-al (19) will lead to extended steroidal side chains with a C22-C23 double bond, which in turn can be elaborated in many fashions, if so desired. As an illustration, for the purpose of synthesizing Becocalcidiol, reaction of aldehydes (30) and (32) with methylenetriphenylphosphorane leads to 20S,3β-(£-butyldimethylsiloxy)22,23- bishomopregna-5,21-diene (36), and 20S,3β-(£-butyldimethylsiloxy)22,23- bishomopregna-5,7,21-triene (37), which can be selectively catalytically reduced to the key intermediates 20S,3β-(t-butyldimethylsiloxy)22,23-bishomopregna-5,7-diene (38) and 20S,3β-(t-butyldimethylsiloxy)22,23-bishomopregna-5,7-diene (39) respectively. The same sequence on aldehyde (31) produced 2OS, 3β- (triisopropylsiloxy)22,23-bishomopregna-5,7-diene (16). Use of more complex Wittig reagents, Homer- Wadsworth-Emmons reagents, etc. will lead very conveniently to more elaborate side chains, and some of these are illustrated below.
Scheme 6A. Elaboration of the side chain
In yet another illustration of the utility of aldehydes (30)-(32) they may be reacted with reagents such as PPri3/CBr4, followed by butyl lithium or diethyl 1- lithio-1-diazophosphonate, thereby producing alkyne derivatives (40)-(42). These compounds can be elaborated to a wide variety of 20-epi-steroids, using reactions familiar to one skilled in the art, such as alkylations, electrocyclic, and electrophilic additions on the alkyne to elaborate out many different kinds of side chain.
Aldehydes (30)-(32) can be reduced to the corresponding primary [R]- alcohols (43)-(45) by a very wide array of reducing agents (as described in Larock's Modern Synthetic Reactions) with no loss of C20 stereochemical purity. Particularly favored reagents include metal hydride reducing agents such as, but not limited to, DIBAL, NaBH4 and LiAlH4. All three [20R] -alcohols are readily distinguished from their [20S]-epimers by thin layer chromatography, and can be obtained essentially diastereomerically pure (2OR: S >200:l) by column chromatography, in 40-60% isolated yield from pregnenolone, or by recrystallization protocols. This means that sufficiently diastereomerically enriched material for drug substances can be obtained in 4-steps and over 40% yield from pregnenolone. These alcohols are also valuable intermediates for the synthesis of pharmaceuticals with a 2OS configuration.
(43) (44) (45)
In an especially favorable manifestation of the invention, the epoxide rearrangement and the aldehyde reduction can be combined into a single step, precluding isolation of the aldehyde. As this can be carried out on crude epoxide, it means that the only purification step introduced during the entire side chain synthetic sequence to this point is the chromatography at this step, although the chromatography can be replaced by recrystallization, albeit at some loss of yield. By way of illustration, carrying out such a two step transformation on epoxide (27),
alcohol (43) can be obtained in 79.5% yield, which is 74% overall on pregnenolone. 20R,3β-(t-Butyldimethylsiloxy)-22-homopregna-5,7-dien-22-ol (45) can be obtained in very high isomeric purity, by using recrystallized aldehyde, or by recrystallization, or column chromatography of less isomerically pure aldehyde. Ethyl acetate has been found to be a good solvent for this recrystallization, and two recrystallizations can improve the DE of alcohol (45) to >98%.
Treatment of alcohols (44) and (45) with tosyl chloride in dichloromethane containing 4-(N,N-dimethylamino)pyridine and triethylamine gives the corresponding tosylates (46) and (47) in over 80% yield, after recrystallization from acetonitrile, which improves the diastereoisomer excess usefully, if the alcohol was of DE <98%. Similarly alcohol (44) was converted into the corresponding mesylate ester, and all three alcohols could be converted to a wide variety of sulfonate esters, which can be used as electrophiles in nucleophilic displacement reactions and coupling reactions, as is known to one skilled in the art.
Another useful transformation of alcohols (43)-(45) is conversion of the alcohol into a halide, preferably bromide or iodide, for example by use of appropriate phosphorus halide derivatives, or Ph3PZCX4, or other techniques disclosed in "Comprehensive Organic Transformations 2nd Edition" by R. C. Larock followed by displacement of the halide by an appropriate nucleophile. The conversion of 20R,3β-(t-butyldimethylsiloxy)22-homopregna-5,7-dien-22-ol (45) into 20R,3β-(t- butyldimethylsiloxy)-22-bromo-22-homopregna-5,7-diene (48) was carried out in 88% yield using CBr4ZPPh3 in presence of collidine as a base. This transformation is especially advantageous since these halides can readily be turned into the corresponding organometallic reagents, such as lithio, magnesio, zincato and cuprato derivatives, all of which can then be reacted with appropriate electrophiles, such as alkyl halidesZsulfonates, Michael acceptors and epoxides, to elaborate the steroidal side chains efficiently, using techniques known to one skilled in the art.
Specific Uses of Intermediates described above.
1. Synthesies of (20S)- 1 α-hydroxy-2 -methylene- 19-norbishomopregnacalciferol (Becocalcidiol)
( 1 R,3 αR,7αR)-7-Methyl- 1 -([ 1 S]methylprop- 1 -yl)octahydroinden-4-one, ((lR,6R,7R)-6-methyl-7-([lS]methylprop-l-yl)bicycle[4.3.0]nonan-2-one) (49), is coupled with the phosphine oxide (50) to form the protected Vitamin D analogue (51), which can be readily desilylated to synthesize (20S)-lα-hydroxy-2-methylene- 19-norbishomopregnacalciferol, (52). Compound (52) is described generically in US Patent 5,936,133, and in US Patent 6,627,622. Its crystalline form is disclosed in US Patent 6,835,723. Compound (52) and its utilities are claimed in US Patent 6,887,860, where the synthesis is stated to involve a classical Lythgoe condensation of the Windhaus-Grundmann ketone analogue (49) with the allylic phosphine oxide (50), to give the bis-silylated product (51), which is deprotected by fluoride ion- induced hydrolysis to give (52). As compound (52) has valuable Vitamin D agonistic effects, whilst having little hypercalcemic effect it is useful as a potential medication for a variety of conditions as disclosed in US 20040033998 Al. As a key intermediate in the synthesis of diene (52), ketone (49) therefore has utility as a synthetic intermediate, and methods of making (49) which would allow it to be produced more readily and/or at lower cost than at current methodologies, which are not particularly efficient, would be advantageous. The current invention can be used to produce ketone (49) much more cheaply, and in considerably better yield than the described route from ergosterol. (DeLuca, H. F.; et al. US Patent, 6,835,723).
Compound (49) presents several synthetic problems. It is chiral, and a trans bicyclo[4.3.0]nonan-2-one. It has a quaternary center and a cώ-6,7-dialkyl substitution pattern, and the steroidal side chain has the unnatural [S]-configuration at C20. By starting with a naturally occurring steroid one can readily solve the
problems of chirality, the quaternary center and the trans-bicyclononanone structure. However, one must be able to ensure that the steroidal A and B rings are efficiently removed, whilst leaving only the C2 (C8 steroidal) position functionalized, and one must also ensure the correct stereochemistry at C17 and C20, and that the C 14 stereochemistry is retained. There are two known processes for ensuring that the AB ring is cleaved, whilst leaving a functionality at C8, which can be used to elaborate the desired Vitamin D analogues. One must either start with a B-ring 5,7-diene or introduce it, and then photochemically open the diene to a triene followed by a 1,7- hydride shift, exactly as occurs in the conversion of pre Vitamin D to Vitamin D. The 7,8-alkene is then cleaved oxidatively to introduce the 8-ketone. Compound (39), like cholesterol, has no functional groups in its C17 side chains, and can therefore be photolysed followed by a 1,7-hydride shift, under the conditions described for the 7- dehydrocholesterol to Vitamin D3 conversion (M. Okabe. Organic Syntheses, 76, 275, (1999) ) to turn it into triene (53), which can then be ozonized to ketone (49). An alternative, which involves the direct ozono lysis of a steroidal monoene, such as (16) or (38) followed by photochemical removal of the entire A-ring, will be discussed later.
Both tosylates (46) and (47) couple very efficiently with MeMgBr in the presence Of Li2CuCl4 catalyst, to give the key intermediates 20S,3β- (triisopropylsiloxy)-22,23-bishomopregn-5-ene (16) and 20S,3β-(£- butyldimethylsiloxy)-22,23-bishomopregna-5,7-diene (39) in 90-100% crude yields and high purity. Both of these compounds can be purified further by chromatography or via crystallization. Conversion of monoene (16) into the corresponding 5,7-diene (15) via the "Confalone" sulfoxide route was described above in Scheme 3.
The dienes (15) and (39) are chemically very close analogues of 7-
dehydrocholesterol, and of ergosterol, and can be photochemically ring opened to the Vitamin D triene analogues under similar conditions to those used in commercial Vitamin D syntheses. (See M. Okabe. Organic Syntheses, 76, 275, (1999). Steroidal 5,7-diene (39) has been photolysed as described by Okabe with a Hanovia mercury lamp, to give a mixture of the pre -Vitamin D analogue (54) and the tachysterol analogue (55). Reirradiation with longer wavelength radiation (uranium filter) converts most of the unwanted tachy-isomer (55) to the pre- Vitamin D analogue (54), which is then thermally equilibrated to a mixture of triene (54) and Vitamin D triene analogue (53), favoring the latter by about a 10:1 ratio. Triene (53) can be ozonized to form the key ketone intermediate (49), a Windhaus-Grundmann ketone, which is a well known reaction in Vitamin D chemistry. Because of the possible lability of the trans ring junction in ketone (49), it was not directly isolated, but was reduced to the known trαns-octahydroindanol (56) in situ. Alcohol (56) was obtained pure, in overall 36% yield from diene (39) in this four step process in up to a gram scale. It is anticipated that this yield can be improved by using better photolysis apparatus, such as recirculating photolysis apparatus, and falling film apparatus. Alcohol (56) can be oxidized to ketone (49) in 99% yield with pyridinium dichromate, as described in the literature. (DeLuca, H. F.; et al. US Patent, 6,835,723 (2004)).
Thus overall, as shown in Scheme 7, this chemistry represents a 16 reaction synthesis of ketone (49) from pregnenolone (1). Two of the steps can be functionally simplified by being carried out in situ, and both photolyses, the thermal isomerization
and the ozonolysis/reduction are carried out without a purification, and only an evaporation down and reconstitution of the reaction solution, leading to an 11 "pot" conversion. Each of the isolated intermediates is a crystalline solid, and can be recrystallized if required.
Scheme 7. Preferred synthesis of (lR.6RJRV6-methyl-7-(TlSlmethylprop-l- yl)bicyclo|"4.3.0"|- nonan-2-one (49) from pregn-3-en-3β-ol-20-one (1).
Compound B 31 8% from 1
39
Ketone (49) was treated with the lithium anion of phosphine oxide (50), as described in the literature, and underwent Lythgoe coupling to give the Vitamin D analogue
(51) in 79.7% yield. TBAF deprotection, and crystallization gave Becocalcidiol (52) in 85.1% yield, as described in the literature. Thus, this process synthesized Becocalcidiol (52) in overall 7.6% yield from pregnenolone (1).
2. Synthesis of (20S)- 1 α,25-dihvdroxy-2-methylene- 19-norcholecalciferol and their 26,27-bishomo and 26,27-cvclobishomo homologues
(57) (58) (59)
Compounds such as (57), (58) and (59) are described as having interesting calcaemic properties, (DeLuca and Sicinski; US Patents 6,392,071 issued May 22nd 2002, 6,544,969, issued May 8th 2003, 6,537,981 issued March 25th 2003. Shevde, N.K et al. Proc. Natl Acad. Sci. USA, 99, 13487-13491, (2002)) and only differ from compound (52) in the nature of their C17 side chain. Thus these compounds can be made from intermediate (47) simply by coupling the appropriate alkyl groups to it. One way this can be done readily is by coupling (47) or (48) with O-protected Grignard reagents, exemplified by the TBDMS derivatives (60), (61) and (62), but which can use other alcohol protecting groups known to one skilled in the art (Greene and Wuts, Protective Groups in Organic Synthesis 3rd Edn.), using copper reagents as described immediately above, to give the 20-epi-7-dehydrocholesterol analogues (63)-(65). Clearly (63)-(65) be also made from compounds such as (32), via a Wittig reaction, followed by reduction at an appropriate later stage, and various other metal- induced coupling reactions obvious to one skilled in the art. Carrying these compounds through the photolysis-ozonolysis sequence will give the CD-ring ketones (66)-(68), which can then be Lythgoe coupled (or Julia sulfone coupled) with phosphine oxide (50) to produce Vitamin D analogues (57)-(59) after desilylation.
Another method by which these side chains may be attached to the [20R],C22-homologated pregnenols, is to convert alcohols such as (45), sulfonates, exemplified by (47) and halides exemplified by (48) to the corresponding sulfides, exemplified by aryl sulfide (69). This can be done via a Mitsunobu reaction on (45), or simple nucleophilic displacement of the leaving groups of (47) and (48) with a thiolate anion. Oxidation of the sulfide to the sulfone (70) may be difficult in the presence of the diene, but (45), (47) and (48) can be converted directly to the sulfone by use of an appropriate sulfmate nucleophile (Schrotter, E., Schonecker, B., Hauschild, U. Droescher, P, Schick, H. Synthesis, 193-5 (1990).). Generation of an anion at the C22 position can be carried out with alkyl lithium or lithium amide bases, and these in turn can be alkylated as described in the literature (Schrotter, E., Schonecker, B., Hauschild, U. Droescher, P, Schick, H. Synthesis, 193-5 (1990)), to produce compounds such as (71), which can be desulfonated to produce the corresponding epi-cholesterol derivatives, in this case (63).
Synthesis of 20-epi Vitamin D^, 25-Hydroxy-20-epi Vitamin D^ and lα,25- Dihydroxy-20-epi Vitamin D^.
One way 20-epi Vitamin D (72) can be readily prepared is by coupling tosylate (47) with isopentyl magnesium bromide to give 20-epicholesta-5,7-diene (73), followed by photolysis and deprotection. Clearly the aldehyde (32) can be converted to (72) by several other methods, obvious to one skilled in the art. Similarly, coupling of (47) with the corresponding 3-silyl ethers, such as (74) to form the protected cholestadiendiol (75), followed by photolysis and deprotection will lead to 20-epi-25 -hydroxy Vitamin D (76).
Because of the economic importance of lα-Vitamin D derivatives, the chemistry of Cl-hydroxylation of cholesterol and its derivatives has been well worked out. (Zhu, G.-D., Okamura, W. H. Chem. Rev. 95, 1877-1952, and references therein). Reaction of tosylate (47) with an appropriately orthogonally protected 4-hydroxy-4-methylbut-l-yl Grignard reagent exemplified by TPS (triphenylsilyl, but TBDPS, t-butyldiphenylsilyl may work as well) ether (77) will give the key intermediate (78). Selective deprotection of the 3-silyl ether under acidic conditions will give alcohol (79) which on oxidation with chloranil or DDQ leads to oxidation to the trienic ketone (80). Treatment of (80) with a strong base leads to abstraction of the H8 proton, and formation of a trienolate, which upon kinetic reprotonation forms the deconjugated l,5,7-trien-4-one (81) (Guest, D. W. and Williams D. H. J.Chem. Soc. Perkin 1, (1979), 1695). Treatment of this compound, or appropriate derivatives of it, with mildly basic hydrogen peroxide forms the lα,2α-epoxide (82), which upon reduction with hydride reducing agents such as LAH or Ca(BH4)2, will open the epoxide trαns-diaxially, and reduce the ketone to the equatorial alcohol to give the lα,3β-diol (83). Alternatively, epoxidation of (80) as described above, followed by a Li/NH3 reduction will give a-lα,3β-6-cholestene derivative, which can be brominated and doubly dehydrobrominated to give (83) (Dreeman, D., Acher, A., Mazur, Y. Tet. Letters, 16, 261-4 (1975)). Photolysis under the usual Vitamin D wavelength restraints with appropriate sensitizers at low temperature gives the corresponding pre- Vitamin D3 derivative (84). Thermal 1,7- hydride shift gives the protected Vitamin D3 analogue, which can be deprotected with fluoride ion to form 20-epi-lα,25-dihydroxy Vitamin D (85). Alternatively, the TPS (TBDPS) group may be removed before the photolysis. Or the 1,3-dihydroxy groups may need to be appropriately protected before the photolysis, and deprotected after the photolysis, along with the TPS (TBDPS) group. Other protecting group strategies could be used in the side chain, as loss of the tertiary alcohol protecting group prior to the DDQ oxidation should not be problematic, and a wide variety of protecting groups could be reintroduced to the tertiary alcohol immediately after DDQ oxidation.
An alternative preparation of (85) involves photolysing the protected diol (75) and thermally isomerizing it to triene (86). (R. Hesse, US Patent 4,772,433. Andrews, D. R. et al. J. Org. Chem., 51, 4819 (1986). DeLuca, H. F. et al. US Patent 4,265,822) Dissolving triene (86) in liquid sulfur dioxide will produce the sulfolene (87), which on thermal cheleotropic elimination gives the isomerized triene (88). This can be allylically oxidized with SeO2 or similar reagent described in "Comprehensive Organic Transformations 2nd Edition" by R. C. Larock to give the alcohol (89). Photoisomerization of the 5,6-double bond and deprotection will give (85).
4. Synthesis of 20-epi Calcipotriene (90), 20-epi Falecalcitriol (91) and 20-epi Seocalcitol (92).
(90) (91) (92)
The chemistry described above can be used to efficiently produce the C20 epimers of several important Vitamin D derivatives. The above three compounds are
lα-hydroxy Vitamin D derivatives, and can be readily obtained in protected form from either compound (32) or (47/88), or their TIPS-protected analogues. Thus, for example to prepare (90), the sequence in Scheme 8 can be used.
Scheme 8. Synthesis of 20-epi Calcipotriol.
Treatment of aldehyde (32) with stabilized ylide (93) or other appropriate olefmating agent, followed by a chiral ketone reduction, (see "Handbook of Reagents for Organic Synthesis; Chiral Reagents for Asymmetric Synthesis. Ed L. A. Paquette) and PG-Cl = MEM or TBDPS chloride will give the steroidal 5,7-diene precursor (94, R = MEM or TBDPS). This can be hydroxylated by the DDQ/cloranil route, described above, to give the protected steroid (95, R = MEM or TBDPS) or, for example, the diacetate (96, R = MEM or TBDPS) if required. Photo lysis/isomerization of this compound gives the protected precursors (97, R = MEM or TBDPS) or (98, R = MEM or TBDPS), which can be deprotected to (90) by a variety of methods familiar to one skilled in the art. Alternatively, photolysis/isomerization of (94, R = MEM or TBDPS) to give 5Z-Vitamin D analogue (99, R = MEM or TBDPS) can be followed by the two step 5,6- isomerization to give the 5E-triene (100, R = MEM or TBDPS), which can be
allylically hydroxylated to triene (101, R = MEM or TBDPS), followed by long wavelength reisomerization to the 5Z-triene and deprotection to (90). (R. Hesse, US Patent 4,772,433. Andrews, D. R. et al. J. Org. Chem., 51, 4819 (1986). DeLuca, H. F. et al. US Patent 4,265,822)
A similar route for making 20-epi Falecalcitriol is shown in Scheme 9.
Scheme 9. A Preparation of 20-epi Falecalcitriol.
Copper-catalysed reaction of tosylate (47) with a silyl-protected hexafluorinated Grignard reagent (102) will give the steroidal diene (103), which can be converted, either to the lα-hydroxylated steroid (104) or a 1,3-diprotected analogue, as discussed in Specific Use 3 above. IfR is TMS in compounds (102) and (103), it will be removed along with TBDMS from (103), and replaced if needed at the trienone stage by a different protecting group, in which case R will not necessarily be TMS, although it may be most convenient to simply retrimethylsilate one of these intermediates. Compound (104), or its appropriately 1,3-diprotected analogue can then photo lysed/isomerized and appropriately deprotected to give (91), or can be photo lysed/isomerized directly to triene (105), which in turn can be 5Z to 5E- isomerized via sulfur dioxide cycloaddition-elimination to give (106), which can be allylically hydroxylated to (107), and then 5E to 5Z isomerized by long wavelength photolysis and deprotected, to give (91).
A preparation of (92) can be carried out by analogy with the preparation of (90) from aldehyde (19) as described above. Reaction of (32) with the conjugated stable ylide (108) will give the E,E-dienone (109), which can be reacted with two equivalents of ethyl lithium, and pivaloyl chloride/DMAP to produce key intermediate (110). Desilylation of this, followed by the same DDQ-deconjugation- oxidation-reduction sequence as described previously will give the desired dienediol (111). This can be protected as the bis-silyl (exemplified here by TMS) ether (112), and photolysed/isomerized to 5Z,7E-ΔiO-i9,5-6j-8 triene (113), which can be deprotected to (92). If the pivaloyl group is lost during introduction of the 1 -hydroxy group, the 1,3,25-triol corresponding to (111) can simply be trisilylated to give the 25-TMS analogues of (112) and (113).
An alternative preparation of 20-epi compounds with a 22,E-double bond is illustrated above. Alcohol (45) can be protected, for example by treatment with pivaloyl chloride or TPS chloride to form (114, R1 = TBDMS, R2 = pivaloyl or TPS) and then desilylated to (115, R2 = pivaloyl or TPS). Another illustrative example would be to desilylate (45) to diol (114, R1 = R2 = H), and then exploit the exceptionally low reactivity of the 3-hydroxy towards TIPS chloride, by selectively silylating the 22-hydroxy to give (115, R2 = TIPS). The DDQ oxidation could then be carried out to give trienone (116, R2 = Piv, TPS or TIPS) followed by base induced deconjugation to trienone (117, R2 = Piv, TPS or TIPS). Peroxide induced oxidation will give epoxide (118, R2 = Piv, TPS or TIPS), and appropriate hydride reduction will give diol (119, R2 = Piv, TPS or TIPS). Diol (119) can now be orthogonally 1,3- protected, for example if R2 = TPS or TIPS, R3 = Ac, and if R2 = Piv, R3 = TMS or TBDMS, with this pattern holding through the protected 5,7-diene (120), the initial photolysis product (121), and the thermally isomerized triene (122). R2 can then be removed to give primary alcohol (123, R3 = Ac, TMS or TBDMS), and that can be oxidized to aldehyde (124, R3 = Ac, TMS or TBDMS). Aldehyde (124) is a very
useful common intermediate for lα-hydroxy-20-epi-22-alkenyl Vitamin D analogues. Reaction of aldehyde (124) with an appropriate crotonate anion derivative, such as ylide (83) will give the unsaturated E,E-ester (125, R3 = Ac, TMS or TBDMS), which can be converted to 20-epi-Seocalcitol (92) by treatment with excess ethyl lithium which will both form the desired side chain and cleave the protecting groups, or in the case of TBDMS with an additional TBAF treatment to cleave the fluoride. Alternatively, reaction of (124, R3 = Ac, TMS or TBDMS) with stabilized ylide (93) will give enone (126), which can be selectively reduced with many known chiral reducing agents to the 24 alcohol (127, R3 = Ac, TMS or TBDMS), followed by a simple deacetylation or desilylation to give 20-epi-Calcipotriol (90).
5. Synthesis of Vitamin D derivatives extended at C21, and at the normal steroidal side chain.
As the above disclosures demonstrate, the processes and intermediates disclosed herein have general utility for the preparation of 20-epi Vitamin D analogues, and of 20-epi steroids with more than a simple alkene functionality in the B-ring. The examples given above are illustrative of the utility of the process and the key intermediates claimed in this patent, and are not meant to limit the methodology. For example, the ready preparation of O-silylpregna-5,7-dien-3-ol-20-ones exemplified by (20) allows for extension of the normal C 17 side chain in both directions off of C20. We have described above the building out of the steroidal side chain via epoxidation-rearrangement in the normal C22-C27 direction, albeit maintaining the unnatural stereochemistry at C20, and whilst leaving C21 as a methyl group. However, compound (20), upon generation of the kinetic enolate (128), which can be done straightforwardly by treatment of compound (20) with LDA at low temperature in solvents such as THF, a process well known to those skilled in the art, activates the C21 methyl towards electrophilic attack. (Konopelski, J. P., Djerassi, C. J. Med. Chem., 23, 722-6, (1980)). This allows especially for new carbon-carbon bonds to be formed at C21, via the very well established process of enolate alkylation, whilst also regenerating the C20 carbonyl to form a derivative (129). The reformed carbonyl of (129) can then be epoxidized with dimethylsulfonium methylide to give (130), and rearranged with a Lewis acid to the corresponding aldehyde (131), in
exactly the same way as is done for converting compound (20) into compounds (29) and (32). Then this new aldehyde (131) can be chain extended as described previously to form formally 20-epi-21 -extended steroid derivatives (132). However, as shown below in Scheme 10, depending on the nature of the substituents put on C21 and C22, one can envision that the main "natural" steroid side chain extension on C22 and the "unnatural" C21 extension may be reversed, in which case the product would have the formal "natural" 20R-stereochemistry. In the most extreme case the C22 aldehyde can be reduced directly to the corresponding methyl group, for example, by reduction to the alcohol, tosylation and LiALH4 reduction, to form the natural 20R,21 -methyl side chain. The usual photolyses/thermolysis of (132) will give the Vitamin D triene analogues (133), which can be converted to the corresponding Windhaus-Grundmann ketones (134) as described above.
Scheme 10. Use of Pregna-5,7-dienolone Derivatives to Extend Vitamin D C17 Side Chain in both C21 and C22 directions.
As C21 -extended steroids are not readily produced, let alone Vitamin D deriviatives, this invention also applies to the synthesis of C21 -extended steroids with both the "natural" 2OR, and the "unnatural" 2OS configuration, as well as their corresponding B-ring opened trienic Vitamin D analogues. Therefore, the process described in Scheme 10 can also use O-silylpregn-5-en-3-ol-20-ones, such as (7) and
(8) to form intermediates such as (135)-(139) which can then be used in conventional steroidal chemistry, as (20-epi)-21-norcholesterol derivatives, as illustrated in Scheme 11.
Scheme 11. Use of Pregn-5-enolone Derivatives to Extend Steroid Side Chain in both C21 and C22 directions.
Although the electrophiles reacted with enolates (128) and (135) in the above illustrations are described as alkyl halides, which would obviously include allylic and benzylic halides, there are many other electrophiles, obvious to one skilled in the art, such as aldehydes, ketones, esters, amides and acyl halides, and Michael acceptors which could be used in this process. Additionally, intermediates (136) and (139) can be desaturated to form the corresponding 5,7-dienes, and then converted to Vitamin D derivatives.
As illustrations of possible uses of these obvious extensions of the technology described in this patent application, synthetic schemes to prepare 21,23-bisnor Becocalcidiol (140) and its C20 epimer (141), Schemes 12 and 13, both 21R and 21S epimers of the so-called Gemini Vitamin D derivatives (141) and (142), Schemes 14 and 15, and both 2OS and 2OR 21-norcholesterols (143) and (144), Schemes 16 and 17, are shown below.
Scheme 12 starts with alkylation of ketone (20) with LDA and methyl iodide, to give ketone (146), which is epoxidized, rearranged with magnesium bromide and reduced to alcohol (147) with NaBH4. Tosylation and copper-catalysed coupling of ethylmagnesium bromide gives the photolysis precursor (148). Going through the photolysis-isomerization and ozonolysis sequence gives the corresponding Windhaus- Grundmann ketone, which is reduced in situ to alcohol (149). Oxidation of the alcohol, back to the Windhaus-Grundmann ketone, followed by Lythgoe coupling and deprotection, as demonstrated for Becocalcidiol will give its bis-homo analogue (140).
Scheme 12. Synthesis of 20S-21.22-bisnor-Becocalcidiol (140) from TBDMS Pregna-5.7-dien-3-ol-20-one (20).
Scheme 13 is very similar to Scheme 12, starting with alkylation of ketone (20) with LDA and ethyl iodide, to give ketone (150). The sequence is continued exactly as in Scheme 12, except that the tosylate derived from alcohol (151) is coupled with methylmagnesium bromide and LiCuCl4, to form the steroid (152), which is converted as before to bicycloalcohol (153) and Becocalcidiol analogue (141).
Scheme 13. Synthesis of 20R-21.22-bisnor-Becocalcidiol (141) from TBDMS Pregna-5.7-dien-3-ol-20-one (20).
One very interesting variant on normal Vitamin D structures which has been reported is the so-called "Gemini" Vitamin D derivatives, (Adorini, L., Penna, G., Uskovic, R., Maehr, H. WO 2004/098522), where C21 is extended to form a second, natural-like C22-27 side chain. In most of the published cases, the C21 and C22- extended side chains are different from one another, meaning that C20 is a chiral center. Because the methodology described herein allows for complete stereocontrol at C20, it is especially suitable for the efficient synthesis of such compounds, as is illustrated by the synthesis of both C20 isomers of a simple "Gemini" derivative below. In Scheme 14, the enolate of (20) is reacted with prenyl promide to make ketone (154), which is homologated to alcohol (155) as described previously. Reaction of the corresponding tosylate with isopentylmagnesium bromide and copper catalyst gives the steroid (156), which can be converted to the corresponding Vitamin D derivative by the usual photolytic sequence, and then deblocked to give "Gemini" Vitamin D deriviative (142) stereospecifϊcally. In Scheme 15 switching the
alkylating agent to isopentyl bromide, to give ketone (157) and the Grignard reagent to prenylmagnesium bromide on the tosylate derived from alcohol (158) gives epi- steroid (159), which is photolysed and deblocked to (143).
Scheme 14. Synthesis of 20R-"Gemini Vitamin D derivative.
Scheme 15. Synthesis of 20S-"Gemini Vitamin D derivative.
It should be noted that some "Gemini" derivatives contain an A-ring, which will have to be introduced by a Lythgoe coupling to an appropriate Windhaus- Grundmann ketone, and which contain a double or triple bond in one of the "Gemini" side chains. In such cases, an appropriate "orthogonal" protection of the alcohol corresponding to (155) or to (158), followed by photolysis and isomerization, and ozono lysis will give the equivalent of the Imhoffen-Lythgoe ketone, which can be be coupled with the appropriate A-ring synthon, and then the C22 (C22') alcohol can be
selectively deprotected, activated to displacement (or oxidized to the corresponding aldehyde) and chain extended by methods known to one skilled in the art.
The use of either silyl ether (16) or silyl ether (38) to make simple steroid derivatives, homologated at C21 is illustrated in Schemes 16 and 17. For example, silyl ether (16) can be methylated on C21 to give the 21-homopregnenolone (160), which can be epoxidized with dimethylsulfonium methylide to form (161), which can be rearranged to the aldehyde (162). Reaction of aldehyde (162) with an isopentyl Wittig reagent gives the homocholesterol derivative (163), whereupon selective side chain hydrogenation and desilylation gives 20S-21 -homocholesterol (144). Using silyl ether (38) in a sequence where the enolate is alkylated with isopenyl bromide, to give (164), followed by epoxidation to (165), rearrangement to aldehyde (166), and methylenation will give the vinyl steroid (167), which can be reduced and deblocked to give 21 -homocholesterol (145).
Scheme 16. Synthesis of 20S-21 -homocholesterol
Scheme 17. Synthesis of 21 -homocholesterol
6. An Alternative Synthesis of 20-epi- Vitamin D derivatives.
An alternative strategy of removing the A-ring from steroids has been described, by ozonation of steroidal 5-enes, elimination of the 3-oxy substituent, and loss of the A-ring via a Norrish Type II photocleavage, as described by Dauben (Tet. Letters, 35, 2149-52, (1994) and Gao (Tet. Letters, 40, 131-2, (1999). This will be exemplified by two possible preparations of Becocalcidiol (52) from the silyl ethers (15) and (38). In Scheme 18, silyl ether (15) is ozonized, and worked up oxidatively to give ketoacid (168). Treatment of (168) with two equivalents of strong base at low temperature, leads to siloxide elimination to give the enone (169). Photolysis of this compound will lead to cleavage of the A-ring in good yield to give the unsaturated CD-ring acetic acid (170). The double bond is reduced out catalytically, to give acid (171). Hell-Vollhardt-Zelinsky bromination of this acid followed by methanol workup gives bromoester (172). This can be eliminated with a strong base to give the unsaturated ester (173), which is reduced with LiAlH4, to the allyl alcohol (174). Tosylation of (174) gives allyl tosylate (175). This can either be displaced with lithium diphenyl phosphide or sodium 2-thiobenzothiazole, followed by oxidation to give allyl phosphine oxide (176) or allyl sulfone (177). Either of these can be treated with butyl lithium or LDA, followed by ketone (178) (DeLuca and Sicinski, US Patent 5,843,928) to give protected Becocalcidiol analogue (51), which is deprotected to Becocalcidiol (52).
Scheme 18. A Synthesis of Becocalcidiol from Silyl Ether (15).
In Scheme 19 the TBDMS ether (38) is ozonized, and worked up reductively, and acetalized as described by Gao, to give acetal (179). This is treated with a strong base to give enone (180), and the A-ring is cleaved photo lyrically to give bicycloalkene (181), which is reduced to (182). Acetal (182) can be treated with tosylhydrazine and acid to make tosylhydrazone (183) directly. A B amford- Stevens reaction will give the vinyl compound (184), which can be oxidized to the allyl alcohol (185) by SeO2, either stoichiometrically or catalytically, with another oxidant such as t-butyl hydroperoxide. The hydrogen at C8 is axial, and other good enophile oxidizing agents such as EtO2CNSO, should also allow for this conversion. Reaction with a strong base and chlorodiphenylphosphine should produce the allylic phosphenite ester (186) which upon 3,2-rearrangement should give purely the E- isomer (176) shown. Alternatively, treatment of allyl alcohol (185) with benzothiazole-2-sulfenyl chloride will give the allyl sulfenate ester (187) which will rearrange thermally to an allyl sulfoxide, which can be oxidized in situ with mCPBA or other mild oxidants to the allyl sulfone (177). The intermediates (176) and (177) can then be taken onto Becocalcidiol as described in Scheme 18.
Scheme 19. A Synthesis of Becocalcidiol Intermediates (176) and (177) from TBDMS Pregnenolone (38).
In this disclosure, the term photolysis can be used to describe several different photochemical processes. If the process is simply described as a photolysis, or photo lysis/isomerization, to turn a steroidal B-ring 5,7-diene into a Vitamin D derivative, with no further elaboration, it can refer to one of two processes. One involves an initial photolysis at a wavelength of below 300 nM, at temperatures close 0 0C, to open the diene to the 6E-Δs_io,6-7,8-9 trienic "pre Vitamin D" analogue, which usually involves generating a photostationary equilibrium, which includes large amounts, or a preponderance, of the corresponding 6E-stereoisomer, the "Tachysterol" analogue. This is followed by a second irradiation at longer wavelength, preferably around 350 nM, for example using a uranium glass filter, to isomerize most of the Tachysterol analogue back to the desired "pre Vitamin D" analogue, and is then followed by a thermal 1,7-hydride shift to give the desired 5Z,7E-Δio-i9,5-6,7-8 trienic "Vitamin D" analogue. The second process involves a descending film photolysis technique carried out at room temperature or above, in a specialized photolysis apparatus, which allows for the ring opening and 1 ,7-hydride shift to be done, producing a preponderance of the desired 5Z,7E-Δ10-19j5-6,7-8 trienic "Vitamin D" analogue in a single pass. If photolysis to produce the 6E-Δs_io,6-7,8-9 trienic "pre Vitamin D" analogue is specifically described, depending on the context,
it will refer either to a single shorter wavelength photolysis, which is understood to produce a 6E-Δs_io,6-7,8-9 trienic "pre Vitamin D"/ 6Z-Δs_io,6-7,8-9 trienic "tachysterol" analogue mixture, or the short wavelength photolysis, followed by the longer wavelength 6Z to 6E deequilibration photolysis, and in each case done at low enough temperatures to suppress the 1,7-hydride shift to the 5Z,7E-Δ10-19j5-6,7-8 trienic "Vitamin D" analogue.
EXPERIMENTALS
The invention is illustrated further by the following examples, which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the invention, as demonstrated by the following examples. Those skilled in the art will also recognize that it may be necessary to utilize different solvents or reagents to achieve some of the above transformations. In some cases, protection of reactive functionalities may be necessary to achieve the above transformations. In general, such need for protecting groups, as well as the conditions necessary to attach and remove such groups, will be apparent to those skilled in the art of organic synthesis. When a protecting group is employed, deprotection step may be required. Suitable protecting groups and methodology for protection and deprotection such as those described in Protective Groups in Organic Synthesis by T. Greene and P. Wuts are well known and appreciated in the art.
Unless otherwise specified, all reagents and solvents are of standard commercial grade and are used without further purification. The appropriate atmosphere to run the reaction under, for example, air, nitrogen, hydrogen, argon and the like, will be apparent to those skilled in the art.
Example 1. 3,O-^ButyldimethylsilvP)pregn-5-en-3β-ol-20-one
Pyridine (4.0 mL) was added in one portion to a vigorously stirred suspension of 3β-pregn-5-en-20-one (6.33 g, 20 mmol) and 4-(Λ/,Λ/-dimethylamino)pyridine (0.244 g, 2.0 mmol) in DMF (40 mL) containing t-butyldimethylsilyl chloride (3.77 g, 25 mmol) under nitrogen at 25 0C. After 20 h, the reaction mixture was stirred on
an ice-bath for 1 h, and then Buchner filtered through a glass frit. The residue was rinsed with cold DMF (2 x 20 mL), and was dried in a vacuum oven at 60 0C for 5 h, to give 3β-(£-butyldimethylsiloxy)pregn-5-en-20-one (8.46 g) as a white crystalline solid, containing 0.54% DMF by weight. Yield = 97.7%. 1H NMR (CDCl3 500 MHz) δ: 0.086 (6H, s), 0.654 (3H, s), 0.916 (9H, s), 0.92-1.05 (IH, m), 1.026 (3H, s), 1.06- 1.33(3H, m), 1.45-1.76 (9H, m), 1.82-1.86 (IH, brd), 2.00-2.15 (2H, m), 2.151 (3H, s), 2.21-2.30 (3H, m), 2.558 (IH, t, J = 9.0 Hz), 3.509 (IH, approx septet, J = 4.6 Hz), 5.328 (IH, brd, J = 5.0 Hz).
Example 2: 3β-(Triisopropylsiloxy)pregn-5-en-20-one
To a suspension of pregnenolone (6.28 g, 19.8 mmol) in DMF (20 mL) and DCM (20 mL) at 25 0C was added imidazole (2.7 g, 39.7 mmol) followed by triisopropylsilyl chloride (5.5 mL, 25.8 mmol). The mixture became homogeneous after a few hours and was stirred for 24 h. The solution was partitioned between EtOAc and water, and extracted with EtOAc (2x), washed with sat. sodium bicarbonate, water, brine, dried over magnesium sulfate, and concentrated to give 12.9 g of a crude white solid. Recrystallization from isopropanol afforded 5.98 g of the title compound. A second crop of 0.95 g (identical by IH NMR) was obtained from the mother liquor for a combined yield of 74%. 1H NMR (CDCl3 500 MHz) δ: 0.654 (3H, s), 0.92-1.33 (4H, m), 1.033 (3H, s), 1.139 (21H, s), 1.43-1.76 (8H, m), 1.82-1.88 (2H, m), 1.96-2.10 (2H, m), 2.150 (3H, s), 2.21-2.34 (3H, m), 2.558 (IH, t, J = 9.0 Hz), 3.586 (IH, approx septet, J = 4.6 Hz), 5.344 (IH, brs).
Example 3 : 3β-(t-Butyldimethylsiloxy)-22-homopregn-5-en-20R,22-epoxide
A slurry of potassium hexamethyldisilazane (4.01 g, 20 mmol) and trimethylsulfonium iodide (4.08 g, 20 mmol) in THF (20 mL) was stirred under nitrogen at 25 0C for 10 minutes to form a very pale yellow slurry. Then toluene (20 mL) was added and the mixture was cooled to -70 0C on a dry ice/isopropanol bath for 20 minutes. Then a solution of 3β-(£-butyldimethylsiloxy)pregn-5-en-20-one (4.19 g, 9.73 mmol) in toluene (60 mL) was added dropwise over 45 minutes. The reaction was allowed to stir at -7O0C for another hour, and was then allowed to warm slowly to -6O0C over 1 hour and to -50C over another hour. The reaction was
quenched by the rapid addition of acetic acid (2.0 rnL) forming a much thicker slurry. Water (100 mL) and NaHSO3 (0.10 g) were added with rapid stirring, and the phases were separated. The aqueous phase was extracted with MTBE (2 x 50 mL), and the combined organic extracts were washed with water (2 x 50 mL), saturated aqueous sodium bicarbonate solution (50 mL) and saturated brine (50 mL), and dried (MgSO4). The solvent was removed rigorously under reduced pressure to give crude 3β-(t-butyldimethylsiloxy)-22-homopregn-5-en-20R,22-epoxide (4.12 g, 95%) as a free flowing white solid, which NMR analysis showed to contain a 44:1 ratio of the desired and undesired C20 epimers. 1H NMR (CDCl3 500 MHz) δ: 0.084 (6H, s), 0.838 (3H, s), 0.916 (9H, s), 0.95-1.05 (IH, m), 1.05-1.10 (IH, m), 1.12-1.16 (IH, d of d of t), 1.407 (3H, s), 1.41-1.66 (HH, m), 1.571 (3H, s), 1.716 (2H, brt), 1.80-1.84 (IH, brd), 1.97-2.03 (IH, brd), 2.18-2.23 (IH, brd), 2.26-2.32 (IH, brt), 2.352 (IH, d, J = 4.9 Hz), 2.527 (IH, d, J = 4.9 Hz), 3.506 (IH, approx septet, J = ~5.0Hz), 5.339 (IH, brd, J = 5.2 Hz).
Example 4: 3β-(Triisopropylsiloxy)-22-homopregn-5-en-20R,22-epoxide.
A stirred suspension of potassium hexamethyldisilazane (7.3 g, 36.7 mmol) in THF (50 mL) was cooled to -50C in a dry ice / isopropanol bath under nitrogen. Trimethylsulfonium iodide (7.5 g, 36.7 mmol) was added in one portion and the mixture was stirred 15 min. After cooling to -650C, a solution of 3β-(triisopropylsiloxy)pregn-5-en-20-one (6.95 g, 14.7 mmol) in THF (20 mL) was added dropwise over 20 min. The mixture was stirred for 3 h, then allowed to warm slowly to room temperature and stirred 30 min. The mixture was cooled in an ice bath, quenched with 0.2 M citric acid (50 mL), and then allowed to warm to room temperature and stirred for 15 min. The mixture was partitioned between EtOAc and water, extracted with EtOAc (2x), washed with dilute aqueous sodium thiosulfate, brine, dried over magnesium sulfate, and concentrated to give
3β-(triisopropylsiloxy)-22-homopregn-5-en-20R,22-epoxide (7.16 g, 100%) as white plates with a 40: 1 20R:S ratio (by 1H NMR). 1H NMR (CDCl3 500 MHz) δ: 0.838 (3H, s), 0.946 (IH, si brd oft, Jd = 5 Hz, J, = 11 Hz), 1.041 (3H, s) 1.083 (21H, s), 1.05-1.10 (IH, m), 1.257 (IH, d of t, Jd = 5 Hz, J, = 12 Hz), 1.406 (3H, s), 1.41-1.66 (8H, m), 1.578 (3H, s), 1.734 (IH, t, J = 9.5 Hz), 1.80-1.88 (2H, m), 1.97-2.03 (IH,
brd), 2.192 (IH, d of of d of d, J = 2.5, 5, 13 Hz), 2.26-2.32 (IH, brt), 2.352 (IH, d, J = 4.8 Hz), 2.527 (IH, d, J = 4.8 Hz), 3.580 (IH, approx septet, J = 5.0 Hz), 5.339 (IH, brs).
Example 5 : 20R,3 β-(t-Butyldimethylsiloxy)-22-homopregn-5-en-22-al.
A slurry of magnesium bromide bis(diethyl etherate) (101.3 mg, 0.40 mmol) in toluene (5 mL) was added dropwise over 1 minute to a solution of crude 3β-(t- butyldimethylsiloxy)-22-homopregn-5-en-20R,22-epoxide (889.8 mg, 2.0 mmol) in toluene (20 mL), stirred under nitrogen at 0 0C. The initial cloudy mixture gradually became a clear solution with a very fine white precipitate. After 4 hours, the reaction mixture was capped, and was placed in a 4 0C refrigerator for 45 hours. The cold solution was quenched with dilute hydrochloric acid (0.1 M, 10 mL), and the phases were separated. The aqueous phase was extracted with MTBE (10 mL), and the combined organic phases were washed with water (10 mL), saturated brine (10 mL) and dried (MgSO4). The solvent was removed rigorously under reduced pressure to give 842 mgs of white slightly waxy solid, which nmr analysis showed to contain a 20:1 ratio of 2OR: S aldehyde. This material was recrystallized from acetone at 0 0C to give 20R,3β-(t-butyldimethylsiloxy)-22-homopregn-5-en-22-al (625.8 mg, 70.3%) as white plates with a 65:1 20R:S ratio. A further recrystallization from acetone at 0 0C gave the desired aldehyde (490.3 mg, 55.1%) as white rods with a >250:l 20R:S ratio. Combining the second crop from the first recrystallization and the mother liquors from the second recrystallization (203 mg) and recrystallizing this material twice more from acetone at 0 0C, gave further aldehyde (96.0 mg, 10.8 %) as white rods with a 100:1 20R:S ratio. 1H NMR (CDCl3 500 MHz) δ: 0.079 (6H, s), 0.711 (3H, s), 0.911 (9H, s), 0.947 (IH, d oft, Jd = 5 Hz, J, = 11 Hz), 1.012 (3H, s), 1.059 (3H, D, J = 6.8 Hz), 1.01-1.21 (5H, m), 1.34-1.77 (9H, m), 1.80-1.85 (IH, br d oft), 1.86-1.95 (IH, m), 1.97-2.05 (IH, m), 2.17-2.22 (IH, brd), 2.25-2.38 (2H, m), 3.497 (IH, approx septet, J = 4.6 Hz), 5.337 (IH, narrow m), 9.570 (IH, D, J = 5.0 Hz).
Example 6: 20R,3β-(Triisopropylsiloxy)-22-homopregn-5-en-22-al.
A stirred solution of 3β-(triisopropylsiloxy)-22-homopregn-5-en-20R,22- epoxide (1.30 g, 2.67 mmol) in toluene (8 mL) was cooled in an ice bath under
nitrogen. A solution of magnesium bromide in ether (3.1 mL, 0.53 mmol, 0.17 M) was added, and the solution was allowed to warm to room temperature and stirred for 3 h. The solution was partitioned between EtOAc and 0.5 M HCl, extracted with EtOAc (2x), washed with sat. sodium bicarbonate, brine, dried over magnesium sulfate, and concentrated to give 1.35 g of a white solid. Recystallization from isopropanol afforded 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-al (0.85 g, 65%) as white needles with a 30:1 20R:S ratio by 1H NMR. Further crystallization improved the 20R:S ratio to 65:1 in overall 50% yield, also determined by 1H NMR 1H NMR (CDCl3 500 MHz) δ: 0.712 (3H, s), 0.947 (IH, d oft, Jd = 5 Hz, J, = 11 Hz), 1.019 (3H, s), 1.059 (3H, d, J = 6.9 Hz), 1.078 (21H, s), 1.01-1.21 (5H, m), 1.34- 1.74 (8H, m), 1.78-1.94 (3H, m), 1.97-2.05 (IH, br d oft ), 2.25-2.38 (3H, m), 3.567 (IH, approx septet, J = 4.6 Hz), 5.333 (IH, si brd J = 4.8 Hz), 9.570 (IH, d, J = 5.0 Hz).
Example 7: 20S,3β-^Butyldimethylsiloxy)-22,23-bishomopregna-5,22-diene. n-Butyl lithium (2.5 M in hexanes, 0.65 mL, 1.625 mmol) was added dropwise over 2 minutes to a light yellow suspension of methyltriphenylphosphonium iodide (608 mg, 1.5 mmol) in THF (5 mL) stirred under nitrogen at 0 0C. After 10 minutes 20R,3β-(t-butyldimethylsiloxy)-22-homopregn-5-en-22-al (222.4 mg, 0.50 mmol) was added in one portion to the reaction mixture. After 30 minutes at 0 0C, celite (Ig) and hexanes (40 mL) were added to the reaction mixture, which was stirred at 0 0C for a further 30 minutes, before vacuum filtration through a short silica gel plug. The plug was rinsed with 4% MTBE in hexanes (50 mL) and the combined filtrates were concentrated rigorously under reduced pressure to give 20S,3β-(£- butyldimethylsiloxy)-22,23-bishomopregna-5,22-diene (219.5 mg, 99.1%) as glistening white plates with a >200: 1 20R:S ratio by 1H NMR. 1H NMR (CDCl3 500 MHz) δ: 0.081 (6H, s), 0.688 (3H, s), 0.913 (9H, s) 0.948, (3H, d, J = 6.6 Hz), 1.034 (3H, s), 0.089-1.21 (6H, m), 1.26-1.34 (IH, brq), 1-36-1.65 (6H, m), 1.70-1.77 (IH, m), 1.78-1.88 (2H, m), 1.96-2.04 (2H, m), 2.07-2.16 (IH, m), 2.18 (IH, brd of d of d), 2.28 (IH, brt), 3.499 (IH, septet, J = 4.9 Hz), 4.859 (IH, d of d, J = 1.8 10.1 Hz), 4.958 (IH, d of d, J = 1.8, 17.2 Hz), 5.338 (IH, si brd J = 5.1 Hz), 5.718 (IH, d oft, Jd = 17.2 Hz, J, = 10.1 Hz).
Example 8: 20S,3β-(Triisopropylsiloxy)-22,23-bishomopregna-5,22-diene.
A stirred suspension of methyltriphenylphosphonium iodide (747 mg, 1.85 mmol) in THF (5 mL) was cooled in an ice bath under nitrogen. Butyllithium (0.69 rnL, 1.72 mmol, 2.5 M in hexane) was added dropwise and the resulting orange mixture was stirred for 20 min. 20R,3β-(Triisopropylsiloxy)-22-homopregn-5-en-22- al (290 mg, 0.60 mmol) was added in one portion, and the mixture was allowed to warm to room temperature and stirred for 2 h. The mixture was poured into hexane (25 mL) and stirred for 15 min, then filtered through a pad of magnesium sulfate, and rinsed with hexane. The filtrate was concentrated to give 300 mg of a crude white solid. Flash chromatography (1-2% EtOAc / hexanes) gave 20S,3β-(triisopropylsiloxy)-22,23-bishomopregna-5,22-diene (245 mg, 85%) as a white solid with a 63 : 1 2OS :R ratio determined by 1U NMR. 1U NMR (CDCl3 500 MHz) δ: 0.690 (3H, s), 0.923 (IH, d oft, Jd = 4.7 Hz, J, = 11.2 Hz), 0.949, (3H, d, J = 6.6 Hz), 1.018 (3H, s), 1.081 (21H, s), 1.01-1.21 (5H, m), 1.26-1.34 (IH, brq), 1.36- 1.74 (6H, m), 1.78-1.90 (3H, m), 1.97-2.05 (2H, m), 2.07-2.16 (IH, m), 2.22-2.36 (2H, m), 3.573 (IH, approx septet, J = 4.6 Hz), 4.859 (IH, d of d, J = 1.5 10.1 Hz), 4.959 (IH, d of d, J = 1.5, 17.1 Hz), 5.335 (IH, si brd J = 5.0 Hz), 5.718 (IH, d oft, Jd = 17.1 Hz, J, = 10.1 Hz).
Example 9: 20S,3β-( t-Butyldimethylsiloxy)-22,23-bishomopregn-5-ene.
A slowly stirred slurry of 5% Pd/C (19 mg) and 20S,3βH> butyldimethylsiloxy)-22,23-bishomopregna-5,22-diene (182.4 mg, 0.412 mmol) in THF/MeOH (2:1, 6 mL) was put through 4 cycles of vacuum degassing and reconstitution with a hydrogen atmosphere. The mixture was then stirred rapidly under hydrogen for 3 hours at 25 0C. The hydrogen was vented, and the reaction mixture, which appeared to have precipitated extensively, was filtered under vacuum through a 1.5 x 1.5 cm celite plug, and the plug was rinsed with 4% MTBE in hexanes (50 mL) The solvent was stripped rigorously under reduced pressure to give 20S,3βH>butyldimethylsiloxy)-22,23-bishomopregn-5-ene (181.9 mg, 99.2%) as fine white plates, with about 10% of the starting alkene still present. 1H NMR (CDCl3 500 MHz) δ: 0.083 (6H, s), 0.695 (3H, s), ), 0.837 (3H, d, J = 6.6 Hz), 0.854
(3H, t, J = 7.2 Hz), 0.914 (9H, s) 1.038 (3H, s), 0.98-1.24 (5H, m), 1.26-1.34 (2H, m), 1.38-1.65 (9H, m), 1.72-1.86 (3H, m), 1.95-2.05 (2H, m), 2.19 (IH, brd), 2.28 (IH, brt), 3.505 (IH, approx septet, J = 4.6 Hz), 5.339 (IH, si brd J = 5.0 Hz).
Example 10: 20S,3β-(Triisopropylsiloxy)-22,23-bishomopregn-5-ene.
A slurry of 5% Pd/C (20 mg) and 20S,3β-(trϋsopropylsiloxy)-22,23- bishomopregna-5,22-diene (95 mg, 0.196 mmol) in THF/MeOH (2:1, 3 mL) was put through 3 cycles of vacuum degassing and reconstitution with a hydrogen atmosphere. The mixture was then stirred rapidly under hydrogen for 4 hours at 25 0C. The hydrogen was vented, and the reaction mixture was filtered under vacuum through a small plug of anhydrous MgSO4, rinsing with 10% EtOAc in hexanes. The solvent was stripped rigorously under reduced pressure to give 20S,3β-(triisopropylsiloxy)-22,23-bishomopregn-5-ene (81 mg, 85%) as a light yellow. 1U NMR (CDCl3 500 MHz) δ: 1U NMR (CDCl3 500 MHz) δ: 0.697 (3H, s), 0.838 (3H, d, J = 6.6 Hz), 0.855 (3H, t, J = 7.2 Hz), 0.940 (IH, d oft, Jd = 5.2 Hz, J, = 11.6 Hz), 1.033 (3H, s), 1.063 (21H, s), 0.98-1.21 (5H, m), 1.26-1.34 (IH, brq), 1.38- 1.65 (8H, m), 1.77-1.86 (3H, m), 1.95-2.05 (2H, m), 2.26-2.36 (2H, m), 3.580 (IH, approx septet, J = 4.6 Hz), 5.339 (IH, si brd J = 5.0 Hz).
Example 11 : 20R.3β-(t-Butyldimethylsiloxy)-22-homopregn-5-en-22-ol.
20R,3β-(t-Butyldimethylsiloxy)-22-homopregn-5-en-22-al (613 mg, 1.38 mmol, 11.75:1 2OR: S ratio) was dissolved with warming in ethanol/toluene (2:1, 9 mL), and the solution was stirred on an ice bath under nitrogen for 10 minutes, producing a fine precipitate. Sodium borohydride (50.0 mg, 1.32 mmol) was added in one portion, and within 1 minute solution had clarified, with mild gas evolution. After 20 minutes aqueous sodium hydroxide (0.25 M, 10 mL) and MTBE (10 mL) were added to the cold mixture. The phases were separated, and the aqueous phase was extracted with MTBE (2 x 10 mL). The combined organic extracts were washed with water (2 x 10 mL), saturated brine (10 mL) and dried (MgSO4). The solvent was removed under reduced pressure to give crude product as a white solid (574 mg). The material was purified by flash chromatography on silica gel, eluting with 5% then 7.5% ethyl acetate/hexanes to give 20R,3β-(t-butyldimethylsiloxy)-22-homopregn-5-
en-22-ol (388.2 mg, 62.9%) as a white solid with a >200:l 20R:S ratio by 1H NMR. 1H NMR (CDCl3 500 MHz) δ: 0.082 (6H, s), 0.726 (3H, s), 0.914 (9H, s), 0.984 (3H, d, J = 6.5 Hz), 1.026 (3H, s), 0.91-1.30 (5H, m), 1.32-1.42 (IH, m), 1.43-1.68 (9H, m), 1.71-1.78 (IH, m), 1.81-1.88 (2H, m), 1.90-1.95 (IH, brd), 1.97-2.05 (IH, brd), 2.17-2.22 (IH, brd), 2.25-2.34 (IH, brt), 3.46-3.56 (2H, m), 3.73-3.80 (IH, brd of d), 5.343 (IH, brd, J = 4.5 Hz).
Example 12: One flask, 2 step, preparation of 20R,3β-(f-butyldimethylsiloxy)-22- homopregn-5 -en-22-ol from 3 β-(t-butyldimethylsiloxy)-22-homopregn-5-en-20R,22- epoxide.
A fine suspension of magnesium bromide bis(diethyl etherate) complex (419 mg. 1.62 mmol) in toluene (10 mL) was added dropwise over 10 minutes to a solution of crude 3β-(t-butyldimethylsiloxy)-22-homopregn-5-en-20R,22-epoxide (1.4455 g, 3.25 mmol) in toluene (30 mL), stirred under nitrogen at -10 0C, forming a cloudy suspension. After 1.5 h, the reaction mixture was allowed to warm up slowly to 0 0C, and after 5 hours lithium aluminum hydride (75.6 mg. 1.99 mmol was added in one portion, followed by dropwise addition of THF (5 mL) over 2 minutes. After a further 10 minutes at 0 0C, the reaction mixture was quenched by addition of dilute hydrochloric acid (CAUTION!, 0.4 M, 25 mL), the first 1 mL being added dropwise, and the remainder only after gas evolution had ceased. The phases were separated, and the aqueous phase was extracted with MTBE (2 x 25 mL), and the combined organic extracts were rinsed with water (2 x 25 mL), saturated brine (25 mL) and dried (MgSO4). The solvent was removed under reduced pressure to give the crude alcohol (1.3516 g), which was purified by flash chromatography on silica gel, eluting with 7.5%, then 10% ethyl acetate in hexanes to give 20R,3β-(£- butyldimethylsiloxy)-22-homopregn-5-en-22-ol (1.1546 g, 79.5%) as glistening white plates with a >200:l 20R:S ratio by 1H NMR.
Example 13 : 20R,3 β-(Triisopropylsiloxy)-22-homopregn-5-en-22-ol.
A stirred solution of 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-al (423 mg, 0.87 mmol) in THF (5 mL) and MeOH (1 mL) was cooled in an ice bath under nitrogen. Sodium borohydride (33 mg, 0.87 mmol) was added in one portion
and the mixture was stirred for 30 min at 0 0C. After quenching with 0.5 M hydrochloric acid, the mixture was partitioned between EtOAc and water, extracted with EtOAc (2x), washed with brine, dried over magnesium sulfate, and concentrated to give 414 mg of a crude white foam. Flash chromatography (15% EtOAc / hexanes) gave 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-ol (313 mg, 74%) as a white crystalline solid with a >100: 1 2OR: S ratio by 1H NMR. 1H NMR (CDCl3 500 MHz) δ: 0.727 (3H, s), 0.947 (IH, d oft, Jd = 5 Hz, J, = 11 Hz), 0.987 (3H, d, J = 6.5 Hz), 1.033 (3H, s), 1.082 (21H, s), 1.00-1.30 (4H, m), 1.33-1.41 (IH, m), 1.43- 1.68 (9H, m), 1.78-1.88 (3H, m), 1.90-1.95 (IH, brd), 1.96-2.04 (IH, brd), 2.23-2.34 (2H, m), 3.512 (IH, brt, J = 7.9 Hz), 3.577 (1 H, approx septet, J = 5.3 Hz), 3.761 (IH, brd, J = IO Hz), 5.338 (IH, brd, J = 4.9 Hz).
Example 14: 20R,3β-(Triisopropylsiloxy)-22-homopregn-5-en-22-yl methanesulfonate .
A stirred solution of 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-ol (0.44 g, 0.90 mmol) in DCM (5 mL) and triethylamine (0.38 mL, 2.70 mmol) was cooled in an ice bath under nitrogen. Methanesulfonyl chloride (0.10 mL, 1.35 mmol) was added dropwise and the solution was stirred for 2 h at 0 0C. The reaction mixture was partitioned between EtOAc and water, extracted with EtOAc (2x), washed with 0.5 M HCl, sat. sodium bicarbonate solution and saturated brine, dried over magnesium sulfate, and concentrated to give 0.52 g of a gummy white foam. Flash chromatography (20% EtOAc / hexanes) gave 20R,3β-(triisopropylsiloxy)-22- homopregn-5-en-22-yl methanesulfonate (0.42 g, 82%) as a white foam, with a >200:l 20R:S ratio (by 1U NMR). 1U NMR (CDCl3 500 MHz) δ: 0.739 (3H, s), 0.946 (IH, d of t, Jd = 5 Hz, J, = 11.4 Hz), 1.028 (3H, s), 1.029 (3H, d, J = 6.5 Hz), 1.081 (21H, s), 1.00-1.70 (13H, m), 1.78-1.93 (4H, m), 1.95-2.03 (IH, brd), 2.23-2.35 (2H, m), 3.029 (3H, s), 3.578 (1 H, approx septet, J = 5.3 Hz), 4.007 (IH, d of d, J = 7.8, 9.3 Hz), 4.401 (IH, d of d, J = 3.6, 9.4 Hz), 5.332 (IH, brd, J = 5.0 Hz).
Example 15 : 20R,3 β-(Triisopropylsiloxy)-22-homopregn-5-en-22-yl p- toluenesulfonate.
To a stirred solution of 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-ol
(305 mg, 0.62 mmol) in DCM (5 mL) was added triethylamine (0.26 mL, 1.87 mmol) and a crystal of dimethylaminopyridine under nitrogen at 25 0C. Toluenesulfonyl chloride (178 mg, 0.94 mmol) was added and the solution was stirred for 18 h. The solution was partitioned between EtOAc and 0.5 M hydrochloric acid, and was extracted with EtOAc (2x), washed with 5% aqueous sodium hydroxide solution, saturated brine, and dried over magnesium sulfate. The solvent was removed under reduced pressure to give 404 mg of an off-white solid. Recrystallization from isopropanol gave 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-yl p- tolunesulfonate (346 mg, 86%) as white needles with a >200:l 2OR: S ratio (by 1H NMR). 1H NMR (CDCl3 500 MHz) δ: 0.623 (3H, s), 0.905 (3H, d, J = 6.5 Hz), 1.012 (3H, s), 1.084 (21H, s), 0.87-1.67 (14H, m), 1.78-1.93 (4H, m), 1.93-2.00 (IH, brd), 2.23-2.35 (2H, m), 2.480 (3H, s), 3.576 (1 H, approx septet, J = 5.3 Hz), 3.836 (IH, t, J = 8.3 Hz), 4.165 (IH, d of d, J = 3.2, 9.3 Hz), 5.322 (IH, brd, J = 4.5 Hz), 7.370 (2H, d, J = 8.0 Hz), 7.814 (2H, d, J = 8.0 Hz).
Example 16: 20S,3β-(Triisopropylsiloxy)-22,23-bishomopregn-5-ene.
A solution of 20R,3β-(triisopropylsiloxy)-22-homopregn-5-en-22-yl/> toluenesulfonate (340 mg, 0.53 mmol) in THF (3 mL) was cooled in an ice bath. Dilithium tetrachlorocuprate (1.16 mL, 0.116 mmol, 0.1 M in THF), was added followed by the dropwise addition of methylmagnesium bromide (0.88 mL), 2.64 mmol, 3.0 M in ether). The mixture was allowed to warm slowly to room temperature and stirred for 22 h. The mixture was cooled in an ice bath and quenched with 0.5 M HCl. The mixture was partitioned between EtOAc and water, extracted with EtOAc (2x), washed with saturated sodium bicarbonate solution, saturated brine, dried over magnesium sulfate, and concentrated to give 253 mg of an off white solid. Recrystallization from isopropanol afforded 20S,3β-(triisopropylsiloxy)-22,23- bishomopregn-5-ene (220 mg, 86%) as a white solid. DE cannot be determined by 1H NMR. NMR spectrum identical to Example 10.
Example 17: 20S,7α/β-Bromo-3β-(triisopropylsiloxy)-22,23-bishomopregn-5-ene.
Sodium bicarbonate (1.90 g, 22.6 mmol) and lN,3Λ/-dibromo-5,5- dimethylhydantoin (0.97 g, 3.39 mmol) were added to a solution of
20S,3β-(triisopropylsiloxy)-22,23-bishomopregn-5-ene (2.20 g, 4.52 mmol) in cyclohexane (80 mL), which was sparged with nitrogen, and then stirred on a 90oC oil bath for 30 minutes. The reaction mixture was allowed to cool to room temperature, and the solids were removed by vacuum filtration. The solvent was removed under reduced pressure to give crude 20S,7α/β-Bromo- 3β-(triisopropylsiloxy)-22,23-bishomopregn-5-ene, as a viscous light yellow oil which was used directly in the next step. 1H NMR (CDCl3 500 MHz) δ: 0.733 (3H, s), 0.856 (3H, t, J = 7.2 Hz), 0.946 (3H, d, J = 6.6 Hz), 1.052 (3H, s), 1.085 (21H, s), 1.0-1.56 (1OH, m), 1.74-2.06 (7H, m), 2.27-2.40 (2H, m), 3.649 (IH, approx septet, J = 4.6 Hz), 4.745 (IH, si brs), 5.725 (IH, si brd J = 5.3 Hz).
Example 18 : 20S.7β-(4-Chlorophenylthio)-3 β(triisopropylsiloxy)-22.23- bishomopregn-5-ene.
Tetra-n-butylammonium bromide (2.91 g, 9.04 mmol) was added in one portion to a solution of crude 20S,7-α/β-bromo-3β-(triisopropylsiloxy)-22,23- bishomopregn-5-ene (4.52 mmol, obtained from the previous reaction) in toluene/acetone (4: 1 , 40 mL), stirred on an ice bath under nitrogen. After 2 hours, triethylamine (0.94 mL, 6.78 mmol) and 4-chlorothiophenol (0.65 g, 4.52 mmol) were added sequentially, and the ice bath was removed, and the reaction mixture was stirred at 250C for 2 hours. The reaction was worked up by pouring onto water (100 mL), and extracting with EtOAc (2 x 50 mL). The combined organic extracts were washed with dilute hydrochloric acid (0.5 M, 50 mL), saturated sodium bicarbonate solution (50 mL), saturated brine (50 mL) and dried (MgSO4). The solvent was removed under reduced pressure to give crude 20S,7β-(4-chlorophenylthio)- 3β(triisopropylsiloxy)-22,23-bishomopregn-5-ene (3.17 g, quant) as a light orange gum. 1H NMR (CDCl3 500 MHz) δ: 0.596 (3H, s), 0.721 (3H, s), 0.853 (3H, d, J = 6.5 Hz), 0.860 (3H, t, J = 6.5 Hz), 1.085 (21H, s), 0.95-1.95 (16H, m), 1.98 (IH, brd), 2.20 (IH, bit), 2.28 (IH, brd), 3.308 (IH, si brd, J = 8.5 Hz), 3.554 (IH, approx septet, J = 4.6 Hz), 5.343 (IH, si brd J = 5.3 Hz), 7.277 (2H, d, J= 8.6 Hz), 7.306 (2H, d, J = 8.6 Hz).
Example 19: 20S.7β-(4-ChlorophenylsulfinylV3β-(triisopropylsiloxyV22.23- bishomopregn-5-ene. m-Chloroperoxybenzoic acid (77%, 1.11 g, 4.95 mmol) was added in one portion to a solution of crude 20S,7β-(4-chlorophenylthio)-3β(triisopropylsiloxy)- 22,23-bishomopregn-5-ene (3.17 g, 4.52 mmol) in EtOAc (50 mL) stirred under nitrogen at O0C. After 1 hour the reaction mixture was diluted with further EtOAc (100 mL) and rinsed with saturated sodium bicarbonate solution (2 x 100 mL), saturated brine (50 mL) and dried (MgSO4). The solvent was removed rigorously under reduced pressure without heating to give crude 20S,7β-(4- chlorophenylsulfinyl)-3β-(triisopropylsiloxy)-22,23-bishomopregn-5-ene (3.14 g, quant) as a light yellow glassy foam. 1H NMR Major isomer only. (CDCI3 500 MHz) δ: 0.052 (3H, s), 0.706 (3H, s), 0.865 (3H, d, J = 6.5 Hz), 0.871 (3H, d, J = 6.5 Hz), 1.083 (21H, s), 0.95-2.10 (18H, m), 2.43 (IH, brd), 3.551 (IH, approx septet, J = 4.6 Hz), 3.664 (IH, si brd, J = 8.7 Hz), 5.773 (IH, si brs), 7.40-7.50 (4H, m).
Example 20: 20S,3β-(Triisopropylsiloxy)-22,23-bishomopregna-5,7-diene.
A stirred solution of crude 20S,7β-(4-chlorophenylsulfmyl)- 3β-(triisopropylsiloxy)-22,23-bishomopregn-5-ene (3.14 g, 4.52 mmol) and triethylamine (1.38 mL, 9.9 mmol) in toluene (40 mL) was heated to 7O0C under nitrogen for 4 hours. The reaction mixture was allowed to cool, poured onto water (100 mL) and EtOAc (50 mL). The layers were separated, and the aqueous phase was extracted with EtOAc (2 x 25 mL). The combined organic extracts were washed with dilute hydrochloric acid (0.5 M, 50 mL), saturated sodium bicarbonate solution (50 mL) and saturated brine (50 mL) and dried (MgSO4). The solvent was removed under resuced pressure to give 3.10 g of light orange gum which was purified by silica gel chromatography (1.5% EtOAc/hexanes, solid loaded in toluene) and recrystalization from isopropanol to give 20S,3β-(triisopropylsiloxy)-22,23- bishomopregna-5,7-diene (1.17 g, 54%) as light yellow crystals. This contained about 5% bis (4-chlorophenyl) disulfide and about 5% of the monoene starting material. 1U NMR (CDCl3 500 MHz) δ: 0.639 (3H, s), 0.865 (3H, t, J = 7.2 Hz), 0.967 (3H, s), 1.084 (21 H, m), 1.17-1.47 (6H, m), 1.52-1.78 (6H, m), 1.85-1.94 (4H, m), 1.98 (IH, brt), 2.08 (IH, brd), 2.33-2.39 (IH, brt), 2.94 (IH, brd), 3.696 (IH,
approx septet, J -4.5 Hz), 5.410 (IH, narrow m), 5.578 (IH, dd, J = 5.5,2.3 Hz).
Example 21 : 7α-Bromo-3,Q-(t-butyldimethylsilyl)pregn-5-en-3β-ol-20-one
A suspension of 3,0-(£-butyldimethylsilyl)pregn-5-en-3β-ol-20-one (430.6 mg, 1.0 mmol), l,3-dibromo-5,5-dimethylhydantoin (181.0 mg, 0.633 mmol), calcium carbonate (24.4 mg, 0.244 mmol) and 2,2'-azobis(isobutyronitrile) (6.2 mg, 0.0378 mmol) in cyclohexane (10 mL) was degassed by an Ar sparge, and heated to 75 0C, with stirring under nitrogen for 30 minutes. The mixture was filtered hot, and the residue was rinsed with hot cyclohexane (5 mL). The solvent was removed under reduced pressure at 45 0C, and the residual partially solidified light yellow oil was sonicated, and kept at 4 0C for 68 h. The solids were collected by vacuum filtration and rinsed with cyclohexane (1.0 mL) to give 7α-bromo-3,0-(t- butyldimethylsilyl)pregn-5-en-3β-ol-20-one (303.2 mg, 59.5%) as a pale yellow solid. A further amount (17.7 mg, 2.9%) was recovered from the mother liquors. 1H NMR (CDCl3 500 MHz) δ: 0.085 (6H, s), 0.686 (3H, s), 0.903 (9H, s), 1.041 (3H, s), 1.16-1.26 (2H, m), 1.38-1.9.2 (12H, m), 2.07 (IH, brd), 2.146 (3H, s), 2.15-2.27 (2H, m), 2.638 (IH, t, J = 9.3 Hz), 3.584 (IH, approx septet, J = 4.6 Hz), 4.744 (IH, narrow m), 5.725 (IH, d, J = 3.9 Hz).
Example 22: 3,Q-(t-butyldimethylsilyl)-7β-(4-chlorophenylthio)pregn-5-en-3β-ol-20- one
7α-Bromo-3,O-(t-butyldimethylsilyl)pregn-5-en-3β-ol-20-one (228 mg, 0.448 mmol) in CH2Cl2ZMTBE (1 :1, 2 mL) was added dropwise over 3 minutes to a thick white slurry of 4-chlorothiophenol (71.8 mg, 0.496 mmol) and DBU (76.8 mg, 0.504 mmol) in MTBE ( 1.0 mL) stirred under nitrogen at 0 0C. After 1 hour, the reaction mixture was quenched with dilute hydrochloric acid (0.5 mL, 10 mL), and the organic phase was extracted with MTBE (2 x 10 mL). The combined organic extracts were washed with water (10 mL), dilute NaOH solution (0.2 M, 10 mL), water (10 mL) and saturated brine (10 mL) and dried (MgSO4). The solvent was removed rigourously under reduced pressure to give 3,0-(£-butyldimethylsilyl)-7β-(4- chlorophenylthio)pregn-5-en-3β-ol-20-one (238 mg, 92.66%) as a white solid foam. 1H NMR (CDCl3 500 MHz) δ: 0.074 , 0.788(3H, 3H, 2s), 0.576 (3H, s), 0.682 (3H,
s), 0.911 (9H, s), 0.91-1.08 (3H, m), 1.27-1.78 (8H, m), 1.82-1.92 (IH, m), 1.96-2.07 (2H, m), 2.158 (3H, s), 2.15-2.28 (3H, m), 2.542 (IH, t, J = 9.5 Hz), 3.306 (IH, d, J = 8.8 Hz), 3.478 (IH, approx septet, J = 5.2 Hz), 5.353 (IH, s), 7.279, 7.323 (2H, 2H, ABq, J = 8.5 Hz).
Example 23: 3,Q-(t-butyldimethylsilyl)-7β-(4-chlorophenylsulfϊnyl)pregn-5-en-3β- ol-20-one m-Chloroperoxybenzoic acid (77%, 219.2 mg, 0.978 mmol) was added to a light yellow solution of give 3,0-(t-butyldimethylsilyl)-7β-(4- chlorophenylthio)pregn-5-en-3β-ol-20-one (567.3 mg, 0.989 mmol) in dichloromethane (5.0 mL) stirred under nitrogen at 0 oC. After 30 minutes further mCPBA (77%, 11.5 mg, 0.051 mmol) was added, and after 1 hour the cold solution was quenched by addition of dilute NaOH solution, (0.25 M, 10 mL), and the organic phase was extracted with dichloromethane (2 x 10 mL). The combined extracts were washed with dilute NaOH solution (0.25 M, 10 mL), water (10 mL), saturated brine (10 mL), and dried (Na2SO4). The solvent was removed rigourously under reduced pressure to give give 3,O-(t-butyldimethylsilyl)-7β-(4-chlorophenylsulfinyl)pregn-5- en-3β-ol-20-one (523.2 mg, 89.76%) as a very pale yellow foamed glass.
Example 24: 3β-(f-Butyldimethylsiloxy)pregna-5,7-dien-20-one.
A pale yellow solution of
chlorophenylsulfmy^pregn-S-en-Sβ-ol^O-one (518.9 mg, 0.88 mmol) and triethylamine (0.25 mL) in toluene (5 mL) was stirred under nitrogen at 70 0C for 4 hours the mixture darkening somewhat. The yellow solution was filtered through a small pad of silica gel (3 cm x 3.4 cm) with gentle suction, and the silica gel was washed with 5%, then 10% ethylacetate/hexanes (100 mL, 100 mL) collecting 50 mL fractions. The appropriate fractions were concentrated under reduced pressure to give 3β-(t-butyldimethylsiloxy)pregna-5,7-dien-20-one (304.2 mg, 80.6%) as a white solid. 1H NMR (CDCl3 500 MHz) δ: 0.095 (6H, s), 0.602 (3H, s), 0.921 (9H, s), 0.954 (3H, s), 1.306 (IH, d oft, Jd = 3.5 Hz, J, = 13.5 Hz), 1.49-1.63 (3H, m), 1.67- 1.92 (6H, m), 2.02-2.09 (2H, m), 2.12-2.29 (2H, m), 2.174 (3H, s), 2.33-2.41 (2H, m), 2.651 (IH, t, J = 9.0 Hz), 3.619 (IH, approx septet, J = 5 Hz), 5.446 (IH, narrow m),
5.583 (IH, d, J = 5.5 Hz).
Example 25: 3β-Pregn-5-enol-20-one acetate
4-(Λ/,Λ/-dimethylamino)pyridine (0.12 g, 1.0 mmol) was added to a white slurry of 3β-pregn-5-enol-20-one (9.50 g, 30 mmol) in a mixture of triethylamine (10 mL) and acetic anhydride (6.0 mL) stirred vigourously under nitrogen at 25 0C. Within a minute the slurry liquefied slightly, and an exotherm was noted. After 3 min the slurry thickened to a paste, and after about 20 minutes began to yellow. After 30 minutes, the reaction mixture was stirred on an ice-bath and ice-water (150 mL) was added dropwise over 5 minutes. After a further 20 minutes stirring on the ice-bath the reaction mixture was Buchner filtered, and the residue was rinsed with ice-water (4 x 50 mL). The residue was air dried, and then dried in a vacuum oven at 50 0C for 4 hours to give 3β-pregn-5-enol-20-one acetate (10.65 g, 99%) as a very pale yellow free-flowing solid. 1H NMR (CDCl3 500 MHz) δ: 0.657 (3H, s), 1.046 (3H, s), 0.99- 1.07 (IH, m), 1.13-1.31 (3H, m), 1.44-1.77 (8H, m), 1.87-1.94 (2H, m), 1.97-2.12 (2H, m), 2.06 (3H, s), 2.16 (3H, s), 2.16-2.25 (IH, m), 2.19-2.38 (2H, m), 2.56 (IH, t, J = 9.0 Hz), 4.63 (IH, approx septet, J = 5 Hz), 5.40 (IH, d, J = 6.0 Hz).
Example 26: 3β,7α-Bromopregn-5-enol-20-one acetate
3β-Pregn-5-enol-20-one acetate (3.585 g, 10.0 mmol), l,3-dibromo-5,5- dimethylhydantoin (1.876 g, 6.561 mmol), calcium carbonate (201 mg, 2.0 mmol) and 2,2'-azobis(isobutyronitrile) (41 mg, 0.25 mmol) were suspended in cyclohexane (100 mL) and degassed by a vigourous argon sparge, prior to being placed under nitrogen and stirred at 55 0C. The reaction mixture took on a pale yellow cast after ~5 minutes, and around 20 minutes turned pale orange before decolorizing around 24 minutes. Meanwhile the initial fine suspension became a largely flocculent precipitate around 15 minutes, and tic (20% EtOAc/hexanes) showed very little starting material. After 27 minutes the mixture was removed from the heat, and stirring was discontinued, giving a very pale yellow solution and a white precipitate. At 30 minutes the reaction mixture was filtered through a medium frit under slight vacuum, and the residue was rinsed with cold cyclohexane (20 mL). The combined organic filtrates were stripped on a rotorvap at 30 0C or below, to a total volume of
about 10 niL of a light yellow liquid with a granular precipitate, which was allowed to stand at 25 0C for 22 hours, during which time it became brighter yellow and precipitated further. The solid precipitate was collected by Buchner filtration, rinsed with cyclohexane (2 x 2 mL), and air dried to give 3β,7α-bromopregn-5-enol-20-one acetate (2.917 g, 66.68%) as a slightly off-white granular solid. The mother liquors (~6 mL) were allowed to stand at 25 0C for a further 70 hours giving a further desired compound (386 mg, 8.83%) as a light magnolia solid. Nmr analysis of both crops shows purity in the 95-6% range. 1H NMR (CDCl3 500 MHz) δ: 0.695 (3H, s), 1.067 (3H, s), 1.213 (IH, d of q, Jd = 12.2 Hz, Jq = 6.2 Hz), 1.313 (IH, d oft, Jd = 3.8 hz, J, = 13.9 Hz), 1.38-1.47 (2H, m), 1.49-1.97 (9H, m), 2.066 (3H, s), 2.164 (3H, s), 2.05-2.25 (2H, m), 2.37-2.45 (2H, m), 2.644 (IH, t, J = 9.2 Hz), 4.67-4.77 (2H, m), 5.776 (IH, d, J = 5.1Hz).
Example 27: 3β-Pregna-5,7-dienol-20-one acetate
A solution of tetra-n-butylammonium fluoride in THF (1.0 M, 3 mL, 3.0 mmol), which had been predried over activated molecular sieves, was added to a solution of crude 3β,7α-bromopregn-5-enol-20-one acetate (442.5 mg, ~1.0 mmol) in THF (5 mL), stirred under nitrogen at 0 0C. After 1 hour, the reaction mixture was poured onto water (10 mL), and extracted with MTBE (2 x 10 mL). The combined organic extracts were washed with water (2 x 10 mL), saturated brine (10 mL) and dried (MgSO4). The solvent was removed under reduced pressure and the residual light yellow solid (345.4 mg) was purified by flash chromatography on silica gel, eluting with 12% EtOAc/hexanes, to give pregna-5,7-dienol-20-one acetate (162.2 mg, 45.5%) as white plates. 1H NMR (CDCl3 500 MHz) δ: 0.606 (3H, s), 0.972 (3H, s), 1.399 (IH, d of t, Jd = 4.0 Hz, J, = 10 Hz), 1.50-1.65 (2H, m), 1.68-1.88 (5H, m), 1.92-1.98 (2H, m), 2.03-2.30 (5H, m), 2.074 (3H, s), 2.177 (3H, s), 2.390 (IH, brt, J = 12.7 Hz), 2.537 (IH, brd, J = 14.5 Hz), 2.658 (IH, t, J = 9.1 Hz), 4.735 (IH, septet, J = 5 Hz), 5.452 (IH, d, J = 2.7 Hz), 5.603 (IH, d, J = 3.3 Hz).
Example 28: 3β-Pregna-5,7-dienol-20-one
A solution of tetra-n-butylammonium fluoride in THF (1.0 M, 20 mL, 20 mmol), which had been predried over activated molecular sieves, was stirred at 0 0C,
under nitrogen and 3β,7α-bromopregn-5-enol-20-one acetate (2.914 g, 6.663 mmol) was added in one portion. After 3 hours, the ice-bath was removed, and the reaction mixture was stirred at 25 0C for 30 minutes, and then methanol (20 mL) and potassium carbonate (3.454 g, 25 mmol) were added, and the mixture was stirred vigourously at 25 0C. Within an hour the mixture had become a thick beige slurry, and after 2.5 hours the reaction mixture was recooled on an ice-bath with stirring, and cold water (125 mL) was added over 5 minutes. After 30 minutes, the reaction mixture was Buchner filtered, and the residue was rinsed with cold water (2 x 25 mL). The residue was dried in a vacuum oven at 50 0C for 2 hours, and air dried for 48 hours to give 3β-pregna-5,7-dienol-20-one (1.976 g, 94.3%) as a pale yellowish- beige solid. Nmr analysis shows purity in the 95-6% range. 1H NMR (CDCl3 500 MHz) δ: 0.608 (3H,s), 0.966 (3H,s), 1.344 (IH, brt (J = 11.5 Hz), 1.47-1.63 (5H, m), 1.67-1.87 (3H, m), 1.90-1.96 (2H, m), 2.02-2.08 (2H, m), 2.13-2.36 (3H, m), 2.177 (3H, s), 2.509 (IH, brd, J = 14.5 Hz), 2.654 (IH, t, J = 9.2 Hz), 3.669 (H, septet, J = 5.5 Hz), 5.453 (IH, narrow m), 5.611 (IH, narrow m).
Example 29: 3β-(f-Butyldimethylsiloxy)pregna-5,7-dien-20-one. t-Butyldimethylsilyl chloride (76.4 mg, 0.507 mmol), 4-(NJV- dimethylamino)pyridine (4.5 mg, 0.037 mmol) and pyridine (0.1 mL) were added to a light yellow slurry of 3β-pregna-5,7-dienol-20-one (127 mg, 0.404 mmol) in DMF (0.5 mL) stirred under nitrogen at 25 0C. After 20 hours, the reaction mixture was cooled on an ice bath for 15 minutes, and the solids were collected by Buchner filtration, rinsed with cold DMF, (1.0, 0.5 mL) and dried in a vacuum oven at 50 oC, to give 3β-(t-butyldimethylsiloxy)pregna-5,7-dien-20-one (154.4 mg, 89.1%) as a white solid. 1H NMR (CDCl3 500 MHz) δ: 0.095 (6H, s), 0.602 (3H, s), 0.921 (9H, s), 0.954 (3H, s), 1.306 (IH, d oft, Jd = 3.5 Hz, J, = 13.5 Hz), 1.49-1.63 (3H, m), 1.67-1.92 (6H, m), 2.02-2.09 (2H, m), 2.12-2.29 (2H, m), 2.174 (3H, s), 2.33-2.41 (2H, m), 2.651 (IH, t, J = 9.0 Hz), 3.619 (IH, approx septet, J = 5 Hz), 5.446 (IH, narrow m), 5.583 (IH, d, J = 5.5 Hz).
Example 30: 3β-(^Butyldimethylsiloxy)-22-homopregna-5,7-diene-20R,22-epoxide. Potassium hexamethyldisilazane (2.49 g, 12.48 mmol) in THF (15 mL) was
added to a slurry of trimethylsulfonium iodide (2.55 g, 12.48 mmol) in THF (15 mL) stirred under nitrogen at 25 0C. The slurry was stirred 10 minutes, then toluene (10 mL) was added and the mixture was cooled to -7O0C in a dry ice / isopropanol bath for 15 min. A solution of 3β-(£-butyldimethylsiloxy)pregna-5,7-dien-20-one in toluene (30 mL) was added dropwise over 20 min. The mixture was stirred Ih at -70 0C, then allowed to warm slowly to O0C over 2h. The bath was removed and the mixture was allowed to warm to room temperature and stirred 30 min. The mixture was cooled in an ice bath and quenched by the rapid addition of acetic acid (1 mL). Water (30 mL) was added along with NaHSO3 (100 mg) and the mixture was allowed to warm to room temperature and stirred for 15 min. The mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with MTBE (2x25 mL). The combined organic extracts were washed with saturated sodium bicarbonate solution, brine, dried over magnesium sulfate, and concentrated to give 3β-(t-butyldimethylsiloxy)-22-homopregn-5,7-diene-20R,22-epoxide (2.67 g, 99 %) as white glistening plates, which was a greater than 40: 1 mixture of diastereoisomers (est. by 1H NMR). 1H NMR (CDCl3 500 MHz) δ: 0.095 (6H, s), 0.773 (3H, s), ), 0.918 (9H, s), 0.970 (3H, s), 1.25-1.40 (2H, m), 1.403 (3H, s), 1.43- 1.67 (5H, m), 1.72-2.03 (8H, m) 2.14 (IH, brd), 2.35-2.39 (2H, m), 2.555 (IH, d, J = 4.8 Hz), 3.618 (IH, approx septet, J -4.5 Hz), 5.410 (IH, narrow m), 5.576 (IH, d, J = 5.4 Hz).
Example 31 : 20R.3β-("t-ButyldimethylsiloxyV22-homopregna-5.7-dien-22-al.
Magnesium bromide bis-diethyl etherate (40.0 mg, 0.154 mmol) was added in one portion to a solution of 3β-(£-butyldimethylsiloxy)-22-homopregna-5,7-dien- 20R,22-epoxide (143.5 mg, 0.308 mmol) in toluene (3.0 mL), stirred under nitrogen at -10 0C. After 2 hours, the reaction mixture was stirred at 0 0C for 3 hours, and then quenched by addition of dilute hydrochloric acid (0.1 M, 5 mL). The mixture was extracted with MTBE (10 mL), and the organic phase was washed with water (2 x 10 mL), saturated brine (10 mL), and dried (MgSO4). The solvent was removed under reduced pressure to give 20R,3β-(t-butyldimethylsiloxy)-22-homopregn-5-en-22-al (136.4 mg, 95%yield) as a yellow waxy solid. 1H NMR (CDCl3 500 MHz) δ: 0.082 (6H, s), 0.637 (3H, s), 0.909 (9H, s), 0.9321 (3H, s), 1.073 (3H, d, J = 6.8 Hz), 1.13-
1.32 (2H, m), 1.39-2.02 (14H, m), 2.31-2.37 (2H, m), 3.600 (IH, approx septet, J -4.5 Hz), 5.415 (IH, narrow m), 5.561 (IH, d, J = 5.3 Hz) 9.589 (IH, d, J = 4.1 Hz).
Example 32: 20S,3β-^Butyldimethylsiloxy)-22,23-bishomopregna-5,7,22-triene Methyltriphenylphosphonium iodide (405.6 mg, 1.0 mmol) and potassium hexamethyldisilazane (190.1 mg. 0.95 mmol) were stirred together in THF (2.0 mL) under nitrogen at 25 0C, and then the bright yellow slurry was cooled to 0 0C, and 20R,3β-(t-butyldimethylsiloxy)-22-homopregn-5-en-22-al (133.0 mg, 0.30 mmol) in THF (3.0 mL) was added dropwise over 2 minutes. After 15 minutes the reaction mixture was diluted with hexanes (50 mL), and stirred with celite (1.0 g) at 0 0C for 20 minutes. The reaction mixture was eluted through a small silica gel plug, and the solvent was removed under reduced pressure to give 20S,3β-(t- butyldimethylsiloxy)-22,23-bishomopregna-5,7,22-triene (103.5 mg, 78%) as a pale yellow waxy solid. 1H NMR (CDCl3 400 MHz) δ: 0.049 (6H, s), 0.587 (3H, s), 0.878 (9H, s), 0.902 (3H, s), 0.929 (3H, d, J = 6.6 Hz), 1.02-1.11 (IH, m), 1.20-1.98 (15H, m), 2.02-2.14 (2H, m), 2.28-2.33 (2H, m), 3.57 (IH, approx septet, J -4.5 Hz), 4.836 (IH, dd, J = 10.1, 2.1 Hz), 4.963 (IH, dd, J = 17.1, 2.1 Hz), 5.363 (IH, dt, Jd= 5.3 Hz, J, = 2.8 Hz), 5.534 (IH, d, J = 5.3 Hz) 5.717 (IH, ddd, J = 9.5, 10.1,17.1 Hz).
Example 33: One flask, 2 step, preparation of 20R,3β-(f-butyldimethylsiloxy)-22- homopregna-5 ,7-dien-22-ol from 3 β-(t-butyldimethylsiloxy)-22-homopregna-5 ,7- diene-20R,22-epoxide.
A suspension of magnesium bromide bis diethyletherate (106 mg, 0.41 mmol) in toluene (4 mL) was cooled in an ice bath. 3β-(£-Butyldimethylsiloxy)-22- homopregna-5,7-dien-20R,22-epoxide (365 mg, 0.82 mmol) was added in one portion. The mixture was stirred for 2 h at O0C, then MeOH (1 mL) was added followed by sodium borohydride (16 mg, 0.41 mmol). After 20 min., the reaction was quenched by the dropwise addition of 0.5 M HCl. After 10 min, the ice bath was removed and the mixture was transferred to a separatory funnel and extracted with MTBE (2x). The combined organic extracts were washed with saturated sodium bicarbonate solution, saturated brine, dried over magnesium sulfate, and concentrated to give 390 mg of a white solid, which was taken up in toluene (3 mL) with
sonication. Flash chromatography (15% EtOAc/hexane) gave 20R,3β-(£- butyldimethylsiloxy)-22-homopregna-5,7-dien-22-ol (267 mg, 73%) as a white solid. 1H NMR analysis was consistent with a single (R)-alcohol diastereomer of approximately 97% purity (approx. 3% of allylic alcohol byproduct). 1H NMR (CDCl3 500 MHz) δ: 0.093 (6H, s), 0.665 (3H, s), 0.927 (9H, s), 0.961 (3H, s), 1.003 (3H, d, J = 6.7 Hz), 1.232 (IH, brs), 1.293 (IH, d oft, Jd = 3.9 Hz, J, = 13.5 Hz), 1.35-1.48 (2H, m), 1.51-1.83 (8H, m), 1.85-2.03 (5H, m), 2.33-2.37 (2H, m), 3.554 (IH, dd, J = 10.3, 11.5 Hz), 3.614 (IH, approx septet, J -4.5 Hz), 3.771 (IH, si brd, J = 9.1 Hz), 5.418 (IH, narrow m), 5.578 (IH, d, J = 5.3 Hz).
Example 34: 20R.3β-(t-Butyldimethylsiloxy)-22-homopregna-5.7-dien-22-yl p- toluenesulfonate
To a solution of 20R,3β-(t-butyldimethylsiloxy)-22-homopregn-5,7-dien-22- ol (261 mg, 0.59 mmol) in dichloromethane (5 mL) was added triethylamine (0.25 mL, 1.76 mmol) and a crystal of 4-(N,N-dimethylamino)pyridine. p-Toluenesulfonyl chloride (134 mg, 0.70 mmol) was added and the solution was stirred for 18 h. The solution was partitioned between EtOAc and water and extracted with EtOAc (2x). The combined organic extracts were washed with saturated sodium bicarbonate solution, saturated brine, dried over magnesium sulfate, and concentrated to give 345 mg of a light yellow gum. Flash chromatography (15% EtOAc/hexane) gave 20R,3 β-(t-butyldimethylsiloxy)-22-homopregna-5 ,7-dien-22-yl /?-toluenesulfonate (236 mg, 67%) as a white foam. 1U NMR (CDCl3 500 MHz) δ: 0.094 (6H, s), 0.562 (3H, s), ), 0.920 (3H, d, J = 6.3 Hz), 0.927 (9H, s), 0.935 (3H, s), 1.204 (IH, d oft, Jd = 4.5 Hz, J, = 13.0 Hz), 1.23-1.45 (3H, m), 1.43-1.98 (12H, m), 2.33-2.37 (2H, m), 2.480, (3H, s), 3.610 (IH, approx septet, J -4.5 Hz), 3.888 (IH, dd, J = 7.1, 9.3 Hz), 4.158 (IH, dd, J = 3.5, 9.3 Hz), 5.390 (IH, narrow m), 5.561 (IH, d, J = 5.4 Hz) 7.373 (2H, d, J = 8.0 Hz), 7.818 (2H, d, J = 8.) Hz).
Example 35: 20S,3β-(t-Butyldimethylsiloxy)-22,23-bishomopregna-5,7-diene
A solution of 20R,3β-(t-butyldimethylsiloxy)-22-homopregna-5,7-dien-22-yl /?-toluenesulfonate (230 mg, 0.38 mmol) in THF (3 mL) was cooled in an ice bath. Dilithium tetrachlorocuprate (0.1 M in THF, 0.84 mL, 0.084 mmol) was added
followed by the dropwise addition of methylmagnesium bromide (3.0 M in ether, 0.64 rnL, 1.92 mmol). The mixture was allowed to warm slowly to room temperature and stirred for 23 h. The mixture was cooled in an ice bath and quenched with 0.5 M HCl. The mixture was partitioned between EtOAc and water and extracted with EtOAc (2x). The combined organic extracts were washed with saturated sodium bicarbonate solution, saturated brine, dried over magnesium sulfate, and concentrated to give 20S,3β-(t-butyldimethylsiloxy)-22,23-bishomopregna-5,7-diene (169 mg, 99%) of the title compound as an off-white solid. 1U NMR (CDCl3 500 MHz) δ: 0.093 (6H, s), 0.638 (3H, s), ), 0.859 (3H, d, J = 6.7 Hz), 0.866 (3H, t, J = 7.1 Hz), 0.927 (9H, s), 0.960 (3H, s), 1.17-1.47 (6H, m), 1.51-1.98 (HH, m), 2.07 (IH, brd), 2.33-2.39 (2H, m), 3.617 (IH, approx septet, J -4.5 Hz), 5.408 (IH, narrow m), 5.577 (IH, d, J = 5.4 Hz).
Example 36: 20R,3β-(^Butyldimethylsiloxy)-22-homopregna-5,7-dien-22-yl bromide
Triphenylphosphine (65.1, 65.4, 64.9 mg) was added in three batches at intervals of 10 minutes to a colourless solution of 20R,3β-(£-butyldimethylsiloxy)- 22-homopregna-5,7-dien-22-ol (222.3 mg, 0.50 mmol), carbon tetrabromide (247.1 mg, 0.745 mmol) and collidine (103.2 mg, 0.852 mmol) in dichloromethane (5 mL), stirred under nitrogen at 25 0C. The reaction mixture became a pale yellow solution, and 45 minutes after the first phosphine addition, celite (2 g) was added followed by hexanes (20 mL). The mixture was passed through a silica gel plug (3 x 3.4 cm), eluting with 5% EtOAc/hexanes (200 mL), collecting four fractions. The second fraction was concentrated under reduced pressure, and the volatiles removed on a vacuum pump to give 20R,3β-(t-butyldimethylsiloxy)-22-homopregna-5,7-dien-22- yl bromide (223.1 mg, 87.9%) as a white crystalline solid. 1H NMR (CDCl3 500 MHz) δ: 0.064 (6H, s), 0.658 (3H, s), ), 0.915 (9H, s), 0.956 (3H, s), 1.055 (3H, d, J = 6.5 Hz), 1.230 (IH, dt, Jd = 4.1 Hz, J, = 13.8 Hz), 1.37-2.04 (XXH, m), 2.33-2.38 (2H, m), 3.346 (IH, dd, J = 9.8, 6.3 Hz), 3.624 (IH, approx septet, J -4.5 Hz), 3.661 (IH, dd, J = 9.9, 3.1 Hz), 5.413 (IH, narrow m), 5.571 (IH, d, J = 4.5 Hz).
Example 37: Photolysis of 20S,3β-(t-Butyldimethylsiloxy)-22,23-bishomopregna-
5J-diene to 20S.6Z.3β-(t-Butyldimethylsiloxy)-22.23-bishomo-9J0-secopregna- 5(10).6.8(9)-triene
A 500 niL "Ace Glass" photo-reaction vessel with a quartz immersion well, magnetic stirrer, thermocouple, nitrogen inlet tube, drying tube and cooling bath, was charged with a solution of 20S,3β-(t-butyldimethylsiloxy)-22,23-bishomopregna-5,7- diene (5.00 g, 11.3 mmol) and ethyl 4-dimethylaminobenzoate (0.116 g, 0.60 mmol) in MTBE (500 mL). The solution was thoroughly degassed with a gentle nitrogen sparge overnight, and cooled to between -10 and -2O0C, and was then photo lysed with a Hanovia medium pressure mercury lamp for 3 h. At this point nmr analysis shows about a 6:47:47 mixture of starting material (Compound 39), pre-Vitamin D isomer (compound 54), and Tachy-isomer (compound 55). NMR. Olefmic protons, ppm: starting diene: 5.55 (m), 5.38 (m); Pre-isomer: 5.94 (d, 12.3 Hz), 5.66 (d, 12.3 Hz) 5.49 (m); Tachy-isomer: 6.70 (d, 16.2 Hz), 6.00 (d, 16.2 Hz). 9-acetylanthracene (0.026 g, 0.118 mmol) was added to the solution and a uranium glass filter was placed in the lamp well, to cut off shorter wavelengths than 350 nm, and irradiation was continued at -1O0C for another 20 minutes, when nmr analysis showed almost complete disappearance of tachy isomer (55). The solution was then stripped to dryness to give crude 20S,6Z,3β-(t-butyldimethylsiloxy)-22,23-bishomo-9,10- secopregna-5(10),6,8(9)-triene as a light yellow oil.
Example 38: Thermal rearrangement of 20S,6Z,3β-(t-butyldimethylsiloxy)-22,23- bishomo-9 J0-secopregna-5(10).6.8(9Vtriene to 20S.7Z.7E.3B-(f- butyldimethylsiloxy)-22,23-bishomo-9J0-secopregna-5,7,10(19)-triene.
Crude 20S,6Z,3β-(t-butyldimethylsiloxy)-22,23-bishomo-9,10-secopregna- 5(10),6,8(9)-triene (~5g, ~11.3 mmol) from the previous photolysis was dissolved in warm EtOH (120 mL), and refluxed under nitrogen in the dark for 12 hours. The reaction mixture was allowed to cool slowly to 250C, and was stirred at that temperature for a further 72 hours, at which time the ratio of product to starting material (by nmr) had improved from 1 :2.9 at the end of the reflux to 1 :5.2. (Pre- isomer: 5.94 (d, 12.3 Hz), 5.66 (d, 12.3 Hz) 5.49 (m); Vitamin D type-isomer: 6.16 (d, 11.4 Hz), 6.00 (d, 11.4 Hz), 5.00 (m~bs), 4.77 (m~bs). The crude ethanolic solution was used directly in the next step.
Example 39: (lR.2S.6R.7R)-6-Methyl-7-(riS1metfaylpn)p-l-yl)bicvcler4.3.01nonan- 2-ol
A stirred solution of crude 20S,7Z,7E,3β-(£-butyldimethylsiloxy)-22,23- bishomo-9,10-secopregna-5,7,10(19)-triene (~5 g, -11.3 mmol) in EtOH (120 mL) with a fritted gas inlet was cooled to -7O0C under nitrogen. Once the reaction vessel temperature had been stabilized, an oxygen sparge was initiated, and after 10 minutes, the ozonizer was turned on, and ozone was passed through the solution, producing a noticeable exotherm, but cooling was adjusted to keep the temperature at or below - 650C. The solution became greenish as the reaction ceased to be exothermic, and after a few minutes further, ozone addition was stopped, and the reaction vessel was purged with nitrogen for 10 minutes. Then NaBH4 (4.5 g, 119 mmol) was added in portions at -7O0C with stirring, and the reaction mixture was allowed to warm up slowly to 250C over several hours. After 12 hours, the volatiles were removed under reduced pressure, and the residue was added to water (60 mL), and extracted with MTBE (2 x 60 mL). The combined organic extracts were washed with saturated brine (40 mL), dried, (MgSO4), and the solvent was removed under reduced pressure to give a thick oily residue which was purified by silica gel column chromatography eluting with 2-5% EtOAc/heptanes, to give (lR,2S,6R,7R)-6-methyl-7- ([lS]methylprop-l-yl)bicycle[4.3.0]nonan-2-ol (0.86 g, 36.18%) as a very pale yellow oil.
Example 40: (lR.6R.7RV6-Methyl-7-(riSlmethylprop-l-vπbicvcler4.3.01nonan-2- one
Pyridinium dichromate (2.26 g, 6.00 mmol) was added to a solution of (lR,2S,6R,7R)-6-methyl-7-([lS]methylprop-l-yl)bicycle[4.3.0]nonan-2-ol (0.84 g, 3.99 mmol) in dichloromethane (20 mL), stirred under nitrogen at 250C for 7 hours. The reaction mixture was then passed through a short silica gel column, eluting with MTBE. The solvent was removed under reduced pressure at 250C to give (lR,6R,7R)-6-methyl-7-([lS]methylprop-l-yl)bicycle[4.3.0]nonan-2-one (0.82 g, 98.6%) as a pale yellow liquid.
Example 41 : (20S)- 1 α-(f-Butyldimethylsiloxy)-30-(t-butyldimethylsilvO-2- methylene- 19-nor-22,23-bishomopregnacalciferol n-Butyl lithium (1.6 M in hexanes, 3.3 mL, 5.28 mmol) was added dropwise over 5 min to a solution of P-(2-{[3S,5R]-3,5-bis(t-butyldimethylsiloxy)-4- methylidenecyclohexylidene}ethyl)diphenylphosphine oxide (3.45 g, 5.92 mmol) in THF (30 mL). stirred under nitrogen at -7O0C. After 15 minutes a solution of (lR,6R,7R)-6-methyl-7-([lS]methylprop-l-yl)bicycle[4.3.0]nonan-2-one (0.82 g, 3.94 mmol) in THF (5 mL), was added over 5 minutes to the deep red solution. After 3 hours, the reaction mixture was allowed to warm up slowly to 250C, and the tan slurry was stirred at that temperature for a further 10 hours. The reaction mixture was cooled on an ice bath and water (0.80 mL) was added dropwise. The volatiles were removed under reduced pressure, and the residue was diluted with water (35 mL), and extracted with heptanes (35, 15 mL). The combined extracts were washed with saturated brine (15 mL), dried (MgSO4) and concentrated to ~5 mL under reduced pressure. The solution was purified by silica gel chromatography eluting with heptanes, and the solvent was removed under reduced pressure to give (20S)-lα-(t- butyldimethylsiloxy)-3O-(t-butyldimethylsilyl)-2-methylene-19-nor-22,23- bishomopregnacalciferol (1.80 g, 79.7%) as a pale yellow oil.
Example 42 : (20S)- 1 α-Hydroxy-2-methylene- 19-nor-22,23-bishomopregnacalciferol
Tetra-n-butylammonium fluoride hydrate (7.80 g, 30 mmol) was added to a solution of (20S)- 1 α-(£-butyldimethylsiloxy)-30-(£-butyldimethylsilyl)-2-methylene- 19-nor-22,23-bishomopregnacalciferol (1.72 g, 3.00 mmol) in THF (25 mL), stirred under nitrogen at 2O0C. A modest endotherm was noted, and the pale gray solution was stirred at 2O0C for a further 20 hours. The solution was concentrated under reduced pressure with slight heating, and the residual solution was added to water (50 mL) and was extracted with MTBE (50 mL). The organic phase was washed with water (3 x 15 mL), saturated brine (15 mL) and dried rapidly over MgSO4. The solvent was removed under reduced pressure, and the residue was triturated with acetonitrile (10 mL), and kept overnight at 250C. The solids were collected by Buchner filtration, rinsed with cold acetonitrile (2 x 2 mL), and dried in vacuo to give (20S)- 1 α-Hydroxy-2-methylene- 19-nor-22,23-bishomopregnacalciferol (0.88 g,
85.1%) as a white crystalline solid.
The steroids and Vitamin D derivatives disclosed herein may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a pharmaceutical formulation comprising a compound which may be made via this process and a pharmaceutically acceptable carrier. One or more compounds which may be made via this process may be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing compounds which may be made via this process may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques. In some cases such coatings may be prepared by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.
Formulations for oral use may also be presented as hard gelatin capsules,
wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
Formulations for oral use may also be presented as lozenges.
Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropyl- methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
Pharmaceutical compositions of the invention may also be in the form of oil- in- water emulsions. The oily phase may be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The compounds which may be made via this process may also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.
Compounds which may be made via this process disclosed herein may be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
For disorders of the eye or other external tissues, e.g., mouth and skin, the formulations are preferably applied as a topical gel, spray, ointment or cream, or as a suppository, containing the active ingredients in a total amount of, for example, 0.0001 to 0.25%w/w, preferably, 0.0005-0.1% w/w and most preferably 0.0025- 0.05% w/w. When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base.
Alternatively, the active ingredients may be formulated in a cream with an oil- in- water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane- 1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogs. The compounds of this invention can also be administered by a transdermal device. Preferably topical administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane. The transdermal patch may include the compound in a suitable solvent system with an adhesive system, such as an acrylic emulsion, and a polyester patch. The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so- called emulsifying wax, and the wax together with the oil and fat make up the so- called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifϊers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl
alcohol, glyceryl monostearate, and sodium lauryl sulfate, among others. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The antiinflammatory active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. For therapeutic purposes, the active compounds of this combination invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants
and modes of administration are well and widely known in the pharmaceutical art.
Dosage levels of the order of from about 0.000001 mg to about 0.01 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 μg to about 0.5 mg per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 μg to about 5 mg of an active ingredient. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
For administration to non-human animals, the composition may also be added to the animal feed or drinking water. It may be convenient to formulate the animal feed and drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It may also be convenient to present the composition as a premix for addition to the feed or drinking water.
The invention and the manner and process of making and using it, are now described in such full, clear, concise and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the invention and that modifications may be made therein without departing from the spirit or scope of the invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.
Claims
1. A method of preparing the compound of the formula:
where R is alkyl, alkenyl, alkynyl, -O-alkanoyl, alkoxy, alkoxyalkoxy, -O-silyl, OH, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein each is optionally substituted with one or more groups that are independently alkyl, halogen, alkoxy, amino, monoalkylamino, dialkylamino, cyano, -O-trityl, or -O-pivaloyl, the method comprising a) reacting the 3 -hydroxy group of pregn-5-en-3β-ol-20-one with a protecting group to form a compound of the formula:
where PG is a protecting group; b) converting the product from step a) into a compound of the formula:
d) if necessary for removal or exchange of the protecting group, converting the product from step c) into a compound of the formula:
e) if necessary for exchange of the protecting group converting the product from step d) into a compound of the formula:
f) converting the product from step e) into a compound of the formula, where PG and PG* may be the same or different:
where R represents a desired Vitamin D side chain, which may be a carbon radical singly, doubly or triply bonded to C22, or a carbon radical substituted heteroatom; i) converting the product from step g) into a compound of the formula: and, converting the product from step h) into the desired product.
2. The method of claim 1 where R is methyl.
3. The method of claim 1, where PG is an alkanoyl group and PG* is a silyl protecting group.
4. The method of claim 1, where PG is acetate and PG* is the t- butyldimethylsilyl group.
5. The method of claim 1, where PG is acetate and PG* is the t- butyldimethylsilyl group and R is methyl.
6. The method according to claim 1, where the product of step e) is converted to the product of step f) by treatment with CH2=S(CHs)2, in a solvent, at low temperature.
7. The method of claim 6, wherein the solvent is THF with toluene as cosolvent, if required, and PG* is a TBDMS or TIPS group.
8. The method according to claim 1, wherein PG is acetate and PG* is TIPS.
9. The method according to claim 1, wherein the silyl group is TMS, TBDMS, TPS, TIPS, or TBDPS.
10. Intermediates of the formulas:
12. The use of one or more of the compounds of claim 10 in the preparation of the compounds of claim 11.
13. A method of producing a compound of the formula:
where R is alkyl, alkenyl, alkynyl, -O-alkanoyl, alkoxy, alkoxyalkoxy, -O-silyl OH, cycloalkyl, aryl, heteroaryl, or heterocycloalkyl, wherein each is optionally substituted with one or more groups that are independently alkyl, halogen, alkoxy, amino, monoalkylamino, dialkylamino, cyano, -O-trityl, or -O-pivaloyl, the method comprising a) reacting the 3 -hydroxy group of pregnenolone with a protecting group to form a compound of the formula:
b) converting the product from step a) into a compound of the formula: c) converting the product from step b) into a compound of the formula:
14. The method of claim 13, where R is methyl.
15. The method of claim 13, where PG is a C1-C4 alkyl, benzyl or silyl group.
16. The method of claim 15, where PG is a silyl group that is TBS, TES, or TIPS.
17. The method according to claim 13, where the product of step e) is converted to the product of step f) by treatment with CH2=S(CHs)2, in a solvent, at low temperature.
18. The method of claim 17, wherein the solvent is THF with toluene as cosolvent, if required, and PG* is a TBDMS or TIPS group.
19. The method according to claim 13, wherein the silyl group is TMS, TBDMS, TPS, TIPS, or TBDPS.
20. A pharmaceutical composition comprising steroids and Vitamin D derivates made using the method of claim 1 or 13 and at least one pharmaceutically acceptable carrier, excipient, adjuvant or glidant.
21. A pharmaceutical composition comprising the compounds of claim 11 and at least one pharmaceutically acceptable carrier, excipient, adjuvant or glidant.
22. The use of the methods of Claiml or Claim 13 to prepare stereospecifically at C20 compounds of the formula
wherein: the C23-C24 bond may be a single, double or triple bond; R1, R2, R3 and R4 are each independently C1-C4 alkyl, C1-C4 deuteroalkyl, hydroxyalkyl or haloalkyl; R5, R6 and R7 are each independently OH, OC(O)Ci-C4 alkyl,
OC(O)hydroxyalkyl or OC(O)haloalkyl;
Xi is CH2;
Z is H, OH, =0, SH or NH2.
23. Compounds according to claim 11 of the formulas:
24. The use of the methods of Claim 1 or Claim 13 to prepare stereospecifϊcally at C20 the compounds of claim 23.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88466107P | 2007-01-12 | 2007-01-12 | |
US60/884,661 | 2007-01-12 | ||
US91518607P | 2007-05-01 | 2007-05-01 | |
US60/915,186 | 2007-05-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008089093A2 true WO2008089093A2 (en) | 2008-07-24 |
WO2008089093A3 WO2008089093A3 (en) | 2009-06-04 |
Family
ID=39529798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/050906 WO2008089093A2 (en) | 2007-01-12 | 2008-01-11 | Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone |
Country Status (2)
Country | Link |
---|---|
US (1) | US20080171728A1 (en) |
WO (1) | WO2008089093A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018197296A1 (en) | 2017-04-28 | 2018-11-01 | Newchem S.P.A. | Process for the preparation of des-a-steroids, intermediates useful for the synthesis of 9beta,10alfa-steroids |
US11072632B2 (en) | 2011-03-25 | 2021-07-27 | UNIVERSITé LAVAL | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 |
CN116102479A (en) * | 2023-04-13 | 2023-05-12 | 南京海融医药科技股份有限公司 | Preparation method and application of calcipotriol related isomer impurities |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
ES2407407T3 (en) | 2005-06-01 | 2013-06-12 | Glaxosmithkline Intellectual Property Development Limited | Vitamin formulation |
PT2709631T (en) | 2011-05-20 | 2017-04-19 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Antagonists of cb1 receptor |
US8993547B2 (en) * | 2011-06-14 | 2015-03-31 | Wisconsin Alumni Research Foundation | 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses |
SI2925770T1 (en) | 2012-11-28 | 2017-07-31 | Institut National De La Sante Et De La Recherche Medicale(Inserm) | 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone |
CN115010781B (en) * | 2022-07-15 | 2022-10-25 | 中节能万润股份有限公司 | Preparation method of high-purity cholesterol |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
WO2003051828A2 (en) * | 2001-12-13 | 2003-06-26 | Wisconsin Alumni Research Foundation | (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
WO2005074389A2 (en) * | 2004-02-03 | 2005-08-18 | Chugai Pharmaceutical Co Ltd | Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4265822A (en) * | 1979-09-10 | 1981-05-05 | Wisconsin Alumni Research Foundation | Process for preparing 1-hydroxylated vitamin D compounds from 5,6-trans-vitamin D compounds |
DE3276167D1 (en) * | 1981-11-02 | 1987-06-04 | Res Inst Medicine Chem | Intermediates in the synthesis of vitamin d derivatives |
US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
US6316642B1 (en) * | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
US6835723B2 (en) * | 2001-12-13 | 2004-12-28 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form |
US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
-
2008
- 2008-01-11 US US12/013,231 patent/US20080171728A1/en not_active Abandoned
- 2008-01-11 WO PCT/US2008/050906 patent/WO2008089093A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
WO2003051828A2 (en) * | 2001-12-13 | 2003-06-26 | Wisconsin Alumni Research Foundation | (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
WO2005074389A2 (en) * | 2004-02-03 | 2005-08-18 | Chugai Pharmaceutical Co Ltd | Process for the synthesis of vitamin d compounds and intermediates for the synthesis of the compounds |
Non-Patent Citations (4)
Title |
---|
ANTONUCCI, R. ET AL: "Delta5,7-steroids. VI. The preparation of delta5,7-steroidal hormones" JOURNAL OF ORGANIC CHEMISTRY, vol. 16, 1951, pages 1126-1133, XP002485956 * |
SCHAUDER, J. R. ET AL.: "Regio and sterochemically controlled ring opening of epoxides with Grignard reagents. Stereocontrolled synthesis of the steroid side chains. First stereoselective hemisynthesis of 20S isolanosterol" TETRAHEDRON LETTERS, vol. 23, no. 42, 1982, pages 4389-4392, XP002485957 * |
SUCROW, W. ET AL.: "Partialsynthese des "Sargasterols" und des (20S)-Cholesterols" LIEBIGS ANN CHEM, 1982, pages 1897-1906, XP002485954 * |
SYDYKOV, ZH. S. AND SEGAL M. G.: "Synthesis of (20R)-3beta-acetoxy-delta5-bisnorcholenal" RUSSIAN CHEMICAL BULLETIN, vol. 25, no. 11, 1976, pages 2402-2404, XP002485955 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11072632B2 (en) | 2011-03-25 | 2021-07-27 | UNIVERSITé LAVAL | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 |
WO2018197296A1 (en) | 2017-04-28 | 2018-11-01 | Newchem S.P.A. | Process for the preparation of des-a-steroids, intermediates useful for the synthesis of 9beta,10alfa-steroids |
CN116102479A (en) * | 2023-04-13 | 2023-05-12 | 南京海融医药科技股份有限公司 | Preparation method and application of calcipotriol related isomer impurities |
Also Published As
Publication number | Publication date |
---|---|
US20080171728A1 (en) | 2008-07-17 |
WO2008089093A3 (en) | 2009-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008089093A2 (en) | Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone | |
US4717721A (en) | Sidechain homo-vitamin D compounds with preferential anti-cancer activity | |
JP3494637B2 (en) | Method for producing intermediate of 19-nor-vitamin D compound | |
JPH02209862A (en) | Vitamin d2-related compound | |
US5756489A (en) | 18,19-dinor-vitamin D compounds | |
JP2002544137A (en) | Steroid compounds for use in therapy having a C17 alkyl side chain and an aromatic A ring | |
JPH0672995A (en) | 24-cyclopropanevitamin d derivative | |
JP2731839B2 (en) | Homogenized Vitamin D <2> compounds and corresponding 1α-hydroxylated derivatives | |
KR100361556B1 (en) | Vitamin Damide Derivatives | |
EP3906228A1 (en) | Improved, cost effective process for synthesis of vitamin d3 and its analogue calcifediol from ergosterol | |
US20020010163A1 (en) | 17-side chain alkynl-and 20-oxopregna-derivatives of vitamin d, methods for their production and pharmaceutical compositions thereof | |
JPH0569103B2 (en) | ||
US5721224A (en) | Method of treating metabolic bone diseases with 18-nor-vitamin D compounds | |
EP0468037B1 (en) | Process for preparing vitamin d2 compounds and the corresponding 1 alpha-hydroxylated derivatives | |
JPH0597796A (en) | Preparation of 1alpha-hydroxy-secosterol compound | |
JP4187437B2 (en) | Intermediates for synthesis of vitamin D and steroid derivatives and method for producing the same | |
EP1219599B1 (en) | Vitamin d derivatives having substituents at the 2 alpha-position | |
MXPA97003720A (en) | Compounds of 18-nor-vitamin | |
MXPA97003721A (en) | Compounds of 18, 19-dinop-vitamin | |
JPH06329622A (en) | Iodo vitamine d3 compound and its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08727605 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08727605 Country of ref document: EP Kind code of ref document: A2 |